<SEC-DOCUMENT>0001641172-25-016520.txt : 20250625
<SEC-HEADER>0001641172-25-016520.hdr.sgml : 20250625
<ACCEPTANCE-DATETIME>20250625172213
ACCESSION NUMBER:		0001641172-25-016520
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20250625
DATE AS OF CHANGE:		20250625

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		251074555

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>formdefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:CYCC="http://cyclacel.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_ECD%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_CYCC_cyclacel.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001130166 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:EntityCentralIndexKey">0001130166</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0011" name="dei:DocumentType">DEFA14A</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cycc-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_PeoMember_custom_ReportedSCTStockOptionAwardValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ReportedSCTStockOptionAwardValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_ReportedSCTStockOptionAwardValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ReportedSCTStockOptionAwardValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_PeoMember_custom_ReportedSCTStockOptionAwardValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ReportedSCTStockOptionAwardValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_ReportedSCTStockOptionAwardValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ReportedSCTStockOptionAwardValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_PeoMember_custom_ReportedSCTStockOptionAwardValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ReportedSCTStockOptionAwardValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_ReportedSCTStockOptionAwardValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ReportedSCTStockOptionAwardValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_PeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_PeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_PeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000017" toRefs="Footnote000035 Footnote000036"/>
  <ix:relationship fromRefs="Fact000018" toRefs="Footnote000035 Footnote000037"/>
  <ix:relationship fromRefs="Fact000019" toRefs="Footnote000035 Footnote000036"/>
  <ix:relationship fromRefs="Fact000020" toRefs="Footnote000035 Footnote000037"/>
  <ix:relationship fromRefs="Fact000023" toRefs="Footnote000035 Footnote000036"/>
  <ix:relationship fromRefs="Fact000024" toRefs="Footnote000035 Footnote000037"/>
  <ix:relationship fromRefs="Fact000025" toRefs="Footnote000035 Footnote000036"/>
  <ix:relationship fromRefs="Fact000026" toRefs="Footnote000035 Footnote000037"/>
  <ix:relationship fromRefs="Fact000029" toRefs="Footnote000035 Footnote000036"/>
  <ix:relationship fromRefs="Fact000030" toRefs="Footnote000035 Footnote000037"/>
  <ix:relationship fromRefs="Fact000031" toRefs="Footnote000035 Footnote000036"/>
  <ix:relationship fromRefs="Fact000032" toRefs="Footnote000035 Footnote000037"/>
  <ix:relationship fromRefs="Fact000021" toRefs="Footnote000038"/>
  <ix:relationship fromRefs="Fact000027" toRefs="Footnote000038"/>
  <ix:relationship fromRefs="Fact000033" toRefs="Footnote000038"/>
  <ix:relationship fromRefs="Fact000022" toRefs="Footnote000039"/>
  <ix:relationship fromRefs="Fact000028" toRefs="Footnote000039"/>
  <ix:relationship fromRefs="Fact000034" toRefs="Footnote000039"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt">UNITED
STATES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 18pt"><b>AMENDMENT
NO. 1</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 18pt"><b>TO</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90B_edei--DocumentType_dxL_c20240101__20241231_zZ8UOfFzFZ7d" title="::XDX::DEFA14A"><span style="-sec-ix-hidden: xdx2ixbrl0011">SCHEDULE
14A</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxy
Statement Pursuant to Section 14(a) of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Securities Exchange Act of 1934 (Amendment No. )</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by the Registrant &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by a Party other than the Registrant &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary
    Proxy Statement</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9744;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential,
    for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive
    Proxy Statement</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive
    Additional Materials</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    Material under Rule 14a-12</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27.35pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_909_edei--EntityRegistrantName_c20240101__20241231_z9wL9eRdv2q9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000012" name="dei:EntityRegistrantName">CYCLACEL
PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27.35pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant as Specified In Its Charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; font-family: Times New Roman, Times, Serif; width: 80%"><div style="border-top: Black 1pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Person(s) Filing Proxy Statement, if other than the Registrant)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
of Filing Fee (Check the appropriate box):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    fee required.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee
    paid previously with preliminary materials.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee
    computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPLANATORY
NOTE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0">This Amendment No. 1 to Schedule 14A
(the &#8220;Amendment&#8221;) is being filed to amend Cyclacel Pharmaceutical, Inc.&#8217;s (the &#8220;Company&#8221;) definitive proxy
statement for its 2025 Annual Meeting of Shareholders (the &#8220;Proxy Statement&#8221;), which was filed with the Securities and Exchange
Commission on April 24, 2025. The Amendment corrects (on pages 2 and 7) a scrivener&#8217;s error in total shares outstanding from 381,202,294
to 356,357,531 shares outstanding on the record date. No other changes have been made to the Proxy Statement or to the matters to be
considered by the stockholders. All other items of the Proxy Statement are incorporated herein by reference without change.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CYCLACEL PHARMACEUTICALS, INC.</b></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
10, Tower 11, Avenue 5, No. 8</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jalan
Kerinchi, Kuala Lumpur, Malaysia 59200</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">April
24, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
Our Stockholders:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
are cordially invited to attend the 2025 Annual Meeting of Stockholders of Cyclacel Pharmaceuticals, Inc. (the &#8220;<b>Company</b>&#8221;)
to be held at 10:00 a.m., E.D.T., on June 30, 2025. We have decided to hold this year&#8217;s annual meeting via live audio
webcast on the internet (the &#8220;<b>Meeting</b>&#8221;). We believe hosting a virtual annual meeting enables greater stockholder attendance
and participation from any location around the world, improves meeting efficiency and our ability to communicate effectively with our
stockholders, and reduces the cost and environmental impact of our annual meeting. You will be able to attend the annual meeting, vote
and submit your questions during the annual meeting by visiting www.proxyvote.com. You will not be able to attend the annual meeting
in person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
attached Notice of Annual Meeting and proxy statement describe the business we will conduct at the annual meeting and provide information
about us that the holders of our common stock (the &#8220;<b>Common Stock</b>&#8221;) should consider when voting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the annual meeting, we will ask our holders of Common Stock to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">re-elect
    each of Datuk Dr. Doris Wong, Kiu Cu Seng, Kwang Fock Chong, Dr. Satis Waran Nair Krishnan, and Inigo Angel Laurduraj, nominees to
    our Board of Directors; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approve
    a proposed amendment to the Company&#8217;s 2018 Equity Incentive Plan to increase the number of shares of Common Stock available
    for the grant of awards by 4,281,987 shares; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approve
    by an advisory vote the compensation of our named executive officers and directors, as disclosed in this proxy statement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our holders of Common Stock shall consider and act upon such other business and matters as may properly come before the Meeting
or any adjournments thereof. The Board of Directors recommends the approval of each of these proposals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Securities and Exchange Commission rules that allow companies to furnish proxy materials to stockholders over the Internet, we have elected
to deliver our proxy materials to the majority of our stockholders over the Internet. This delivery process allows us to provide stockholders
with the information they need, while at the same time conserving natural resources and lowering the cost of delivery. On or about May
16, 2025, we will commence mailing to our stockholders a Notice of Internet Availability of Proxy Materials (the &#8220;<b>Notice</b>&#8221;)
containing instructions on how to access our proxy statement for our 2025 Annual Meeting of Stockholders and our 2024 annual report to
stockholders. The Notice also provides instructions on how to vote online or by telephone, how to access the virtual annual meeting and
how to receive a paper copy of the proxy materials by mail.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hope you will be able to attend the annual meeting. Whether you plan to attend the annual meeting or not, it is important that you cast
your vote either at the meeting or by proxy. You may vote over the Internet as well as by telephone or by mail. Therefore, when you have
finished reading the proxy statement, you are urged to vote in accordance with the instructions set forth in this proxy statement. We
encourage you to vote by proxy so that your shares will be represented and voted at the annual meeting, whether or not you can attend.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thank
you for your ongoing support of Cyclacel Pharmaceuticals, Inc. We look forward to seeing you at the annual meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
Datuk Dr. Doris Wong</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
Dr. Doris Wong</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer and Executive Director</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CYCLACEL PHARMACEUTICALS, INC.</b></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
10, Tower 11, Avenue 5, No. 8</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jalan
Kerinchi, Kuala Lumpur, Malaysia 59200</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April
24, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE
OF 2025 ANNUAL MEETING OF STOCKHOLDERS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Time:</i></b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10:00
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.m. E.D.T</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Date:</i></b></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Access:</i></b></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    year&#8217;s annual meeting will be a virtual meeting via live audio webcast on the Internet. You will be able to attend the annual
    meeting, vote and submit your questions during the meeting by visiting www.proxyvote.com and entering the 16-digit control
    number included in the Notice of Internet Availability or proxy card that you receive. For further information about the virtual
    annual meeting, please see the Questions and Answers about the Meeting beginning on page 2 of the accompanying proxy statement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purposes:</i></b></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the holders of our common stock (&#8220;<b>Common Stock</b>&#8221;):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">re-elect
    each of Datuk Dr. Doris Wong (to Class 3), Kiu Cu Seng (to Class 2), Kwang Fock Chong (to Class 2), Dr. Satis Waran Nair Krishnan
    (to Class 1), and Inigo Angel Laurduraj (to Class 1), nominees to our Board of Directors; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approve
    a proposed amendment to the Company&#8217;s 2018 Equity Incentive Plan to increase the number of shares of Common Stock available
    for the grant of awards by 4,281,987 shares; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approve
    by an advisory vote the compensation of our named executive officers and directors, as disclosed in this proxy statement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our holders of Common Stock shall consider and act upon such other business and matters as may properly come before the Meeting
or any adjournments thereof. The Board of Directors recommends the approval of each of these proposals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHO
MAY VOTE?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may vote if you were the record holder of our Common Stock at the close of business on May 1, 2025. A list of stockholders
of record will be available at the annual meeting and during the ten days prior to the annual meeting at the office of our Secretary
at the above address.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
stockholders are cordially invited to attend the annual meeting. <b>Whether you plan to attend the annual meeting or not, we urge you
to vote by following the instructions in the Notice of Internet Availability of Proxy Materials that you previously received and submit
your proxy by the Internet, telephone or mail in order to ensure the presence of a quorum</b>. You may change or revoke your proxy at
any time before it is voted at the meeting. If you participate in and vote your shares at the annual meeting, your proxy will not be
used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
order of the Board of Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
Kiu Cu Seng</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kiu
Cu Seng, Secretary</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
OF CONTENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMPORTANT
    NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE SHAREHOLDER MEETING TO BE HELD ON JUNE 30, 2025</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">7</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT AND CORPORATE GOVERNANCE</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">9</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTIVE AND DIRECTOR COMPENSATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">14</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EQUITY COMPENSATION PLAN INFORMATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">16</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PAY VERSUS PERFORMANCE</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPORT OF AUDIT COMMITTEE</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">21</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">22</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPOSALS TO BE VOTED UPON BY HOLDERS OF COMMON STOCK</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">23</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPOSAL 1: ELECTION OF CLASS DIRECTORS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPOSAL
                                            2: AMENDMENT TO 2018 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK
                                            AVAILABLE FOR THE GRANT OF AWARDS BY 4,281,987 SHARES</span></a></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">24</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPOSAL 3: ADVISORY VOTE ON APPROVAL OF EXECUTIVE COMPENSATION AS DISCLOSED IN THIS PROXY STATEMENT</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">29</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CODE OF CONDUCT AND ETHICS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">30</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER MATTERS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">30</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">30</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPENDIX A: 2018 EQUITY INCENTIVE PLAN, AS AMENDED</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-1</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span>&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CYCLACEL PHARMACEUTICALS, INC.</b></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
10, Tower 11, Avenue 5, No. 8</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jalan
Kerinchi, Kuala Lumpur, Malaysia 59200</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROXY
STATEMENT FOR CYCLACEL PHARMACEUTICALS, INC.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 30, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement, along with the accompanying notice of the 2025 Annual Meeting of stockholders, contains information about the 2025 Annual
Meeting of stockholders of Cyclacel Pharmaceuticals, Inc., including any adjournments or postponements of the annual meeting. This year&#8217;s
annual meeting will be held via live audio webcast on the internet. You will be able to participate, vote and submit your questions during
the annual meeting by visiting www.proxyvote.com. You will not be able to attend the annual meeting physically.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this proxy statement, we refer to Cyclacel Pharmaceuticals, Inc. as &#8220;Cyclacel,&#8221; &#8220;the Company,&#8221; &#8220;we&#8221;
and &#8220;us.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement relates to the solicitation of proxies by our Board of Directors for use at the annual meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>On
or about May 16, 2025, we intend to begin sending to our stockholders the Important Notice Regarding the Availability of Proxy
Materials containing instructions on how to access our proxy statement for our 2025 Annual Meeting of stockholders and our 2024 annual
report to stockholders.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>____________________________</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_001"></span>IMPORTANT
NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHAREHOLDER
MEETING TO BE HELD ON JUNE 30, 2025</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement, the notice of 2025 Annual Meeting of stockholders, our form of proxy card and our 2024 annual report to stockholders
are available for viewing, printing and downloading at www.proxyvote.com. To view these materials, please have your 16-digit control
number(s) available that appears on your Internet Availability Notice or proxy card. On this website, you can also elect to receive future
distributions of our proxy statements and annual reports to stockholders by electronic delivery.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additionally,
you can find a copy of our Annual Report on Form 10-K, which includes our financial statements, for the fiscal year ended December 31,
2024 on the website of the Securities and Exchange Commission, or the SEC, at www.sec.gov, or in the &#8220;SEC Filings&#8221; section
of the &#8220;Investors&#8221; section of our website at www.cyclacel.com.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>You
may also obtain a printed copy of our Annual Report on Form 10-K, including our financial statements, free of charge, from us by sending
a written request to: Cyclacel Pharmaceuticals, Inc., Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 59200,
attention: Secretary, Annual Meeting. Exhibits will be provided upon written request and payment of an appropriate processing fee.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_002"></span>IMPORTANT
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Why
is the Company Soliciting My Proxy?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors of Cyclacel is soliciting your proxy to vote at the 2025 Annual Meeting of stockholders, and any adjournments or postponements
of the meeting, which we refer to as the annual meeting, to be held at 10:00 a.m., E.D.T., on June 30, 2025. This year&#8217;s
annual meeting will be held via live audio webcast on the internet. You will be able to participate, vote and submit your questions during
the annual meeting by visiting www.proxyvote.com. If you encounter any difficulties accessing the virtual meeting during check-in
or the meeting, please call the technical support number that will be posted on the virtual shareholder meeting log-in page. We believe
that a virtual meeting will provide expanded stockholder access and participation and improved communications. You will not be able to
attend the annual meeting physically. The proxy statement, along with the accompanying Notice of Annual Meeting of Stockholders, summarizes
the purposes of the meeting and the information you need to know to vote at the annual meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have made available to you on the Internet or have sent you this proxy statement, the 2025 notice of annual meeting of stockholders,
the proxy card or cards and a copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 because you owned shares
of our common stock (&#8220;<b>Common Stock</b>&#8221;) on the record date. We intend to commence distribution of the Important Notice
Regarding the Availability of Proxy Materials, which we refer to throughout this proxy statement as the Internet Availability Notice,
and, if applicable, proxy materials to stockholders on or about May 16, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Why
Did I Receive a Notice in the Mail Regarding the Internet Availability of Proxy Materials Instead of a Full Set of Proxy Materials?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
permitted by the rules of the U.S. Securities and Exchange Commission (the &#8220;<b>SEC</b>&#8221;), we may furnish our proxy materials
to our stockholders by providing access to such documents on the Internet, rather than mailing printed copies of these materials to each
stockholder. Most stockholders will not receive printed copies of the proxy materials unless they request them. We believe that this
process should expedite stockholders&#8217; receipt of proxy materials, lower the costs of the annual meeting and help to conserve natural
resources. If you receive the Internet Availability Notice by mail or electronically, you will not receive a printed or email copy of
the proxy materials, unless you request one by following the instructions included in the Internet Availability Notice. Instead, the
Internet Availability Notice instructs you as to how you may access and review all of the proxy materials and submit your proxy on the
Internet. If you requested a paper copy of the proxy materials, you may authorize the voting of your shares by following the instructions
on the proxy card, in addition to the other methods of voting described in this proxy statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Why
Are You Holding a Virtual Annual Meeting?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
year&#8217;s annual meeting will be held in a virtual meeting format only. We have designed our virtual format to enhance, rather than
constrain, stockholder access, participation and communication. For example, the virtual format allows stockholders to communicate with
us in advance of, and during, the annual meeting so they can ask questions of our board of directors or management, as time permits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">How
do I access the Virtual Annual Meeting?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
live webcast of the Annual Meeting will begin promptly at 10:00 a.m. E.D.T. Online access to the audio webcast will open 15 minutes
prior to the start of the Annual Meeting to allow time for you to log-in and test your device&#8217;s audio system. The virtual Annual
Meeting is running the most updated version of the applicable software and plugins. You should ensure you have a strong internet connection
wherever you intend to participate in the Annual Meeting. You should also allow plenty of time to log in and ensure that you can hear
streaming audio prior to the start of the Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Log-in
Instructions. To be admitted to the virtual Annual Meeting, you will need to log-in at www.proxyvote.com using the 16-digit control
number found on the proxy card or voting instruction card previously mailed or made available to stockholders entitled to vote at the
Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Who
May Vote?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
stockholders who own our Common Stock at the close of business on May 1, 2025 will be entitled to vote at the annual meeting. On this
record date, there were 356,357,531 shares of our Common Stock outstanding and entitled to vote on the proposals submitted to
our holders of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
on May 1, 2025 your shares of our Common Stock were registered directly in your name with our transfer agent, Equiniti Trust Company,
LLC, then you are a stockholder of record.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
on May 1, 2025 your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or other similar
organization, then you are the beneficial owner of shares held in &#8220;street name&#8221; and the Internet Availability Notice or if
applicable, our proxy materials are being forwarded to you by that organization. The organization holding your account is considered
to be the stockholder of record for purposes of voting at the annual meeting. As a beneficial owner, you have the right to direct your
broker or other agent regarding how to vote the shares in your account. You are also invited to attend the annual meeting. However, since
you are not the stockholder of record, you may not vote your shares at the annual meeting unless you request and obtain a valid proxy
from your broker or other agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
do not need to attend the annual meeting to vote your shares. Shares represented by valid proxies, received in time for the annual meeting
and not revoked prior to the annual meeting, will be voted at the annual meeting. For instructions on how to change or revoke your proxy,
see &#8220;<i>May I Change or Revoke My Proxy?</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the ten-day period immediately prior to the annual meeting, the list of the stockholders of record entitled to vote at the annual meeting
will be available for inspection at our offices at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 59200,
by stockholders for such purposes as are set forth in the General Corporation Law of the State of Delaware. The list of the stockholders
will also be available for inspection at the annual meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
Proposals Can I Vote on as a Holder of Preferred Stock?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Preferred Stock are not entitled to vote on any current proposals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Certificate, holders of the Preferred Stock are entitled to receive, when, as and if declared by the Board of Directors,
out of the funds of the Company legally available therefor, cash dividends payable in equal quarterly installments on each of February
1, May 1, August 1, and November 1. The Certificate further provides that, if the Company is in arrears in an aggregate amount equal
to at least six quarterly dividends (whether or not consecutive), the number of members of the Company&#8217;s Board of Directors will
be increased by two, effective as of the time of election of such directors, and the holders of Preferred Stock, voting separately as
a class, will have the right to vote and elect such two additional directors. This right is accrued to the holders of our Preferred Stock
as of August 2, 2010. The Company is currently in arrears in an aggregate amount in excess of six quarterly dividends on the Preferred
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
light of the payment arrearages of the quarterly dividends, the holders of Preferred Stock have a continuing right to elect two directors
on the Company&#8217;s Board of Directors. Coinciding with the closing of a change in control transaction on February 26, 2025, the following
persons were elected by the holders of the Series E Preferred Stock to serve on the Board of Directors effective as of April 2, 2025,
Dr. Satis Waran Nair Krishnan, and Inigo Angel Laurduraj. They will serve as directors until the earlier the 2026 annual meeting or the
time that their successors are duly elected and qualified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">How
Many Votes Do I Have?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of our Common Stock that you own entitles you to one vote with respect to each of the proposals to be voted on by holders of Common
Stock presented in the proxy statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">How
Do I Vote?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
you plan to attend the annual meeting or not, we urge you to vote by proxy. All shares represented by valid proxies that we receive through
this solicitation, and that are not revoked, will be voted in accordance with your instructions on the proxy card or as instructed via
the Internet or telephone. You may specify whether your shares should be voted for or withheld for each nominee for director, and whether
your shares should be voted for, against or abstain with respect to each of the other proposals. If you properly submit a proxy without
giving specific voting instructions, your shares will be voted in accordance with our board of directors&#8217; recommendations as noted
below. Voting by proxy will not affect your right to attend the annual meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
your shares are registered directly in your name through our transfer agent, Equiniti Trust Company LLC, or you have stock certificates
registered in your name, you may vote:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BY
INTERNET OR BY TELEPHONE. FOLLOW THE INSTRUCTIONS ON YOUR NOTICE TO VOTE OVER THE INTERNET. IF YOU RECEIVED A PROXY CARD IN THE MAIL,
THE PROXY CARD WILL HAVE INSTRUCTIONS FOR VOTING OVER THE INTERNET OR BY TELEPHONE.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BY
MAIL. IF YOU RECEIVED ONE OR MORE PROXY CARDS BY MAIL, YOU CAN VOTE BY MAIL BY COMPLETING, SIGNING, DATING AND RETURNING THE ENCLOSED
PROXY CARD IN THE ENCLOSED POSTAGE PREPAID ENVELOPE. YOUR PROXY WILL BE VOTED IN ACCORDANCE WITH YOUR INSTRUCTIONS. IF YOU SIGN THE PROXY
CARD BUT DO NOT SPECIFY HOW YOU WANT YOUR SHARES VOTED, THEY WILL BE VOTED AS RECOMMENDED BY OUR BOARD OF DIRECTORS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AT
THE MEETING. YOU MAY VOTE YOUR SHARES ELECTRONICALLY AT THE VIRTUAL ANNUAL MEETING. YOU WILL NEED THE 16-DIGIT CONTROL NUMBER ON YOUR
NOTICE OR PROXY CARD IN ORDER TO VOTE AT THE MEETING. EVEN IF YOU PLAN TO ATTEND THE ANNUAL MEETING VIRTUALLY, WE ENCOURAGE YOU TO VOTE
IN ADVANCE SO THAT YOUR VOTE WILL BE COUNTED IN THE EVENT YOU DECIDE NOT TO ATTEND.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
your shares are held in &#8220;street name&#8221; by a bank, broker or other nominee, please see the materials you received from your
bank, broker or other nominee for voting instructions. To participate and vote during the annual meeting, you will need the 16-digit
control number included on your Notice or your voting instruction form. If you do not have your 16-digit control number, you may gain
access to and vote at the meeting by logging in to website of your bank, broker or other nominee and selecting the stockholder communications
mailbox to access the meeting. Even if you plan to attend the annual meeting virtually, we encourage you to vote in advance so that your
vote will be counted in the event you later decide not to attend. Telephone and Internet voting facilities for all stockholders of record
will be available 24-hours a day and will close at 11:59 p.m., E.D.T., on June 29, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>How
Does the Board of Directors Recommend that I Vote on the Proposals?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors recommends that you, as a holder of Common Stock, vote as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b>FOR</b>&#8221;
    the re-election of each of Datuk Dr. Doris Wong (to Class 3), Kiu Cu Seng (to Class 2), Kwang Fock Chong (to Class 2), Dr. Satis
    Waran Nair Krishnan (to Class 1), and Inigo Angel Laurduraj (to Class 1), nominees for directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b>FOR</b>&#8221;
    the approval of the amendment to our 2018 Equity Incentive Plan to increase the number of shares of Common Stock available for the
    grant of awards by 4,281,987 shares; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b>FOR</b>&#8221;
    the compensation of our named executive officers and directors, as disclosed in this proxy statement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our holders of Common Stock shall consider and act upon such other business and matters as may properly come before the Meeting
or any adjournments thereof. The Board of Directors recommends the approval of each of these proposals. If any other matter is properly
presented at the annual meeting, your proxy provides that your shares will be voted by the proxy holder listed in the proxy in accordance
with the proxy holder&#8217;s best judgment. At the time this proxy statement was first made available, we knew of no matters that needed
to be acted on at the annual meeting, other than those described in this proxy statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
I Change or Revoke My Proxy?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you submit a proxy, you may change or revoke it at any time before the annual meeting. You may change or revoke your proxy in any one
of the following ways:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    submitting a new proxy card with a date later than your previously delivered proxy and submitting it as instructed above or by providing
    written notice of revocation to us before the annual meeting at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur,
    Malaysia 59200, Attention: Kiu Cu Seng, Chief Financial Officer, Executive Director and Secretary;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    submitting a later proxy by Internet or by telephone as instructed above; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    attending the annual meeting and voting at the meeting. Attending the annual meeting will not, in and of itself, change or revoke
    a previously submitted proxy unless you specifically request it or vote at the annual meeting. Your most current vote, whether by
    telephone, Internet or proxy card is the one that will be counted.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
if I Receive More Than One Internet Availability Notice or Proxy Card?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may receive more than one Internet Availability Notice or proxy card if you hold shares of our Common Stock in more than one account,
which may be in registered form or held in street name. Please vote in the manner described above under &#8220;<i>How Do I Vote?</i>&#8221;
for each account to ensure that all of your shares are voted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Will
My Shares be Voted if I Do Not Vote?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
your shares are registered in your name or if you have stock certificates, they will not be counted if you do not vote as described above
under &#8220;<i>How Do I Vote?</i>&#8221;. If your shares are held in street name and you do not provide voting instructions to the bank,
broker or other nominee that holds your shares as described above, the bank, broker or other nominee that holds your shares has no authority
to vote your unvoted shares without receiving instructions from you. Therefore, we encourage you to provide voting instructions to your
bank, broker or other nominee. This ensures your shares will be voted on at the annual meeting and in the manner you desire. A &#8220;broker
non-vote&#8221; will occur if your broker, bank or other nominee cannot vote your shares on a particular matter because it has not received
instructions from you and does not have discretionary voting authority on that matter or because your broker, bank or other nominee chooses
not to vote on a matter for which it does have discretionary voting authority. Therefore, if you hold your shares in street name, it
is critical that you cast your vote if you want your vote to be counted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>What
Vote Is Required to Approve Each Proposal and How Are Votes Counted?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Proposal
1</span>: Elect Datuk Dr. Doris Wong (to Class 3), Kiu Cu Seng (to Class 2), Kwang Fock Chong (to Class 2), Dr. Satis Waran Nair Krishnan
(to Class 1), and Inigo Angel Laurduraj (to Class 1), as Directors:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three nominees for director who receive the most votes (also known as a &#8220;plurality&#8221; of the votes cast) will be elected. You
may vote FOR all of the nominees, WITHHOLD your vote from all of the nominees or WITHHOLD your vote from any one of the nominees. Votes
that are withheld will not be included in the vote tally for the election of directors. Brokerage firms do not have authority to vote
customers&#8217; unvoted shares held by the firms in street name for the election of directors. As a result, any shares not voted by
a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Proposal
2</span>: Approval of a Proposed Amendment to our 2018 Equity Incentive Plan to increase the number of shares of Common Stock available
for the grant of awards by 4,281,987 shares:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
affirmative vote of a majority of the votes cast for this proposal is required to approve the amendment to the 2018 Equity Incentive
Plan. Abstentions will have no effect on this proposal. Brokerage firms do not have authority to vote customers&#8217; unvoted shares
held by the firms in street name on this proposal. As a result, any shares not voted by a customer will be treated as a broker non- vote.
Such broker non-votes will have no effect on the results of this vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Proposal
3</span>: Approve an Advisory Vote on the Compensation of our Named Executive Officers and Directors:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
affirmative vote of a majority of the votes cast for this proposal at the annual meeting is required to approve, on an advisory basis,
the compensation of our named executive officers, as described in this proxy statement. Abstentions will have no effect on this proposal.
Brokerage firms do not have authority to vote customers&#8217; unvoted shares held by the firms in street name on this proposal. As a
result, any shares not voted by a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the results
of this vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
Voting Confidential?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will keep all of the proxies, ballots and voting tabulations private. We only let our Inspector of Election, a representative of Broadridge
Financial Solutions, Inc., examine these documents. Management will not know how you voted on a specific proposal unless it is necessary
to meet legal requirements. Broadridge Financial Solutions, Inc., however, will forward to management any written comments you make,
on the proxy card or elsewhere.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
Can I Find the Voting Results of the Annual Meeting?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preliminary voting results will be announced at the annual meeting, and we will publish preliminary, or final, results, if available,
in a Current Report on Form 8-K within four business days of the annual meeting. If final results are unavailable at the time we file
the Form 8-K, then we will file an amended report on Form 8-K to disclose the final voting results within four business days after the
final voting results are known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
Are the Costs of Soliciting these Proxies?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay all of the costs of soliciting these proxies. Our directors and employees may solicit proxies in person or by telephone, fax
or email. We will pay these employees and directors no additional compensation for these services. We will ask banks, brokers and other
institutions, nominees and fiduciaries to forward these proxy materials to their principals and to obtain authority to execute proxies.
We will then reimburse them for their expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged Laurel Hill Advisory Group, LLC, to act as our proxy solicitor in connection with the proposals to be acted upon at our
annual meeting. Pursuant to our agreement, Laurel Hill Advisory Group, LLC will, among other things, provide advice regarding proxy solicitation
issues and solicit proxies from our stockholders on our behalf in connection with the annual meeting. For these services, we will pay
a fee of approximately $20,000 plus expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
Constitutes a Quorum for the Annual Meeting?</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
presence, at the meeting or by proxy, of the holders of a majority of the voting power of all outstanding shares of our Common Stock
entitled to vote at the annual meeting is necessary to constitute a quorum at the annual meeting. Votes of stockholders of record who
are present at the annual meeting or by proxy, abstentions, and broker non-votes are counted for purposes of determining whether a quorum
exists. Broker non-votes will be counted for purposes of determining whether a quorum exists with respect to all of the Proposals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attending
the Annual Meeting</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
year, the annual meeting will be held in a virtual meeting format only. To attend the annual meeting, go to www.proxyvote.com
shortly before the meeting time, and follow the instructions. You need not attend the annual meeting in order to vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Householding
of Annual Disclosure Documents</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
brokers or other nominee record holders may be sending you a single set of our proxy materials if multiple of our stockholders live in
your household. This practice, which has been approved by the SEC, is called &#8220;householding.&#8221; Once you receive notice from
your broker or other nominee record holder that it will be &#8220;householding&#8221; our proxy materials, the practice will continue
until you are otherwise notified or until you notify them that you no longer want to participate in the practice. Stockholders who participate
in householding will continue to have access to and utilize separate proxy voting instructions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will promptly deliver a separate copy of our Internet Availability Notice. If you would like to request a copy of the material(s) for
this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639, or (3) send an email to
<span style="text-decoration: underline">sendmaterial@proxyvote.com</span>.</span> If you send an email, please include your control number (indicated below) in the subject
line. Unless requested, you will not otherwise receive a paper or email copy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electronic
Delivery of Company Stockholder Communications</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
stockholders can elect to view or receive copies of future proxy materials over the Internet instead of receiving paper copies in the
mail. You can choose this option and save us the cost of producing and mailing these documents by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">following
    the instructions provided on your Internet Availability Notice or proxy card;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">following
    the instructions provided when you vote over the Internet; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">going
    to <i>www.proxyvote.com</i> and following the instructions provided. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_003"></span>SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information with respect to the beneficial ownership of our Common Stock and our preferred stock (the
&#8220;Preferred Stock&#8221;) as of April 24, 2025 for (a) each of our named executive officers, (b) each of our directors and
director nominees, (c) all of our current directors and executive officers as a group, and (d) each stockholder known by us to own beneficially
more than 5% of our Common Stock or Preferred Stock, relying solely upon the amounts and percentages disclosed in their public filings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities.
We deem shares of Common Stock that may be acquired by an individual or group within 60 days of April 24, 2025 pursuant to the
exercise of options or warrants to be outstanding for the purpose of computing the percentage ownership of an individual or group but
do not deem them to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Except
as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with
respect to all shares of stock shown to be beneficially owned by them based on information provided to us by these stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
percentage of ownership of Common Stock is based on 356,357,531 shares of Common Stock outstanding as of April 24, 2025. The percentage
of ownership of Preferred Stock is based on 135,537 shares of Preferred Stock outstanding as of April 24, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
address for each of the directors, director nominees and named executive officers is c/o Cyclacel Pharmaceuticals, Inc., Level 10, Tower
11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 59200. Addresses of other beneficial owners are noted in the table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of Beneficial Owners <sup>(1)</sup></b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Shares of Common Stock Beneficially Owned</b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock<sup>(2)</sup></b></span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Shares of Preferred Stock Beneficially Owned <sup>(2)</sup></b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
    of Preferred Stock Owned <sup>(2)</sup></b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">David
    Lazar</span></td><td style="font-family: Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,021,180</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.95</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Armistice
    Capital Master Fund Ltd.<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,844,725</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.97</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ho
    Kee Wee<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,500,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.72</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tan
    Kok Hui<sup>(5)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,500,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.72</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suria
    Sukses Engineering Sdn. Bhd.<sup>(6)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,500,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.72</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ho
    Jien Shiung<sup>(7)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,500,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.72</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong Sing Ee<sup>(8)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">194,628,820</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">54.61</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Kiu
    Cu Seng</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Kwang
    Fock Chong</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dr.
    Satis Waran Nair Krishnan</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Inigo
    Angel Laurduraj</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    beneficial ownership of less than one percent of our outstanding shares of Common Stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    otherwise indicated, the address of each beneficial owner listed below is c/o Cyclacel Pharmaceuticals, Inc., Cyclacel Pharmaceuticals,
    Inc., Level 10, Tower 11, Avenue 5, No. 8 Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes
    the sale of all shares of Common Stock being offered pursuant to this prospectus.</span></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Armistice
    Capital Master Fund Ltd. (&#8220;Armistice&#8221;) and the Company entered into that certain Warrant Exchange Agreement dated January
    2, 2025 (&#8220;Warrant Exchange Agreement&#8221;), pursuant to which they agreed to exchange certain Exchanged Warrants (as defined
    in the Warrant Exchange Agreement) previously acquired by Armistice for 24,844,725 shares of common stock and cash consideration.
    The address for Armistice is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, New York 10022. Armistice is a
    Cayman Islands exempted company operating as a hedge fund focused primarily on the health care and consumer sectors. We have been
    advised that Steven Boyd has the power to vote or direct the vote and power to dispose or to direct the disposition of all securities
    owned directly by Armistice. We have been advised that Armistice is a member of the Financial Industry Regulatory Authority (&#8220;FINRA&#8221;),
    or an independent broker-dealer, and that neither Armistice nor any of its affiliates is an affiliate or an associated person of
    any FINRA member or independent broker-dealer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    solely on the Securities Purchase Agreement dated March 21, 2025 between the Company and Ho Kee Wee, as filed within the Company&#8217;s
    Current Report on Form 8-K filed with the SEC on March 24, 2025 for the purchase of 250,000 shares of Series E Preferred Stock that
    are convertible into 27,500,000 shares of common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    solely on the Securities Purchase Agreement dated March 21, 2025 between the Company and Tan Kok Hui, as filed within the Company&#8217;s
    Current Report on Form 8-K filed with the SEC on March 24, 2025 for the purchase of 250,000 shares of Series E Preferred Stock that
    are convertible into 27,500,000 shares of common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    solely on the Securities Purchase Agreement dated March 21, 2025 between the Company and Suria Sukses Engineering Sdn. Bhd. (&#8220;Suria&#8221;),
    as filed within the Company&#8217;s Current Report on Form 8-K filed with the SEC on March 24, 2025 for the purchase of 250,000 shares
    of Series E Preferred Stock that are convertible into 27,500,000 shares of common stock. The address for Suria is 26-13A Stellar
    Suites, Jalan Puteri 4/7, Bandar Puteri, 47100 Puchong, Selangor, Malaysia. Suria is in the business of production of the Giant HVLS
    fan in Malaysia sold under the brand Suria Giant Fan. We have been advised that Chen Choon Seng has power to vote or direct the vote
    and power to dispose or to direct the disposition of all securities owned directly by Suria. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    solely on the Securities Purchase Agreement dated March 21, 2025 between the Company and Ho Jien Shiung, as filed within the Company&#8217;s
    Current Report on Form 8-K filed with the SEC on March 24, 2025 for the purchase of 250,000 shares of Series E Preferred Stock that
    are convertible into 27,500,000 shares of common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s Chief Executive Officer, Datuk Dr. Doris Wong Sing Ee is the Majority Stockholder referred to herein who controls
    the management and affairs of the Company, and currently can control matters requiring the approval by the Company&#8217;s stockholders,
    including the election of directors, any merger, consolidation or sale of all or substantially all of its assets, and any other significant
    corporate transaction.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>MANAGEMENT
AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
charter provides that our business is to be managed by or under the direction of our Board of Directors. Our Board of Directors is divided
into three classes for purposes of election. One class is elected at each annual meeting of stockholders to serve for a three-year term.
Our Board of Directors currently consists of three classes, as set forth below. We also have two directors who are elected by holders
of our Series E Preferred Stock (the &#8220;Preferred Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of February 26, 2025, the Board of Directors appointed Datuk Dr. Doris Wong Sing Ee, as Chief Executive Officer and, in such role,
she will serve as the Company&#8217;s principal executive officer. Datuk Dr. Doris Wong Sing Ee was also elected to the Board of Directors
as an Executive Director of the Company as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of February 26, 2025, the Board appointed Kiu Cu Seng, as Chief Financial Officer and, in such role, he will serve as the Company&#8217;s
principal financial office and as Executive Director and Secretary. The Company&#8217;s Board of Directors also appointed Mr. Kiu as
Executive Director and Secretary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of April 2, 2025, the following persons were elected by the holders of the Series E Preferred Stock to serve on the Board of Directors,
Dr. Satis Waran Nair Krishnan and Inigo Angel Laurduraj.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below are the names of the persons who are nominated as directors for election at the annual meeting as well as the directors whose
terms do not expire this year, their ages, their offices in the Company, if any, their principal occupations or employment for at least
the past five years, the length of their tenure as directors and the names of other public companies in which such persons hold or have
held directorships during the past five years. Additionally, information about the specific experience, qualifications, attributes or
skills that led to our Board of Directors&#8217; conclusion at the time of filing this proxy statement that each person listed below
should serve as a director is set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Executive Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kiu
    Cu Seng</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, Executive Director and Secretary</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kwang
    Fock Chong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Satis Waran Nair Krishnan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inigo
    Angel Laurduraj</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
Diversity Matrix (as of April 24, 2025)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
table provides information on the diversity of our current Board of Directors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; width: 60%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    Number of Directors</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Female
                                            </b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Male</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Part
    I: Gender Identity</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Directors</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Part
    II: Demographic Background</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">African
    American or Black</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Hispanic
    or Latinx</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Asian</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">White</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Datuk
Dr. Doris Wong. </i></b>Datuk Dr. Wong brings more than 20 years of management experience to her roles as Chief Executive Officer and
Executive Director of the Company across various industries ranging from oil and gas, property development, solar, engineering, advertising,
food and beverage, raw materials and more. She specializes in business development, strategic consultancy and corporate advisory in mergers
and acquisition and joint venture across Malaysia, Singapore, China, Japan, Thailand and Indonesia. Since October 2020, Datuk Dr. Wong
has been serving as an Executive Director of Metronic Global Bhd, an investment holding company, where she has been optimizing financial
operations, establishing business goals, advising the board of directors on organizational activities and executing special business
projects. She has also been involved in various investment opportunities in business diversification, generating new revenue and increasing
shareholders&#8217; wealth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
Dr. Wong has also been serving as the Executive Director of BSL Corporation Berhad (KLSE: BSLCORP) since May 2024, a public listed company
with its business segments constituting stamping and manufacturing of precision metal parts and fabrication of tools and dies, printed
circuit boards (PCB) assembly of all types of electronics and electrical components, devices and systems, fabrication and forging of
base metal components for consumer products. Datuk Dr. Wong served as an independent director and member of the audit committee and the
compensation committee of Energem Corp from its initial public offering on November 16, 2021 until her appointment as Executive Director
on January 27, 2023. Following Energem Corp&#8217;s completion of a series of transactions that resulted in its business combination
with Graphjet Technology Sdn. Bhd. (Nasdaq: GTI), a Malaysian private limited company (&#8220;Graphjet&#8221;) on March 14, 2024, Datuk
Dr. Doris Wong Sing Ee served as a director of Graphjet until January 6, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
February 2017, Datuk Dr. Wong has been a non-independent non-executive director at Trive Property Group Bhd (0118.KL). Previously, from
January 2019 to September 2020, Datuk Dr. Wong served as Chief Corporate Officer in Metronic Engineering Sdn. Bhd. (0043.KL) where she
oversaw HR operations, set objectives for the HR team and helped shape the brand strategy of the company. Datuk Dr. Wong served as General
Manager from 2015 to 2016 in Dai-Ichi Kikaku Sdn. Bhd. where she was overseeing and handling business development, client strategy and
direction, creative, production, media planning, procurement and research. From 2012 to 2015, Datuk Dr. Wong served as Strategic Business
Consultant for JLPW Law Firm where she handled mergers and acquisitions and joint venture deals internationally for various industries
and from 2002 to 2012, Datuk Dr. Wong started her career as a Managing Director at Niagamatic Sdn. Bhd., where she controlled all business
operations to give strategic guidance and directions to the board and staff to ensure the company achieved its financial vision, mission
and long-term goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kiu
Cu Seng.</i></b> Mr. Kiu brings significant accounting and audit experience involving publicly listed companies during his years working
with accounting standards. Mr. Kiu served as Energem Corp&#8217;s Chief Financial Officer from August 12, 2021 through its completion
of a series of transactions that resulted in its business combination with Graphjet on March 14, 2024. Since March 2021, Mr. Kiu has
served as Group Accountant for BCM Alliance Bhd, Sanichi Technology Bhd. and Trive Property Group Bhd. His responsibility is on group
consolidation issues. From June 2019 to February 2021, Mr. Kiu served as Manager in SBY &amp; Partners PLT (formerly known as Siew Boon
Yeong &amp; Associates) an established professional accounting organization providing a comprehensive range of services ranging from
audit and assurance, taxation and accounting where he specialized in auditing matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
June 2017 to February 2019, Mr. Kiu served as a Senior Auditor with Siew Boon Yeong &amp; Associates. Prior to that, from December 2016
to June 2017, Mr. Kiu served as a semi-senior auditor at the corporate compliance firm, Z. AMIN and he started his career in 2013 until
December 2016 with YTS &amp; Associate. Mr. Kiu graduated from Infrastructure University Kuala Lumpur in the year 2013 with a bachelor&#8217;s
degree (with Honors) in Accounting and from Kuala Lumpur Infrastructure University College with a Diploma in Accounting in 2009.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kwang
Fock Chong</i></b>. Mr. Chong is a Chartered Accountant in Malaysia, and brings nearly 20 years of working experience to the Company.
He served as an Independent Director, Chair of the Audit Committee and member of the Compensation Committee of Energem Corp since its
initial public offering on November 16, 2021 until its business combination with Graphjet on March 14, 2024. His experience includes
auditing of public listed companies, multinationals and private limited companies in various industries. Other than conducting statutory
audit in Malaysia, he also performed audit for companies based in China and the AIPAC region. He was also involved in Reporting Accountants&#8217;
engagement on initial public offering exercise, due diligence, reviewing financial forecast and projections.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Chong serves as Auditor and Partner of KHLC PLT where his main responsibility is reviewer and signing partner since October 2020. From
July 2014 to September 2020, Mr. Chong served as Auditor and Partner of SBY Partners PLT that provides audit and assurance services where
his main responsibilities were to serve as reviewing and signing partner. Mr. Chong received his Diploma in 2002 from Tunku Abdul Rahman
College in Financial Accounting and achieved his Association of Chartered Certified Accountants certification in 2005.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Satis Waran Nair Krishnan.</i></b> Dr. Krishnan is a Medical Doctor at Centric Health in Drogheda, County Louth, Ireland. Dr. Krishnan
is a highly experienced practitioner originally from Malaysia. Dr. Krishnan joined Centric Health in Ireland September 2023. Prior to
that, from 2010 to August 2023, Dr. Krishnan was a Doctor in the public health field for the Ministry of Health Malaysia, With a decade
of practice in Malaysia and training in Dermatology from the Association of Family Physicians of Malaysia (AFPM) and the Institute of
Dermatology in Bangkok, Thailand, Dr. Krishnan brings a wealth of expertise to our team. Dr. Nair is proficient in English, Russian and
Ukrainian, he is dedicated to providing patient-centered care and promoting overall well-being. Dr. Krishnan received his medical degree
in 2010 and a Professional Diploma of General Dermatology in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inigo
Angel Laurduraj.</i></b> Ms. Laurduraj brings extensive audit and accounting services to the Company over her 20 years in that industry.
Ms. Laurduraj served as a Senior Accounting Manager at IOI Oleochemicals Sdn. Bhd., an edible oil refining and oleochemicals company
for 11 years from 2007 through 2018. Prior to that, she served from 2005 through 2005 as an Auditor for Moore Stephens (now Moore Global),
a global firm operating in 114 countries specializing in accounting and finance services, audit and assurance, fund services, private
client services, corporate services, and tax services. Ms. Laurduraj earned an Association of Chartered Certified Accountants (ACCA)
in 2015 and a Bachelor of Arts in Accounting in 2014.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
Independence</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has reviewed the materiality of any relationship that each of our directors has with the Company, either directly
or indirectly. Based upon this review, our Board of Directors has determined that each of the following directors is an &#8220;independent
director&#8221; as such term is defined by rules of The Nasdaq Stock Market, Inc., or Nasdaq:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kwang
    Fock Chong, </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Satis Waran Nair Krishnan, and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inigo
    Angel Laurduraj</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">In
connection with Ms. Laurduraj and Dr. Krishnan&#8217;s appointment, as well as the Board of Directors appointment of Mr. Kwang Fock Chong
as independent director on February 26, 2025, on April 2, 2025, the Board of Directors also approved the following committee appointments
after a thorough review of all of the candidates&#8217; backgrounds, relevant experience and professional and personal reputations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Audit
    Committee </span>&#8212; Kwang Fock Chong (Chair); Inigo Angel Laurduraj; and Dr. Satis Waran Nair Krishnan</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Compensation
    and Organization Committee</span> &#8212; Inigo Angel Laurduraj (Chair); Kwang Fock Chong; and Dr. Satis Waran Nair Krishnan</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Nominating
    and Governance Committee</span> &#8212; Dr. Satis Waran Nair Krishnan (Chair), Kwang Fock Chong and Inigo Angel Laurduraj</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.4pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Board also determined that each of Kwang Fock Chong, Inigo Angel Laurduraj, and Dr. Satis Waran Nair Krishnan also satisfy the additional
requirements of financial literacy and audit committee independence for audit committee service under the applicable rules and regulations
of the SEC and the listing standards of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45.6pt; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Committees
of the Board of Directors and Meetings</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Meeting
Attendance</i>. During fiscal 2024, there were 31 meetings of our Board of Directors, and the Compensation and Organization Development
Committee, the Audit Committee, the Nominating and Corporate Governance Committee and the Science and Technology Committee met collectively
a total of 9 times. No director attended fewer than 80% of the total number of meetings of the Board of Directors or of the committees
of the Board of Directors on which they served during fiscal 2024. We have adopted a policy encouraging our directors to attend annual
meetings of stockholders. All of our then directors attended our annual stockholders&#8217; meeting held on June 21, 2024. Each of the
committees of the Board of Directors is described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Committee</i>. Our Audit Committee met 5 times during fiscal 2024. The Audit Committee during such period had four members: Karin L.
Walker (Chair), Dr. Christopher Henney, Dr. Samuel L. Barker and Dr. Robert J. Spiegel. Karin L. Walker was appointed as Chairman of
the Audit Committee on February 18, 2021. All members of the Audit Committee satisfy the current independence standards promulgated by
Nasdaq and the SEC, as such standards apply specifically to members of audit committees. The Board of Directors has determined that Karin
L. Walker is an &#8220;audit committee financial expert,&#8221; as the SEC has defined that term in Item 407 of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee&#8217;s role and responsibilities are set forth in the Audit Committee&#8217;s written charter and include the authority
to retain and terminate the services of our independent registered public accounting firm. In addition, the Audit Committee reviews annual
financial statements, considers matters relating to accounting policy and internal controls and reviews the scope of annual audits. For
additional information, please see the report of the Audit Committee set forth elsewhere in this proxy statement. A copy of the Audit
Committee&#8217;s written charter is publicly available on our website at <i>www.cyclacel.com</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
and Organization Development Committee</i>. Our Compensation and Organization Development Committee met once during fiscal 2024. The
Compensation and Organization Development Committee is composed entirely of directors who are not our current or former employees, all
of whom qualify as independent under the definition promulgated by Nasdaq and the SEC. The Compensation and Organization Development
Committee currently has three members: Dr. Samuel L. Barker (Chairman), Dr. Christopher S. Henney and Dr. Kenneth M. Ferguson. Our Compensation
and Organization Development Committee&#8217;s role and responsibilities are set forth in its written charter and include reviewing,
approving and making recommendations regarding our compensation policies, practices and procedures to ensure that legal and fiduciary
responsibilities of the Board of Directors are carried out and that such policies, practices and procedures contribute to our success.
The Compensation and Organization Development Committee also administers our 2020 Inducement Equity Incentive Plan, our 2018 Equity Incentive
Plan, our 2015 Equity Incentive Plan and our Amended and Restated 2006 Equity Incentive Plan, as amended. Our Compensation and Organization
Development Committee is responsible for the determination of the compensation of our chief executive officer, and shall conduct its
decision making process with respect to that issue without the chief executive officer present. A copy of the Compensation and Organization
Development Committee&#8217;s written charter is publicly available on our website at www.cyclacel.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nominating
and Corporate Governance Committee</i>. Our Nominating and Corporate Governance Committee met once during fiscal 2024. The Nominating
and Corporate Governance Committee consists of Dr. Christopher S. Henney (Chairman), Karin L. Walker and Dr. Robert J. Spiegel, all of
whom qualify as independent under the definition promulgated by Nasdaq and the SEC. Dr. Brian Schwartz resigned from the Nominating and
Corporate Governance Committee when appointed interim Chief Medical Officer on January 25, 2024. The functions of the Nominating and
Corporate Governance Committee are set forth in the Nominating and Corporate Governance Committee&#8217;s charter and include evaluating
and making recommendations to the full Board of Directors as to the size and composition of the Board of Directors and its committees,
evaluating and making recommendations as to potential candidates, and evaluating the performance of the Board of Directors. Generally,
our Nominating and Corporate Governance Committee considers candidates recommended by stockholders as well as from other sources such
as other directors or officers, third party search firms or other appropriate sources. Once identified, the Nominating and Corporate
Governance Committee will evaluate a candidate&#8217;s qualifications in accordance with its guiding principles as set forth in the Nominating
and Corporate Governance Committee&#8217;s written charter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Nominating Committee will consider issues of diversity among its members in identifying and considering nominees for director, and
strive where appropriate to achieve a diverse balance of backgrounds, perspectives, professional experience, age, gender, ethnicity and
country of citizenship on our board of directors and its committees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a stockholder wishes to nominate a candidate for director who is not to be included in our proxy statement, it must follow the procedures
described in our By-Laws and in &#8220;<i>Stockholder Proposals and Nominations for Director</i>&#8221; at the end of this proxy statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under our current corporate governance policies, the Nominating and Corporate Governance Committee may consider candidates
recommended by stockholders as well as from other sources, such as other directors or officers, third party search firms or other appropriate
sources. For all potential candidates, the Nominating and Corporate Governance Committee may consider all factors it deems relevant,
such as a candidate&#8217;s personal integrity and sound judgment, business and professional skills and experience, independence, knowledge
of the industry in which we operate, possible conflicts of interest, diversity, the extent to which the candidate would fill a present
need on the Board of Directors and concern for the long-term interests of the stockholders. In general, persons recommended by stockholders
will be considered on the same basis as candidates from other sources. A copy of the Nominating and Corporate Governance Committee&#8217;s
written charter is publicly available on our website at <i>www.cyclacel.com</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Science
and Technology Committee</i>. The Science and Technology Committee, which met twice during fiscal 2024, consists of Dr. Robert J. Spiegel
(Chairman), Dr. Samuel L. Barker, Dr. Kenneth M. Ferguson and Dr. Brian Schwartz.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
responsibilities of the Science and Technology Committee are set forth in the Science and Technology Committee&#8217;s charter and include
providing oversight on behalf of the Board of Directors of our overall strategic direction and investment in research and development
(&#8220;R&amp;D&#8221;) and technological and scientific initiatives. The Science and Technology Committee also assists the Board of
Directors and our management in evaluating the risks and potential commercial value of technical profiles regarding our R&amp;D programs
and technology, as they might impact our business performance, growth and competitive position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
Leadership Structure</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, Datuk Dr. Doris Wong serves as the Chairman of our Board of Directors, Chief Executive Officer and Executive Director. We recognize
that different board leadership structures may be appropriate for companies in different situations. We will continue to re-examine our
corporate governance policies and leadership structures on an ongoing basis to ensure that they continue to meet the Company&#8217;s
needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Role
in Risk Oversight</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is responsible for managing the risks that we face. The Board of Directors is responsible for overseeing management&#8217;s approach
to risk management that is designed to support the achievement of organizational objectives, including strategic objectives and risks
associated with our clinical trials, to improve long-term organizational performance and enhance stockholder value. The involvement of
the full Board of Directors in reviewing our strategic objectives and plans, including with respect to our clinical trials, is a key
part of the Board of Directors&#8217; assessment of management&#8217;s approach and tolerance to risk. A fundamental part of risk management
is not only understanding the risks a company faces and what steps management is taking to manage those risks, but also understanding
what level of risk is appropriate for us. In setting our business strategy, our Board of Directors assesses the various risks being mitigated
by management and determines what constitutes an appropriate level of risk for us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Board of Directors has ultimate oversight responsibility for overseeing management&#8217;s risk management process, various committees
of the Board of Directors assist it in fulfilling that responsibility. Notably, the Audit Committee assists the Board of Directors in
its oversight of risk management in the areas of financial reporting, internal controls and compliance with legal and regulatory requirements,
the Nominating and Corporate Governance Committee reviews legal and regulatory compliance risks and the Compensation and Organization
Development Committee assists the Board of Directors in its oversight of the evaluation and management of risks related to our compensation
policies and practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Policy
Prohibiting Hedging</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eecd--InsiderTrdPoliciesProcNotAdoptedTextBlock_c20240101__20241231_zffJEzcZbxci" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000013" name="ecd:InsiderTrdPoliciesProcNotAdoptedTextBlock">Our
<span id="xdx_90C_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbF_c20240101__20241231_zeFPqbmDt6I" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000014" name="ecd:InsiderTrdPoliciesProcAdoptedFlag">Insider</ix:nonNumeric></span> Trading Policy provides that no employee, officer or director may acquire, sell or trade in any interest or position relating
to the future price of Company securities, such as a put option, a call option or a short sale (including a short sale &#8220;against
the box&#8221;), or engage in hedging transactions (including &#8220;cashless collars&#8221;).</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder
Communications to the Board of Directors</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
stockholders who have questions or concerns should contact our Investor Relations department at (908) 517-7330 or e-mail at <i>ir@cyclacel.com</i>.
However, stockholders wishing to submit written communications directly to the Board of Directors should send their communications to
our Secretary, Kiu Cu Seng, Cyclacel Pharmaceuticals, Inc., Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia
59200. All stockholder communications will be considered by the independent members of our Board of Directors. Items that are unrelated
to the duties and responsibilities of the Board may be excluded, such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">junk
    mail and mass mailings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">resumes
    and other forms of job inquiries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">surveys;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">solicitations
    or advertisements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any material that is unduly hostile, threatening, or illegal in nature may be excluded, provided that any communication that
is filtered out will be made available to any independent director upon request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_005"></span>EXECUTIVE
AND DIRECTOR COMPENSATION</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary
Compensation Table</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the compensation paid or accrued during the last two fiscal years ended December 31, 2023 and 2024 to (1) our Chief
Executive Officer and Executive Director, (2) our Executive Vice President, Finance, Chief Financial Officer and Chief Operating Officer,
and (3) our former Senior Vice President and Chief Medical Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Salary <br/>($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bonus <br/>($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(1)</sup></b></span></p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All Other Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(2)</sup></b></span></p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total <br/>($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Spiro Rombotis, President and Chief Executive Officer</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">560,131</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">24,869</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">585,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">560,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,581</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">661,049</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul McBarron, Executive Vice President, Finance, Chief Financial Officer, Chief Operating Officer, Secretary<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">312,615</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,008</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333,623</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304,214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,398</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">352,615</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Kirschbaum, MD, Former Senior Vice President and Chief Medical Officer<sup>&#65279;(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,365</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,855</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">480,618</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    amounts represent the aggregate grant date fair value for option awards computed in accordance with FASB ASC Topic 718. A discussion
    of the assumptions used in determining grant date fair value may be found in our Financial Statements included in our Annual Report
    on Form 10-K for the year ended December 31, 2024. Options were granted during the year ended December 31, 2023 to Spiro Rombotis,
    Paul McBarron, and Mark Kirschbaum in the amounts of 7,333 shares, 4,680 shares, and 4,680 shares, respectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of the following for all executive officers: Payments for private medical and health insurance, life insurance and permanent health
    insurance; and matching contributions made under the Company&#8217;s U.S. 401(k) Plan and U.K. Group Personal Pension Plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    McBarron&#8217;s compensation was translated from British pound sterling to the U.S. dollar using the exchange rates of 1.27795 as
    of December 31, 2024 and 1.24361 as of December 31, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Kirschbaum was terminated as Chief Medical Officer on January 25, 2024.</span></td></tr>
  </table>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Narrative
Disclosure to Summary Compensation Table</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation and Organization Development Committee of our Board of Directors makes decisions regarding the compensation of our Chief
Executive Officer and Executive Director. The Compensation and Organization Development Committee is composed entirely of independent
directors and meets in executive sessions to discuss and formulate its recommendations for the Chief Executive Officer&#8217;s base salary
and bonus. The Compensation and Organization Development Committee does not rely solely on any predetermined formula or a limited set
of criteria in evaluating the Chief Executive Officer&#8217;s performance for the year but does consider the achievement of preset goals
as part of its deliberations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
evaluation is based on the Chief Executive Officer&#8217;s success in achieving his performance goals, which include financial, strategic
and leadership objectives. The Chief Executive Officer also provides the Compensation and Organization Development Committee with a self-review
of his performance as part of the Company&#8217;s review process. The Compensation and Organization Development Committee also approves
the annual compensation (including base salary, bonus, and stock-based compensation) for our other named executive officers based on:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    executive&#8217;s scope of responsibilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    informed market assessment of competitive practices for similar roles within peer group companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluations
    of performance for the year, as assessed by the Chief Executive Officer, supported by the Company&#8217;s performance review process
    and the executive&#8217;s self-assessment; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommendations
    by our Chief Executive Officer for each named executive officer with respect to base salary, cash bonus, and stock-based compensation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation and Organization Development Committee is authorized to engage and retain independent consultants and other experts to assist
in fulfilling its responsibilities, and the Committee engages periodically an external consultant to provide independent verification
of market position and ensure the appropriateness of executive compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the most recent year ended December 31, 2024, the Board of Directors and the Compensation and Organization Development Committee reviewed
the annual compensation for our executive officers and made no changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not grant stock options or restricted stock units to Spiro Rombotis and Paul McBarron during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Spiro
Rombotis, President and Chief Executive Officer.</i> On April 28, 2023, we entered into a two-year employment agreement with Mr. Spiro
Rombotis, effective January 1, 2023 and which terminated on January 6, 2025 coinciding with his resignation. Mr. Rombotis was paid an
annual base salary of $560,131 for the year ending December 31, 2024 and $560,131, for the year ending December 31, 2023, respectively.
In addition, Mr. Rombotis agreed to certain confidentiality and assignment of inventions obligations and will be subject to certain non-competition
obligations for a period of one year following termination of his employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Paul
McBarron Executive Vice President, Finance, Chief Financial Officer, Chief Operating Officer, Secretary.</i> On April 28, 2023, we entered
into a two-year employment agreement with Mr. McBarron, effective January 1, 2023 and which terminated on January 6, 2025 coinciding
with his resignation. Mr. McBarron was paid an annual base salary of &#163;244,622, or $312,615 for the year ending December 31, 2024
and &#163;244,622, or $304,214, for the year ending December 31, 2023, respectively. In addition, Mr. McBarron agreed to certain confidentiality
and assignment of inventions obligations and will be subject to certain non-competition obligations for a period of one year following
termination of his employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Mark
Kirschbaum, Former Senior Vice President and Chief Medical Officer</i>. On October 17, 2020, we entered into an employment agreement
with Dr. Mark Kirschbaum, effective October 23, 2020. We terminated Dr. Kirschbaum&#8217;s employment on January 25, 2024. Prior to his
termination, Dr. Kirschbaum&#8217; annual base salary was $396,760. Dr. Kirschbaum was paid an annual base salary of $30,365 for the
partial year ending December 31, 2024 and $396,760 for the year ending December 31, 2023. Dr. Kirschbaum also agreed to certain confidentiality
and assignment of inventions obligations and will be subject to certain non-competition obligations for a period of one year following
termination of his employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_006"></span>EQUITY
COMPENSATION PLAN INFORMATION</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
Equity Awards at 2024 Fiscal Year-End</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
following table shows grants of stock options outstanding on the last day of the fiscal year ended December 31, 2024, to each of the
executive officers named in the Summary Compensation Table in the section titled &#8220;EXECUTIVE AND DIRECTOR COMPENSATION&#8221; above.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Securities Underlying Options Exercisable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Securities Underlying Options Unexercisable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
                                            Exercise Price<sup>(1)</sup></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Option
    Expiration Date</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 30%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Spiro
    Rombotis</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">121</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,120.40</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/07/2025</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">104</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">522.00</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/29/2027</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">468.00</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">02/22/2028</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,693</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">213.00</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">01/04/2029</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,666</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">64.80</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/11/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,666</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(6)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51.75</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/13/2031</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(7)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,333</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.70</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">06/27/2033</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paul
    McBarron</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">72</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,120.40</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/07/2025</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">86</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">522.00</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/29/2027</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">79</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">468.00</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">02/22/2028</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">900</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">213.00</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">01/04/2029</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,999</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">64.80</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/11/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,666</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(6)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51.75</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/13/2031</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(7)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,680</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.70</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">06/27/2033</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    option exercise price is the closing price of our Common Stock on The Nasdaq Capital Market on the date the option was granted.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    options were granted on December 7, 2015, and vest ratably on a monthly basis over 36 months.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    performance criteria were deemed to have been met in 2018 and 2019, and as such, performance-based options granted in 2017 and 2018
    vested.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    options were granted on January 4, 2019 and included part of the 2018 bonus award, and vest ratably on a monthly basis over 36 months.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    options were granted on December 11, 2020, and vest ratably on a monthly basis over 36 months.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    options were granted on December 13, 2021, and vest ratably on a monthly basis over 36 months.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    options were granted on June 27, 2023, are performance based vesting, and will lapse May 7, 2025 due to performance criteria not
    being met.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
Payments Upon Termination or Change-in-Control</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into agreements that require us to make payments and/or provide benefits to certain of our executive officers in the event
of a termination of employment or change-in-control. Our 2006 Equity Incentive Plan, or 2006 Plan, our 2015 Equity Incentive Plan, or
2015 Plan, our 2018 Equity Incentive Plan, or 2018 Plan, and our 2020 Inducement Equity Incentive Plan, or 2020 Plan (and collectively
with the 2006 Plan, 2015 Plan, and 2018 Plan the &#8220;Plans&#8221;) provide for payments to named executive officers in connection
with a termination or a change-in-control of the Company. All of such agreements that require us to make payments and/or provide benefits
to certain of our executive officers in the event of a termination of employment or change-in-control have terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
Compensation</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the total compensation paid or accrued during the fiscal year ended December 31, 2024 to each of our non-employee
directors. Directors who are employed by us are not compensated for their service on our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Name</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Fees Earned or</p>
                                                                                                  <p style="text-align: center; margin-top: 0; margin-bottom: 0">Paid in Cash</p>
                                                                  <p style="text-align: center; margin-top: 0; margin-bottom: 0">($)</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>Option Awards</b></p>
                                                                  <p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(1)(2)</sup> &#160;&#160;&#160;</b></span></p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>Stock Awards</b></p>
                                                                  <p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(1)(3)</sup> &#160;</b></span></p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Total</p>
                                                                  <p style="text-align: center; margin-top: 0; margin-bottom: 0">($)</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%; text-align: left">Christopher S. Henney, Ph.D. D.Sc.</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">84,058</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">84,058</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Robert J. Spiegel, M.D.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">84,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">84,500</td><td style="text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Samuel L. Barker, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">85,058</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">85,058</td><td style="text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kenneth M. Ferguson, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">56,637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">56,637</td><td style="text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Brian Schwartz, M.D.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">49,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">28,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">99,904</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Karin L. Walker</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">64,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">64,000</td><td style="text-align: left"/></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    amounts represent the aggregate grant date fair value of options and restricted stock units granted to each director during the year
    ended December 31, 2024 computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant
    date fair value may be found in Note 11 to our financial statements included on our Form 10-K for the fiscal year ended December
    31, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fair value of the options granted on January 29, 2024 was $1.77 per share. A total of 12,500 stock options were granted during the
    year ended December 31, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fair value of RSUs granted on January 29, 2024 was $2.28 per share. A total of 12,500 restricted stock units were granted during
    the year ended December 31, 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
Compensation Program</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of our Director Compensation Program, the members of our Board of Directors for fiscal year 2025 are paid a fixed monthly fee,
payable on a monthly basis, on the first day of each month, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
    Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Non-Management Board Members</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
Compensation Plan Information</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides certain aggregate information with respect to all of our equity compensation plans in effect as of December
31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(a)</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">(b)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(c)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Securities</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">remaining</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">available
    for</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Securities
    to be</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">future
    issuance</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">issued
    upon</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">average</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">under
    equity</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">exercise
    of</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">exercise
    price</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">compensation</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">of
    outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">plans
    (excluding</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">options,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">options,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">securities</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">warrants
    and</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">warrants,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">reflected
    in</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Plan
    Category</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">rights</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">and
    rights</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">column
    (a))</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    equity compensation plans approved by security holders<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">339,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13.46</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">483,041</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
    Compensation Plans Not Approved By Security Holders<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,333</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of our 2018 Plan, our 2015 Plan, and our 2006 Plan. The Plans provide for the grant of incentive stock options, nonqualified stock
    options, stock appreciation rights, restricted stock, restricted stock units and performance units. There were no shares available
    for issuance, as of the date hereof, under the 2006 Plan or the 2015 Plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of our 2020 Plan. The 2020 Plan provides for the grant of nonqualified stock options, stock appreciation rights, restricted stock,
    restricted stock units and performance units.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>PAY
VERSUS PERFORMANCE TABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are providing the following information pursuant to the SEC pay versus performance disclosure requirements set forth in Item 402(v) of
SEC Regulation S-K (the &#8220;<b>Pay Versus Performance Rule</b>&#8221;), which requires disclosure of certain information about the
relationships between our performance and the compensation of our named executive officers. The following table reports, for the three
most-recent fiscal years, the compensation of our Chief Executive Officer and the average compensation of our other non-CEO named executive
officers (&#8220;<b>Non-CEO Named Executive Officers</b>&#8221;), as well as the &#8220;Compensation Actually Paid&#8221; as calculated
in accordance with the Pay Versus Performance Rule and certain performance measures required by the rule. The amounts reported as &#8220;Compensation
Actually Paid&#8221; do not reflect the actual amount of compensation earned by or paid to our Chief Executive Officer or our Non-CEO
Named Executive Officers and differ from the compensation amounts disclosed elsewhere in this proxy statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000016" name="ecd:PvpTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_882_eecd--PvpTableTextBlock_zJPt1OAR181g" summary="xdx: Disclosure - Pay vs Performance Disclosure" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_48C_eecd--PeoTotalCompAmt_zEgUwmHuaGpe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    Compensation Table Total for CEO<sup id="xdx_F51_zsVPO07nSCxe">(1)(2)</sup> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_489_eecd--PeoActuallyPaidCompAmt_zj6JkcwW7uol" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
    Actually Paid to CEO<sup id="xdx_F50_zpE70shQObnf">(1)(3)</sup></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_48B_eecd--NonPeoNeoAvgTotalCompAmt_zEO0q8JuNnhf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate
    Summary Compensation Table Total for Non-CEO Named Executive Officers<sup id="xdx_F50_zR7ojIh3jDGe">(1)(2)</sup> &#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_487_eecd--NonPeoNeoAvgCompActuallyPaidAmt_z2GyD0bH5WQ5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate
    Compensation Actually Paid to Non-CEO Named Executive Officers<sup id="xdx_F5E_z5O92NP8n0ug">(1)(3)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_483_eecd--TotalShareholderRtnAmt_pp2d_zJjHPzgGQRA7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value
    of initial fixed $100 investment based on total shareholder return (TSR)<sup id="xdx_F55_zQkRoOsms684">(4)</sup> &#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_488_eus-gaap--NetIncomeLoss_iN_pn3n3_di_zYgbgYvdMJM" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
    Loss (in thousands)<sup id="xdx_F50_zXBR1Ha20gt5">(5)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_41D_20240101__20241231_zPsDiEJ1CDJ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000017" format="ixt:numdotdecimal" decimals="0" unitRef="USD">585,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000018" format="ixt:numdotdecimal" decimals="0" unitRef="USD">547,706</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000019" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,988</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000020" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,889</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000021" format="ixt:numdotdecimal" decimals="2" unitRef="USD">0.64</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000022" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,212</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_411_20230101__20231231_zXMq8AvNxwu9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000023" format="ixt:numdotdecimal" decimals="0" unitRef="USD">661,049</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000024" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,807</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000025" format="ixt:numdotdecimal" decimals="0" unitRef="USD">833,233</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2023-01-012023-12-31" id="Fact000026" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,676</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2023-01-012023-12-31" id="Fact000027" format="ixt:numdotdecimal" decimals="2" unitRef="USD">4.58</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000028" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,555</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_41C_20220101__20221231_zSps6lkNEcra" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000029" format="ixt:numdotdecimal" decimals="0" unitRef="USD">763,551</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000030" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">77,717</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000031" format="ixt:numdotdecimal" decimals="0" unitRef="USD">918,518</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2022-01-012022-12-31" id="Fact000032" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">36,347</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2022-01-012022-12-31" id="Fact000033" format="ixt:numdotdecimal" decimals="2" unitRef="USD">17.15</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000034" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,198</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_z16BADbyUOE2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zJchKylvZ31e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000035" xml:lang="en-US">For
    each year shown, the CEO was Spiro Rombotis and the Non-CEO named executive officers (the &#8220;<b>NEO</b>s&#8221;) were Paul McBarron
    and Mark Kirschbaum, MD.</ix:footnote></span></td></tr>
</table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F00_zKETMHmtmClk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td id="xdx_F1C_zUMXzdnXM348" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="Footnote000036" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    in this column represent the &#8220;Total&#8221; column set forth in the Summary Compensation Table (&#8220;<b>SCT</b>&#8221;) in
    the &#8220;Executive and Director Compensation&#8221; section. See the footnotes to the SCT for further details regarding the amounts
    in these columns.</span></ix:footnote></td></tr>
</table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0D_zlonFLKpV6C6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_z3jQj3obgdD7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000037" xml:lang="en-US">The
    dollar amounts reported in these columns represent the amounts of &#8220;compensation actually paid.&#8221; The Amounts are computed
    in accordance with SEC rules by deducting and adding the following amounts from the &#8220;Total&#8221; column of the SCT (pursuant
    to SEC rules, fair value at each measurement date is computed in a manner consistent with the fair value methodology used to account
    for share-based payments in our financial statements under GAAP):</ix:footnote></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F00_zu1R6CCleY66" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F19_zLIGIeuh61J9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000038" xml:lang="en-US">Cumulative
    Total Shareholder Return (&#8220;<b>TSR</b>&#8221;) measures the cumulative value of $100 invested on the last trading day before
    the earliest fiscal year in the table, or December 31, 2021, including the reinvestment of dividends, through and including the end
    of the applicable fiscal year for which TSR is calculated, or December 31, 2022, December 31, 2023 and December 31, 2024. We did
    not pay dividends in the periods presented.</ix:footnote></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F06_zZ0WlcYVOWf8" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zPRiKIJCOeub" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000039" xml:lang="en-US">The
    dollar amounts reported represent the amount of net loss reflected in the Company&#8217;s audited financial statements for the applicable
    year.</ix:footnote></span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000041" name="ecd:NamedExecutiveOfficersFnTextBlock"><p id="xdx_890_eecd--NamedExecutiveOfficersFnTextBlock_dU_zPZm4oUoimXd" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    each year shown, the CEO was <span id="xdx_90E_eecd--PeoName_c20240101__20241231_zVr6SEV7L95d"><span id="xdx_90E_eecd--PeoName_c20230101__20231231_z6Nfdkdj3od1"><span id="xdx_901_eecd--PeoName_c20220101__20221231_z9mgvA6fsj32"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000042" name="ecd:PeoName"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact000043" name="ecd:PeoName"><ix:nonNumeric contextRef="From2022-01-012022-12-31" id="Fact000044" name="ecd:PeoName">Spiro Rombotis</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></span></span> and the Non-CEO named executive officers (the &#8220;<b>NEO</b>s&#8221;) were Paul McBarron
    and Mark Kirschbaum, MD.</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A4_zr7oICbE6ddd" style="display: none; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    in this column represent the &#8220;Total&#8221; column set forth in the Summary Compensation Table (&#8220;<b>SCT</b>&#8221;) in
    the &#8220;Executive and Director Compensation&#8221; section. See the footnotes to the SCT for further details regarding the amounts
    in these columns.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    dollar amounts reported in these columns represent the amounts of &#8220;compensation actually paid.&#8221; The Amounts are computed
    in accordance with SEC rules by deducting and adding the following amounts from the &#8220;Total&#8221; column of the SCT (pursuant
    to SEC rules, fair value at each measurement date is computed in a manner consistent with the fair value methodology used to account
    for share-based payments in our financial statements under GAAP):</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000046" name="ecd:EquityValuationAssumptionDifferenceFnTextBlock"><p id="xdx_894_eecd--EquityValuationAssumptionDifferenceFnTextBlock_dU_zfxnDlcNtmH7" style="display: none; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative
    Total Shareholder Return (&#8220;<b>TSR</b>&#8221;) measures the cumulative value of $100 invested on the last trading day before
    the earliest fiscal year in the table, or December 31, 2021, including the reinvestment of dividends, through and including the end
    of the applicable fiscal year for which TSR is calculated, or December 31, 2022, December 31, 2023 and December 31, 2024. We did
    not pay dividends in the periods presented.</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A3_zEpqFGbJgvRb" style="display: none; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    dollar amounts reported represent the amount of net loss reflected in the Company&#8217;s audited financial statements for the applicable
    year.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;&#160;</p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000048" name="ecd:AdjToPeoCompFnTextBlock"><p id="xdx_891_eecd--AdjToPeoCompFnTextBlock_dU_zBMjhFW4DbT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fiscal
    Year 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fiscal
    Year 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fiscal
    Year 2022&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NON-
    CEO NEO&#8217;s</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NON-
    CEO NEO&#8217;s</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NON-
    CEO NEO&#8217;s</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCT
    Total Compensation</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eecd--PeoTotalCompAmt_c20240101__20241231_zc0dwJoSZvea" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">585,000</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_zFXuUQC00M1e" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,988</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eecd--PeoTotalCompAmt_c20230101__20231231_zSBBBOkRw0lb" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">661,049</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_zXcbXM8h6Wzj" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">833,233</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eecd--PeoTotalCompAmt_c20220101__20221231_zrOqzcW4zrj2" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">763,551</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_ziCRRTAM7Oi" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">918,518</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subtract
    Reported SCT Stock Option Award Value ($)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zYOQ3Bio9JL1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_ReportedSCTStockOptionAwardValueMember" id="Fact000055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zzCahFB4mBrj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_ReportedSCTStockOptionAwardValueMember" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zQ9Do2Ux9OM2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_ReportedSCTStockOptionAwardValueMember" id="Fact000057" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">100,421</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zpZQw2OHbF7a" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_ReportedSCTStockOptionAwardValueMember" id="Fact000058" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">118,167</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_z9rdp09mnI3d" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_PeoMember_custom_ReportedSCTStockOptionAwardValueMember" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zThlN5bADQ6a" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_ReportedSCTStockOptionAwardValueMember" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add
    Year-end Fair Value of Unvested Awards Granted in the Applicable Fiscal Year ($)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_ztI6EcOqBu2c" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" id="Fact000061" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_zAGo71P6QmU8" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" id="Fact000062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_zp6pKuMCHrj9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,961</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_zhb5L77soGjk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" id="Fact000064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,051</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_z87U2qJRbbvd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_PeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" id="Fact000065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_ztbpLL5tEdq1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" id="Fact000066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add
    Change in Fair Value of Awards Granted in Prior Years Outstanding and Unvested as of the Applicable Fiscal Year End ($)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_z8hWRNNhV1mj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" id="Fact000067" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,986</ix:nonFraction></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_zB4OtY9dkfcd" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" id="Fact000068" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,042</ix:nonFraction><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_zgEOBUlogWVa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" id="Fact000069" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">164,307</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_zKow5dJEzFK" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" id="Fact000070" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">172,971</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_z7hefwmNlp86" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" id="Fact000071" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">494,733</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_zhqHaVdVfqIc" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" id="Fact000072" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">545,667</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add
    Change in Fair Value of Awards Granted in Prior Years that Vested during the Applicable Year as of the Vesting Date</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: right"><p id="xdx_98A_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_zs3fZW3UWtxf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" id="Fact000073" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,986</ix:nonFraction></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_z55wJ025rOB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" id="Fact000074" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,042</ix:nonFraction></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_zGkh7RQE1DW1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" id="Fact000075" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">352,475</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_zeXn5GKAMRSi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" id="Fact000076" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">395,470</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_z9nY85d5wdS4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" id="Fact000077" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">346,535</ix:nonFraction>)
                                            </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_zDhTwMKp9eHe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" id="Fact000078" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">409,198</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Compensation Actually Paid </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><p id="xdx_989_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_zbD00DjU6oai" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">547,706</ix:nonFraction></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><p id="xdx_982_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_zTDsoWutOJE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,889</ix:nonFraction></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_zcRpHEf1z6i3" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,807</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_zamBkiHKc9X5" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2023-01-012023-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,676</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_zfKILg7y8fC9" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">77,717</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_zXDddc62Sypa" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2022-01-012022-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">36,347</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A7_zliOpXugedb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000086" name="ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock"><p id="xdx_893_eecd--CompActuallyPaidVsTotalShareholderRtnTextBlock_dU_zzGs4pfMW9s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Relationship Between PEO and Non-PEO NEO Compensation
Actually Paid and Company Total Shareholder Return (&#8220;TSR&#8221;)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify">The following chart sets forth
the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and the
Company&#8217;s cumulative TSR over the three most recently completed fiscal years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="formdef14a_001.jpg" alt=""/>&#160;</span></p>

</ix:nonNumeric><p id="xdx_8AC_zkAIUWRE4PKk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000088" name="ecd:CompActuallyPaidVsNetIncomeTextBlock"><p id="xdx_89C_eecd--CompActuallyPaidVsNetIncomeTextBlock_dU_zoAUkXGtd4q9" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Relationship Between PEO and Non-PEO NEO Compensation Actually
Paid and Net Income (Loss)</i></b><b><i> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following chart sets forth the relationship
between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Net Income (Loss)
during the three most recently completed fiscal years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="formdef14a_002.jpg" alt=""/></span></p>

</ix:nonNumeric><p id="xdx_8AB_zEKhBsfQJQlk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_008"></span>REPORT
OF AUDIT COMMITTEE</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee of the Board of Directors, which consists entirely of directors who meet the independence and experience requirements
of The Nasdaq Capital Market, has furnished the following report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee assists the Board of Directors in overseeing and monitoring the integrity of our financial reporting process, compliance
with legal and regulatory requirements and the quality of internal and external audit processes. The Audit Committee&#8217;s role and
responsibilities are set forth in our charter adopted by the Board of Directors. The Audit Committee reviews and reassesses our charter
annually and recommends any changes to the Board of Directors for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
fiscal 2024, the Audit Committee met with management to consider the adequacy of the Company&#8217;s internal controls and the objectivity
of its financial reporting. The Audit Committee discussed these matters with the Company&#8217;s independent registered public accounting
firm and with appropriate Company financial personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee is responsible for overseeing our overall financial reporting process, and for the appointment, retention, and oversight
of the work of Bush &amp; Associates CPA LLC (&#8220;<b>Bush &amp; Associates</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee reviewed and discussed the audited financial statements for the fiscal year ended December 31, 2024 with management and
Bush &amp; Associates, our independent registered public accounting firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee discussed with Bush &amp; Associates the matters required to be discussed in accordance with <i>Auditing Standard No.
18 &#8212; Communications with Audit Committees</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee received written disclosures and the letter from Bush &amp; Associates regarding its independence as required by applicable
requirements of the Public Company Accounting Oversight Board regarding Bush &amp; Associates&#8217; communications with the Audit Committee
and the Audit Committee further discussed with Bush &amp; Associates their independence. The Audit Committee also considered the status
of pending litigation, taxation matters and other areas of oversight relating to the financial reporting and audit process that the Audit
Committee determined appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the Audit Committee&#8217;s review of the audited consolidated financial statements and discussions with management and Bush &amp;
Associates, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2024 for filing with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024
Members of the Audit Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Karin
    L. Walker (Chair) </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Samuel L. Barker</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Christopher S. Henney </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Robert J. Spiegel</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_009"></span>CERTAIN
RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee reviews and approves in advance all related-party transactions. Except as described below, there have been no transactions
during our last two fiscal years with our directors and officers and beneficial owners of more than 5% of our voting securities and their
affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_010"></span>PROPOSALS
TO BE VOTED UPON BY HOLDERS OF COMMON STOCK</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_011"></span>PROPOSAL
1:</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ELECTION
OF DIRECTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Background</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, as amended, the number of directors is fixed from
time to time by the Board of Directors. We have a staggered Board of Directors comprised of three classes, and each director serves until
the annual meeting in which his or her term expires. The Board of Directors has nominated each of the following five director nominees
until their respective successors have been elected and qualified:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong is a Class 3 director and, if re-elected, would serve until our 2028 annual meeting,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kiu
    Cu Seng is a Class 2 director and, if re-elected, would serve until our 2027 annual meeting,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kwang
    Fock Chong is a Class 2 director and, if re-elected, would serve until our 2027 annual meeting,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Satis Waran Nair Krishnan is a Class 1 director and, if re-elected, would serve until our 2026 annual meeting, and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inigo
    Angel Laurduraj is a Class 1 director and, if re-elected, would serve until our 2026 annual meeting.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
authority to vote for either of these nominees is withheld, proxies solicited by the Board of Directors will be voted FOR the re-election
as director of each of Datuk Dr. Doris Wong, Kiu Cu Seng, Kwang Fock Chong, Dr. Satis Waran Nair Krishnan, and Inigo Angel Laurduraj.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that either nominee shall become unable or unwilling to serve, proxies solicited by the Board of Directors will be voted for
the election of such other person as the Board of Directors may recommend in his place. The Board of Directors has no reason to believe
that either nominee will be unable or unwilling to serve.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Required
Vote</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
plurality of the votes cast at the annual meeting by the holders of our Common Stock is required to elect the nominees as director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recommendation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
BOARD OF DIRECTORS RECOMMENDS THE RE-ELECTION BY HOLDERS OF COMMON STOCK OF EACH OF DATUK DR. DORIS WONG, KIU CU SENG, KWANG FOCK CHONG,
DR. SATIS WARAN NAIR KRISHNAN, AND INIGO ANGEL LAURDURAJ, AS DIRECTORS, AND PROXIES SOLICITED BY THE BOARD OF DIRECTORS WILL BE VOTED
IN FAVOR THEREOF UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_012"></span>PROPOSAL
2:</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMENDMENT
TO 2018 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMMON
STOCK AVAILABLE FOR THE GRANT OF AWARDS BY 4,281,987 SHARES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are requesting that you vote to approve an amendment to the Cyclacel Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the &#8220;2018
Plan&#8221;). On April 22, 2025, the Board of Directors adopted a resolution approving, subject to approval by our stockholders, an amendment
of the 2018 Equity Incentive Plan to increase the number of shares of Common Stock available for grant under the 2018 Plan by adding
4,281,987 shares. The 2018 Plan was previously approved by our stockholders at the 2018 annual meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 22, 2025, the equity overhang, represented by all outstanding awards plus those available for future grant under the 2018 Plan,
was 0.2%. The equity overhang from all outstanding awards and shares available for issuance would be 1.3%, assuming approval of this
Proposal. Equity overhang was calculated in each instance above as all shares issuable upon exercise of outstanding options plus shares
available for future grant divided by (a) common shares outstanding plus (b) shares in the numerator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
Considerations for Requesting Additional Shares</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the number of shares to be authorized under the 2018 Plan, as proposed to be amended, the Board considered the following
principal factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Number
    of Shares Available for Grant under Existing Plan</span>: As of the record date, 483,041 shares remained available for
    issuance under the 2018 Plan. Except for 13,333 shares that remained available under our 2020 Inducement Equity Incentive Plan, there
    were no shares available to grant under prior incentive plans.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Number
    of Outstanding Awards Under All Plans</span>: As of the record date, there were 339,000 outstanding stock options, which
    had a weighted average exercise price of $13.46 and a weighted average remaining contractual life of 7.82 years, and
    there were 32,666 RSU awards outstanding.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors, the Compensation Development Committee and management all believe that the proposed amendment of the 2018 Plan is
in the best interests of, and will provide long-term advantages to, us and our stockholders and recommends approval by our stockholders.
The Board of Directors believes that the number of shares of common stock currently available for issuance under the 2018 Plan is insufficient
in view of our compensation structure and strategy. The Board of Directors has concluded that our ability to attract, retain and motivate
top quality employees is material to our success and would be enhanced by our continued ability to make grants under the 2018 Plan. The
Board of Directors has directed that the proposal to approve the amendment of the 2018 Plan be submitted to the stockholders for approval
at the 2025 Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a brief summary of the 2018 Plan, as amended by this Proposal, and is qualified in all respects by the specific language
of the full text of the amended and restated 2018 Plan, a copy of which is attached as Appendix A to the Proxy Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
Features of the 2018 Plan</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eligibility</i>.
The 2018 Plan allows us, under the direction of our Compensation and Organization Development Committee, to make grants of stock options,
restricted and unrestricted stock awards and other stock-based awards to employees, consultants and directors who, in the opinion of
the Compensation and Organization Development Committee, are in a position to make a significant contribution to our long-term success.
The purpose of these awards is to attract and retain key individuals, further align employee and stockholder interests, and to closely
link compensation with Company performance. The 2018 Plan provides an essential component of the total compensation package, reflecting
the importance that we place on aligning the interests of key individuals with those of our stockholders. All employees, directors and
consultants of the Company and its affiliates are eligible to participate in the 2018 Plan. As of the record date, there were
approximately 15 individuals eligible to participate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shares
Available for Issuance</i>. As of the record date 451,802 shares of our common stock were available for future awards under the
2018 Plan. In addition, if any awards granted under the 2018 Plan lapse or are canceled, the shares subject to those awards will again
become available for awards under the 2018 Plan. As of the record date, 362,240 shares were subject to outstanding awards under
the 2018 Plan. Generally, shares of common stock reserved for awards under the 2018 Plan that lapse or are canceled will be added back
to the share reserve available for future awards. However, shares of common stock tendered in payment for an award or shares of common
stock withheld for taxes will not be available again for grant. The 2018 Plan provides that no non-employee director participant may
receive awards for more than an aggregate grant date fair value of $100,000 in any fiscal year. If our stockholders approve this proposal,
an additional 4,281,987 shares of our common stock would be available for future awards under the 2018 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i>. Stock options granted under the 2018 Plan may either be incentive stock options, which are intended to satisfy the requirements
of Section 422 of the Internal Revenue Code of 1986, as amended, or the Code, or non-qualified stock options, which are not intended
to meet those requirements. Incentive Stock Options may be granted to employees of the Company and its affiliates. Non-qualified options
may be granted to employees, directors and consultants of the Company and its affiliates. The exercise price of a stock option may not
be less than 100% of the fair market value of our common stock on the date of grant. If an incentive stock option is granted to an individual
who owns more than 10% of the combined voting power of all classes of our capital stock, the exercise price may not be less than 110%
of the fair market value of our common stock on the date of grant and the term of the incentive stock option may not be longer than five
years. Non-qualified options may not have a term longer than ten years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Award
agreements for stock options include rules for the exercise of the stock options after termination of service. Options may not be exercised
unless they are vested, and no option may be exercised after the end of the term set forth in the award agreement. Generally, stock options
will be exercisable for three months after termination of service for any reason other than death or total and permanent disability,
and for 12 months after termination of service on account of death or total and permanent disability but will not be exercisable if the
termination of service was due to cause.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock</i>. Restricted stock is common stock that is subject to restrictions, including a prohibition against transfer and a substantial
risk of forfeiture, until the end of a &#8220;restricted period&#8221; during which the grantee must satisfy certain vesting conditions.
If the grantee does not satisfy the vesting conditions by the end of the restricted period, the restricted stock is forfeited. During
the restricted period, the holder of restricted stock has the rights and privileges of a regular stockholder, except that the restrictions
set forth in the applicable award agreement apply. For example, the holder of the restricted stock may vote and receive dividends on
the restricted shares; but he or she may not sell the shares until the restrictions are lifted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i>. Restricted stock units are phantom shares that vest in accordance with terms and conditions established by the Board
of Directors or the Compensation and Organization Development Committee and when the applicable restrictions lapse, the grantee shall
be entitled to receive a payout in cash, shares or a combination thereof based on the number of restricted stock units, as specified
in the award agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Stock-Based Awards</i>. The 2018 Plan also authorizes the grant of other types of stock-based compensation including, but not limited
to phantom stock awards, stock appreciation rights and stock unit awards. Our Compensation and Organization Development Committee may
award such stock-based awards subject to such conditions and restrictions as it may determine however each stock appreciation right shall
have an exercise price which shall not be less than the fair market value of our common stock on the date of grant and shall terminate
no more than ten years from the date of grant. These conditions and restrictions may include continued employment with us through a specified
restricted period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Plan
Administration</i>. In accordance with the terms of the 2018 Plan, our Board of Directors has authorized our Compensation and Organization
Development Committee to administer the 2018 Plan. The Compensation and Organization Development Committee may delegate part of its authority
and powers under the 2018 Plan to one or more of our directors and/or officers, but only the Compensation and Organization Development
Committee can make awards to participants who are directors or executive officers of the Company. In accordance with the provisions of
the 2018 Plan, our Compensation and Organization Development Committee determines the terms of awards, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employees,
    directors and consultants will be granted awards;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of shares subject to each award;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    vesting provisions of each award;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    termination or cancellation provisions applicable to awards; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    other terms and conditions upon which each award may be granted in accordance with the 2018 Plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our Compensation and Organization Development Committee may, in its discretion, amend any term or condition of an outstanding
award provided (i) such term or condition as amended is permitted by the 2018 Plan, and (ii) any such amendment shall be made only with
the consent of the participant to whom such award was made, if the amendment is adverse to the participant; and provided, further, that,
without the prior approval of our stockholders, options will not be repriced, replaced or regranted through cancellation or by lowering
the exercise price of a previously granted award and will not be exchanged for another type of award or cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Dividends and Stock Splits</i>. If our common stock shall be subdivided or combined into a greater or smaller number of shares or if
we issue any shares of common stock as a stock dividend, the number of shares of our common stock deliverable upon exercise of an option
or upon vesting of an award shall be appropriately increased or decreased proportionately, and appropriate adjustments shall be made
in the purchase price per share to reflect such subdivision, combination or stock dividend.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
Transactions</i>. Upon a merger or other reorganization event, our Board of Directors, may, in its sole discretion, take any one or more
of the following actions pursuant to the 2018 Plan, as to some or all outstanding awards:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that all outstanding options shall be assumed or substituted by the successor corporation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    written notice to a participant provide that the participant&#8217;s unexercised options will terminate immediately prior to the
    consummation of such transaction unless exercised by the participant;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the event of a merger pursuant to which holders of our common stock will receive a cash payment for each share surrendered in the
    merger, make or provide for a cash payment to the participants equal to the difference between the merger price times the number
    of shares of our common stock subject to such outstanding options, and the aggregate exercise price of all such outstanding options,
    in exchange for the termination of such options;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that outstanding awards shall be assumed or substituted by the successor corporation, become realizable or deliverable, or restrictions
    applicable to an award will lapse, in whole or in part, prior to or upon the merger or reorganization event; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    respect to stock grants and in lieu of any of the foregoing, the Board of Directors or an authorized committee may provide that,
    upon consummation of the transaction, each outstanding stock grant shall be terminated in exchange for payment of an amount equal
    to the consideration payable upon consummation of such transaction to a holder of the number of shares of common stock comprising
    such award (to the extent such stock grant is no longer subject to any forfeiture or repurchase rights then in effect or, at the
    discretion of the Board of Directors or an authorized committee, all forfeiture and repurchase rights being waived upon such transaction).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
in the event that the successor corporation refuses to assume or substitute an award:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">awards
    consisting of options, SARs and rights to purchase restricted stock will become fully vested and immediately exercisable, including
    awards that would not otherwise have become vested or exercisable; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    other awards will become fully earned and eligible to receive a payout.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment
and Termination</i>. The 2018 Plan may be amended by our stockholders. It may also be amended by our Board of Directors, provided that
any amendment approved by our Board of Directors, which is of a scope that requires stockholder approval as required by the rules of
The Nasdaq Stock Market, in order to ensure favorable federal income tax treatment for any incentive stock options under Code Section
422, or for any other reason is subject to obtaining such stockholder approval. However, no such action may adversely affect any rights
under any outstanding award without the holder&#8217;s consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Duration
of Plan</i>. The 2018 Plan will expire, by its terms, on March 29, 2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
Income Tax Considerations</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material federal income tax consequences of the issuance and exercise of stock options and other awards under the 2018 Plan, based on
the current provisions of the Code and regulations, are as follows. Changes to these laws could alter the tax consequences described
below. This summary assumes that all awards granted under the 2018 Plan are exempt from or comply with, the rules under Section 409A
of the Code related to nonqualified deferred compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incentive
    Stock Option:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
    stock options are intended to qualify for treatment under Section 422 of the Code. An incentive stock option does not result in taxable
    income to the optionee or deduction to us at the time it is granted or exercised, provided that no disposition is made by the optionee
    of the shares acquired pursuant to the option within two years after the date of grant of the option nor within one year after the
    date of issuance of shares to the optionee (referred to as the &#8220;ISO holding period&#8221;). However, the difference between
    the fair market value of the shares on the date of exercise and the option price will be an item of tax preference includible in
    &#8220;alternative minimum taxable income&#8221; of the optionee. Upon disposition of the shares after the expiration of the ISO
    holding period, the optionee will generally recognize long term capital gain or loss based on the difference between the disposition
    proceeds and the option price paid for the shares. If the shares are disposed of, prior to the expiration of the ISO holding period,
    the optionee generally will recognize taxable compensation, and we will have a corresponding deduction, in the year of the disposition,
    equal to the excess of the fair market value of the shares on the date of exercise of the option over the option price. Any additional
    gain realized on the disposition will normally constitute capital gain. If the amount realized upon such a disqualifying disposition
    is less than the fair market value of the shares on the date of exercise, the amount of compensation income will be limited to the
    excess of the amount realized over the optionee&#8217;s adjusted basis in the shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Qualified
    Options:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    otherwise qualifying as incentive stock options, to the extent the aggregate fair market value of shares with respect to which such
    options are first exercisable by an individual in any calendar year exceeds $100,000, and options designated as non-qualified options
    will be treated as options that are not incentive stock options. A non-qualified option ordinarily will not result in income to the
    optionee or deduction to us at the time of grant. The optionee will recognize compensation income at the time of exercise of such
    non-qualified option in an amount equal to the excess of the value of the shares over the option price per share. Such compensation
    income of optionees may be subject to withholding taxes, and a deduction may then be allowable to us in an amount equal to the optionee&#8217;s
    compensation income.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    optionee&#8217;s initial basis in shares, so acquired, will be the amount paid on exercise of the non-qualified option plus the amount
    of any corresponding compensation income. Any gain or loss as a result of a subsequent disposition of the shares, so acquired, will
    be capital gain or loss.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
    Grants:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    respect to stock grants under the 2018 Plan that result in the issuance of shares that are either not restricted as to transferability
    or not subject to a substantial risk of forfeiture, the grantee must generally recognize ordinary income equal to the fair market
    value of shares received. We generally will be entitled to a deduction in an amount equal to the ordinary income recognized by the
    grantee.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    respect to stock grants involving the issuance of shares that are restricted as to transferability and subject to a substantial risk
    of forfeiture, the grantee must generally recognize ordinary income equal to the fair market value of the shares received at the
    first time the shares become transferable or are not subject to a substantial risk of forfeiture, whichever occurs earlier. A grantee
    may elect to be taxed at the time of receipt of shares rather than upon lapses of restrictions on transferability or substantial
    risk of forfeiture, but if the grantee subsequently forfeits such shares, the grantee would not be entitled to any tax deduction,
    including as a capital loss, for the value of the shares on which he previously paid tax. If such an election is desired, the grantee
    must file such an election with the Internal Revenue Service within 30 days of the receipt of the shares. We generally will be entitled
    to a deduction in an amount equal to the ordinary income recognized by the grantee.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
    Units:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    grantee recognizes no income until the issuance of the shares. At that time, the grantee must generally recognize ordinary income
    equal to the fair market value of the shares received. We generally will be entitled to a deduction in an amount equal to the ordinary
    income recognized by the grantee.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan
Benefits</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the adoption of the 2018 Plan through the record date, we have granted the following stock options and restricted stock units
under the 2018 Plan to the individuals and groups listed below. In all cases, the securities underlying such equity awards were shares
of our common stock. Since the adoption of the 2018 Plan through the record date, we have granted the following stock options
and restricted stock units under the 2018 Plan to the individuals and groups listed below. In all cases, the securities underlying such
equity awards were shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; width: 80%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Name
    and Position</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; width: 16%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of Shares</b></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Named
    Executive Officers:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Datuk
    Dr. Doris Wong</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Kiu
    Cu Seng</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">All
    current executive officers as a group</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">All
    current directors who are not executive officers as a group</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Each
    nominee for election as a director:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Datuk
    Dr. Doris Wong</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Kiu
    Cu Seng</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Inigo
    Angel Laurduraj</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Kwang
    Fock Chong</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dr.
    Satis Waran Nair Krishnan</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Each
    associate of any executive officers, current directors or director nominees</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Each
    other person who received or is to receive 5% of awards:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">All
    employees, including all current officers who are not executive officers, as a group</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
Plan Benefits</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than the annual grant of stock options or restricted stock units, or any initial grant of restricted stock units to our non-employee
directors, the amounts of future grants under the 2018 Plan are not determinable as awards under the 2018 Plan and will be granted at
the sole discretion of the Compensation and Organization Development Committee, or other delegated persons and we cannot determine at
this time either the persons who will receive awards under the 2018 Plan or the amount or types of any such awards. On April 23,
2025, the closing market price per share of our common stock was $0.22, as reported by the Nasdaq Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Required
Vote</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors has recommended adopting the amendment to the 2018 Plan. The affirmative vote of a majority of the votes cast at the
annual meeting is required to approve the amendment to the 2018 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recommendation</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
BOARD OF DIRECTORS RECOMMENDS APPROVAL OF THE AMENDMENT TO THE 2018 PLAN. PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR OF THE
AMENDMENT UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_013"></span>PROPOSAL
3:</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADVISORY
VOTE ON APPROVAL OF EXECUTIVE COMPENSATION AS DISCLOSED IN THIS PROXY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STATEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Dodd-Frank Wall Street Reform and Consumer Protection of 2010 (the &#8220;<b>Dodd-Frank Act</b>&#8221;) enables our stockholders to vote
to approve on an advisory and non-binding basis, the compensation of our named executive officers as described in the Executive Officer
and Director Compensation section of this proxy statement, the compensation tables and related material contained in this proxy statement.
This &#8220;say-on-pay&#8221; proposal gives our stockholders the opportunity to express their views on our overall compensation decisions
and policies. The Dodd-Frank Act also requires an advisory vote on executive compensation at least once every three years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
are urged to read the Executive and Director Compensation section of this proxy statement, which discusses how our compensation policies
and procedures implement our compensation philosophy. The Compensation and Organization Development Committee and the Board of Directors
believe that these policies and procedures are effective in implementing our compensation philosophy and in achieving its goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
more fully described in the Executive and Director Compensation section of this proxy statement, existing employment contracts provide
for the bulk of the compensation of our executives. A significant portion, however, is discretionary and determined by the Compensation
and Organization Development Committee on an annual basis. Historically (but subject to change in the future), much of the additional
or bonus compensation and equity awards have been based on specific numeric and weighted criteria for these officers. On an annual basis,
the Committee reviews and approves the objectives for each officer&#8217;s goals and the following year analyzes to what extent the objectives
have been achieved. The Committee then determines the resulting additional compensation and equity grants. In so doing, the Committee
considers the interest of the stockholders, current market practices, the clinical goals of the Company, the need to motivate its officers,
and other criteria. The Committee has also considered the extensive experience of our executives in the biotech industry as well as their
related and relevant activities prior to their entry into the biotech industry. These considerations inform the Committee&#8217;s assessment
of the type of compensation program and incentives that are appropriate and necessary to attract, motivate and retain the named executives
who are crucial to the Company&#8217;s long-term success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
your vote is advisory, it will not be binding on our Compensation and Organization Development Committee or our Board of Directors, nor
will it directly affect or otherwise limit any compensation or award arrangements that have already been granted to any of the named
executive officers. However, the Compensation and Organization Development Committee and the Board will review the voting results and
take them into consideration when making future decisions regarding executive compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the rules adopted by the SEC, the following resolution, commonly known as a &#8220;say- on-pay&#8221; vote, is being
submitted for a stockholder vote at the 2025 Annual Meeting:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;RESOLVED,
that the compensation paid to the named executive officers of Cyclacel Pharmaceuticals, Inc., as disclosed pursuant to the compensation
disclosure rules of the Securities and Exchange Commission, including the Executive Officer and Director Compensation section of the
proxy statement for the 2025 Annual Meeting, the compensation tables and the related material disclosed in the proxy statement, is hereby
APPROVED.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Required
Vote</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
affirmative vote of a majority of the votes cast at the annual meeting is required to approve, on an advisory basis, this resolution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recommendation</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
BOARD OF DIRECTORS RECOMMENDS A VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AND PROXIES SOLICITED BY THE BOARD
WILL BE VOTED IN FAVOR OF SUCH APPROVAL UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_014"></span>CODE
OF BUSINESS CONDUCT AND ETHICS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a Code of Business Conduct and Ethics that applies to all of our officers, directors, and employees, including our principal
executive officer, principal financial officer, principal accounting officer, and controller, or persons performing similar functions,
which is posted on our website. Our Code of Business Conduct and Ethics is a &#8220;code of ethics,&#8221; as defined in Item 406(b)
of Regulation S-K. We will make any legally required disclosures regarding amendments to, or waivers of, provisions of our Code of Business
Conduct and Ethics on our website where our Code of Business Conduct and Ethics can be found at: e8e96faf-768b-4ba4-974a-826aba6bb9e3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to being posted on Cyclacel&#8217;s website, the text of the Code of Business Conduct and Ethics will be made available to stockholders
without charge, upon request, in writing to the Corporate Secretary at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur,
Malaysia 59200, Attention: Kiu Cu Seng, Chief Financial Officer, Executive Director and Secretary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
regarding any amendments to, or waivers from, provisions of the code of conduct and ethics that apply to our directors, principal executive
and financial officers will be included in a Current Report on Form 8-K within four business days following the date of the amendment
or waiver, unless website posting of such amendments or waivers is then permitted by the rules of The Nasdaq Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_015"></span>OTHER
MATTERS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors knows of no other business which will be presented to the annual meeting. If any other business is properly brought
before the annual meeting, proxies will be voted in accordance with the judgment of the persons voting the proxies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_016"></span>STOCKHOLDER
PROPOSALS AND NOMINATIONS FOR DIRECTOR</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be considered for inclusion in the proxy statement relating to our 2025 Annual Meeting of Stockholders, we must receive stockholder proposals
(other than for director nominations) by no later than December 15, 2024. To be considered for presentation at the 2025 Annual Meeting
of Stockholders, although not included in the proxy statement, proposals (including director nominations) must be received no earlier
than February 13, 2025 and no later than March 15, 2025. In addition to satisfying the foregoing advance notice requirements, to comply
with the universal proxy rules under the Exchange Act, stockholders who intend to solicit proxies in support of director nominees other
than the Company&#8217;s nominees must follow the requirements set forth in Rule 14a-19 as promulgated under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposals
that are not received in a timely manner will not be presented or voted on at the 2025 Annual Meeting of Stockholders. If a proposal
is received on time, the proxies that management solicits for the meeting may still exercise discretionary voting authority on the proposal
under circumstances consistent with the proxy rules of the SEC. All stockholder proposals should be marked for the attention of Secretary,
Cyclacel Pharmaceuticals, Inc., Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 59200.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as amended (other than exhibits thereto), filed with the SEC,
which provides additional information about us, is available on the Internet at www.cyclacel.com and is available in paper form to beneficial
owners of our stock without charge upon written request to Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia
59200, Attention: Kiu Cu Seng, Chief Financial Officer, Executive Director and Secretary.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_017"></span>Appendix
A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2018
EQUITY INCENTIVE PLAN, AS AMENDED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
June 30, 2025</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
DEFINITIONS.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise specified or unless the context otherwise requires, the following terms, as used in this Cyclacel Pharmaceuticals, Inc. 2018
Equity Incentive Plan, have the following meanings:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Administrator&#8221;
means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the Administrator means
the Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Affiliate&#8221;
means a corporation, which, for purposes of Section 424 of the Code, is a parent or subsidiary of the Company, direct or indirect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Agreement&#8221;
means a written or electronic document setting forth the terms of a Stock Right delivered pursuant to the Plan in such form as the Administrator
shall approve.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Board
of Directors&#8221; means the Board of Directors of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Cause&#8221;
means, with respect to a Participant (a) dishonesty with respect to the Company or any Affiliate, (b) insubordination, substantial malfeasance
or non-feasance of duty, (c) unauthorized disclosure of confidential information, (d) breach by a Participant of any provision of any
employment, consulting, advisory, nondisclosure, non-competition or similar agreement between the Participant and the Company or any
Affiliate, and (e) conduct substantially prejudicial to the business of the Company or any Affiliate; provided, however, that any provision
in an agreement between a Participant and the Company or an Affiliate, which contains a conflicting definition of Cause for termination
and which is in effect at the time of such termination, shall supersede this definition with respect to that Participant. The determination
of the Administrator as to the existence of Cause will be conclusive on the Participant and the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Change
of Control&#8221; means the occurrence of any of the following events: (a) any person, partnership, joint venture, corporation or other
entity, or two or more of any of the foregoing acting as a group (or any &#8220;person&#8221; within the meaning of Sections 13(d) and
14(d) of the Exchange Act), other than the Company, an Affiliate, or an employee benefit plan (or related trust) of the Company or an
Affiliate, become(s) the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Exchange Act) of 30% or more of the then-
outstanding voting stock of the Company; (b) during any period of two consecutive years, individuals who at the beginning of such period
constitute the Board of Directors (together with any new director whose election by the Board of Directors or whose nomination for election
by the Company&#8217;s stockholders, was approved by a vote of at least two-thirds of the directors then still in office who either were
directors at the beginning of such period or whose election or nomination for election was previously so approved) cease for any reason
to constitute a majority of the directors then in office; (c) all or substantially all of the business of the Company is disposed of
pursuant to a merger, consolidation or other transaction in which the Company is not the surviving corporation or the Company combines
with another company and is the surviving corporation (unless the stockholders of the Company immediately following such merger, consolidation,
combination, or other transaction beneficially own, directly or indirectly, more than 50% of the aggregate voting stock or other ownership
interests of (x) the entity or entities, if any, that succeed to the business of the Company or (y) the combined company); (d) the Company
is a party to a merger, consolidation, sale of assets or other reorganization, or a proxy contest, as a consequence of which the Board
of Directors in office immediately prior to such transaction or event constitutes less than a majority of the Board of Directors thereafter;
or (e) the stockholders of the Company approve a sale of all or substantially all of the assets of the Company or a liquidation or dissolution
of the Company; provided, that if any payment or benefit payable hereunder upon or following a Change of Control would be required to
comply with the limitations of Section 409A(a)(2)(A)(v) of the Code in order to avoid an additional tax under Section 409A of the Code,
such payment or benefit shall be made only if such Change of Control constitutes a change in ownership or control of the Company, or
a change in ownership of the Company&#8217;s assets in accordance with Section 409A of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Code&#8221;
means the United States Internal Revenue Code of 1986, as amended including any successor statute, regulation and guidance thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Committee&#8221;
means the committee of the Board of Directors to which the Board of Directors has delegated power to act under or pursuant to the provisions
of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Common
Stock&#8221; means shares of the Company&#8217;s common stock, $0.001 par value per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Company&#8221;
means Cyclacel Pharmaceuticals, Inc., a Delaware corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Consultant&#8221;
means any natural person who is an advisor or consultant who provides bonafide services to the Company or its Affiliates, provided that
such services are not in connection with the offer or sale of securities in a capital raising transaction, and do not directly or indirectly
promote or maintain a market for the Company&#8217;s or its Affiliates&#8217; securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Corporate
Transaction&#8221; means a merger, consolidation, or sale of all or substantially all of the Company&#8217;s assets or the acquisition
of all of the outstanding voting stock of the Company in a single transaction or a series of related transactions by a single entity
other than a transaction to merely change the state of incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Disability&#8221;
or &#8220;Disabled&#8221; means permanent and total disability as defined in Section 22(e)(3) of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Employee&#8221;
means any employee of the Company or of an Affiliate (including, without limitation, an employee who is also serving as an officer or
director of the Company or of an Affiliate), designated by the Administrator to be eligible to be granted one or more Stock Rights under
the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Exchange
Act&#8221; means the United States Securities Exchange Act of 1934, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Fair
Market Value&#8221; of a Share of Common Stock means:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the Common Stock is listed on a national securities exchange or traded in the over-the-counter market and sales prices are regularly
    reported for the Common Stock, the closing or, if not applicable, the last price of the Common Stock on the composite tape or other
    comparable reporting system for the trading day on the applicable date and if such applicable date is not a trading day, the last
    market trading day prior to such date;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the Common Stock is not traded on a national securities exchange but is traded on the over-the- counter market, if sales prices are
    not regularly reported for the Common Stock for the trading day referred to in clause (1), and if bid and asked prices for the Common
    Stock are regularly reported, the mean between the bid and the asked price for the Common Stock at the close of trading in the over-the-counter
    market for the trading day on which Common Stock was traded on the applicable date and if such applicable date is not a trading day,
    the last market trading day prior to such date; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the Common Stock is neither listed on a national securities exchange nor traded in the over-the- counter market, such value as the
    Administrator, in good faith, shall determine in compliance with applicable laws.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;ISO&#8221;
means an option intended to qualify as an incentive stock option under Section 422 of the Code. Non-Qualified Option means an option
which is not intended to qualify as an ISO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Option&#8221;
means an ISO or Non-Qualified Option granted under the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Participant&#8221;
means an Employee, director or Consultant of the Company or an Affiliate to whom one or more Stock Rights are granted under the Plan.
As used herein, &#8220;Participant&#8221; shall include &#8220;Participant&#8217;s Survivors&#8221; where the context requires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Performance-Based
Award&#8221; means a Stock Grant or Stock-Based Award which vests based on the attainment of written Performance Goals as set forth in
Paragraph 9 hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Performance
Goals&#8221; means performance goals determined by the Committee in its sole discretion and set forth in an Agreement. The satisfaction
of Performance Goals shall be subject to certification by the Committee. The Committee has the authority to take appropriate action with
respect to the Performance Goals (including, without limitation, making adjustments to the Performance Goals or determining the satisfaction
of the Performance Goals in connection with a Corporate Transaction) provided that any such action does not otherwise violate the terms
of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Plan&#8221;
means this Cyclacel Pharmaceuticals, Inc. 2018 Equity Incentive Plan. Securities Act means the United States Securities Act of 1933,
as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Shares&#8221;
means shares of the Common Stock as to which Stock Rights have been or may be granted under the Plan or any shares of capital stock into
which the Shares are changed or for which they are exchanged within the provisions of Paragraph 3 of the Plan. The Shares issued under
the Plan may be authorized and unissued shares or shares held by the Company in its treasury, or both.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Stock-Based
Award&#8221; means a grant by the Company under the Plan of an equity award or an equity based award, which is not an Option or a Stock
Grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Stock
Grant&#8221; means a grant by the Company of Shares under the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Stock
Right&#8221; means a right to Shares or the value of Shares of the Company granted pursuant to the Plan-an ISO, a Non-Qualified Option,
a Stock Grant or a Stock-Based Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Survivor&#8221;
means a deceased Participant&#8217;s legal representatives and/or any person or persons who acquired the Participant&#8217;s rights to
a Stock Right by will or by the laws of descent and distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
PURPOSES OF THE PLAN.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Plan is intended to encourage ownership of Shares by Employees and directors of and certain Consultants to the Company and its Affiliates
in order to attract and retain such people, to induce them to work for the benefit of the Company or of an Affiliate and to provide additional
incentive for them to promote the success of the Company or of an Affiliate. The Plan provides for the granting of ISOs, Non- Qualified
Options, Stock Grants and Stock-Based Awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
SHARES SUBJECT TO THE PLAN.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    number of Shares which may be issued from time to time pursuant to this Plan shall be the sum of: (i) 3,535,000 shares of Common
    Stock and (ii) any shares of Common Stock that are represented by awards granted under the Company&#8217;s 2015 Equity Incentive
    Plan and the Company&#8217;s Amended and Restated 2006 Equity Incentive Plan that are forfeited, expire or are cancelled without
    delivery of shares of Common Stock or which result in the forfeiture of shares of Common Stock back to the Company on or after May
    31, 2018, or the equivalent of such number of Shares after the Administrator, in its sole discretion, has interpreted the effect
    of any stock split, stock dividend, combination, recapitalization or similar transaction in accordance with Paragraph 25 of this
    Plan; provided, however, that no more than 35,494 Shares shall be added to the Plan pursuant to subsection (ii).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    an Option ceases to be &#8220;outstanding&#8221;, in whole or in part (other than by exercise), or if the Company shall reacquire
    (at not more than its original issuance price) any Shares issued pursuant to a Stock Grant or Stock-Based Award, or if any Stock
    Right expires or is forfeited, cancelled, or otherwise terminated or results in any Shares not being issued, the unissued or reacquired
    Shares which were subject to such Stock Right shall again be available for issuance from time to time pursuant to this Plan. Notwithstanding
    the foregoing, if a Stock Right is exercised, in whole or in part, by tender or withholding of Shares or if the Company or an Affiliate&#8217;s
    tax withholding obligation is satisfied by the tender or withholding of Shares, the number of Shares deemed to have been issued under
    the Plan for purposes of the limitation set forth in Paragraph 3(a) above shall be the number of Shares that were subject to the
    Stock Right or portion thereof, and not the net number of Shares actually issued. In addition, Shares repurchased by the Company
    with the proceeds of the option exercise price may not be reissued under the Plan. However, in the case of ISOs, the foregoing provisions
    shall be subject to any limitations under the Code.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
ADMINISTRATION OF THE PLAN.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator of the Plan will be the Board of Directors, except to the extent the Board of Directors delegates its authority to the
Committee, in which case the Committee shall be the Administrator. Subject to the provisions of the Plan, the Administrator is authorized
to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpret
    the provisions of the Plan and all Stock Rights and to make all rules and determinations which it deems necessary or advisable for
    the administration of the Plan;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine
    which Employees, directors and Consultants shall be granted Stock Rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine
    the number of Shares for which a Stock Right or Stock Rights shall be granted, provided however that in no event shall Stock Rights
    to be granted to any non-employee director under the Plan in any calendar year exceed an aggregate grant date fair value of $100,000
    except that the foregoing limitation shall not apply to (i) awards made pursuant to an election by a non-employee director to receive
    an award in lieu of cash for all or a portion of cash fees to be received for service on the Board or any Committee thereof and (ii)
    in connection with a non-employee director initially joining the Board of Directors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specify
    the terms and conditions upon which a Stock Right or Stock Rights may be granted;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amend
    any term or condition of any outstanding Stock Right, other than reducing the exercise price or purchase price or extending the expiration
    date of an Option, provided that (i) such term or condition as amended is not prohibited by the Plan; (ii) any such amendment shall
    not impair the rights of a Participant under any Stock Right previously granted without such Participant&#8217;s consent or in the
    event of death of the Participant the Participant&#8217;s Survivors; and (iii) any such amendment shall be made only after the Administrator
    determines whether such amendment would cause any adverse tax consequences to the Participant, including, but not limited to, the
    annual vesting limitation contained in Section 422(d) of the Code and described in Paragraph 6(b)(iv) below with respect to ISOs
    and pursuant to Section 409A of the Code;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine
    and make any adjustments in the Performance Goals included in any Performance-Based Awards; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adopt
    any sub-plans applicable to residents of any specified jurisdiction as it deems necessary or appropriate in order to comply with
    or take advantage of any tax or other laws applicable to the Company, any Affiliate or to Participants or to otherwise facilitate
    the administration of the Plan, which sub-plans may include additional restrictions or conditions applicable to Stock Rights or Shares
    issuable pursuant to a Stock Right;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided,
    however, that all such interpretations, rules, determinations, terms and conditions shall be made and prescribed in the context of
    potential tax consequences under Section 409A of the Code and preserving the tax status under Section 422 of the Code of those Options
    which are designated as ISOs. Subject to the foregoing, the interpretation and construction by the Administrator of any provisions
    of the Plan or of any Stock Right granted under it shall be final, unless otherwise determined by the Board of Directors, if the
    Administrator is the Committee. In addition, if the Administrator is the Committee, the Board of Directors may take any action under
    the Plan that would otherwise be the responsibility of the Committee.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    the extent permitted under applicable law, the Board of Directors or the Committee may allocate all or any portion of its responsibilities
    and powers to any one or more of its members and may delegate all or any portion of its responsibilities and powers to any other
    person selected by it. The Board of Directors or the Committee may revoke any such allocation or delegation at any time. Notwithstanding
    the foregoing, only the Board of Directors or the Committee shall be authorized to grant a Stock Right to any director of the Company
    or to any &#8220;officer&#8221; of the Company as defined by Rule 16a-1 under the Exchange Act.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
ELIGIBILITY FOR PARTICIPATION.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator will, in its sole discretion, name the Participants in the Plan; provided, however, that each Participant must be an Employee,
director or Consultant of the Company or of an Affiliate at the time a Stock Right is granted. Notwithstanding the foregoing, the Administrator
may authorize the grant of a Stock Right to a person not then an Employee, director or Consultant of the Company or of an Affiliate;
provided, however, that the actual grant of such Stock Right shall be conditioned upon such person becoming eligible to become a Participant
at or prior to the time of the execution of the Agreement evidencing such Stock Right. ISOs may be granted only to Employees who are
deemed to be residents of the United States for tax purposes. Non-Qualified Options, Stock Grants and Stock-Based Awards may be granted
to any Employee, director or Consultant of the Company or an Affiliate. The granting of any Stock Right to any individual shall neither
entitle that individual to, nor disqualify him or her from, participation in any other grant of Stock Rights or any grant under any other
benefit plan established by the Company or any Affiliate for Employees, directors or Consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
TERMS AND CONDITIONS OF OPTIONS.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Option shall be set forth in an Option Agreement, duly executed by the Company and, to the extent required by law or requested by the
Company, by the Participant. The Administrator may provide that Options be granted subject to such terms and conditions, consistent with
the terms and conditions specifically required under this Plan, as the Administrator may deem appropriate including, without limitation,
subsequent approval by the shareholders of the Company of this Plan or any amendments thereto. The Option Agreements shall be subject
to at least the following terms and conditions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified
    Options: Each Option intended to be a Non-Qualified Option shall be subject to the terms and conditions which the Administrator determines
    to be appropriate and in the best interest of the Company, subject to the following minimum standards for any such Non-Qualified
    Option:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price: Each Option Agreement shall state the exercise price (per share) of the Shares covered by each Option, which exercise price
    shall be determined by the Administrator and shall be at least equal to the Fair Market Value per share of the Common Stock on the
    date of grant of the Option.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares: Each Option Agreement shall state the number of Shares to which it pertains.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting:
    Each Option Agreement shall state the date or dates on which it first is exercisable and the date after which it may no longer be
    exercised, and may provide that the Option rights accrue or become exercisable in installments over a period of months or years,
    or upon the occurrence of certain performance conditions or the attainment of stated goals or events.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    Conditions: Exercise of any Option may be conditioned upon the Participant&#8217;s execution of a shareholders agreement in a form
    satisfactory to the Administrator providing for certain protection for the Company and its other shareholders, including requirements
    that:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Participant&#8217;s or the Participant&#8217;s Survivors&#8217; right to sell or transfer the Shares may be restricted; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Participant or the Participant&#8217;s Survivors may be required to execute letters of investment intent and must also acknowledge
    that the Shares will bear legends noting any applicable restrictions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    of Option: Each Option shall terminate not more than ten years from the date of the grant or at such earlier time as the Option Agreement
    may provide.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ISOs:
    Each Option intended to be an ISO shall be issued only to an Employee who is deemed to be a resident of the United States for tax
    purposes, and shall be subject to the following terms and conditions, with such additional restrictions or changes as the Administrator
    determines are appropriate but not in conflict with Section 422 of the Code and relevant regulations and rulings of the Internal
    Revenue Service:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minimum
    Standards: The ISO shall meet the minimum standards required of Non- Qualified Options, as described in Paragraph 6(a) above, except
    clause (i) and (v) thereunder.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price: Immediately before the ISO is granted, if the Participant owns, directly or by reason of the applicable attribution rules
    in Section 424(d) of the Code:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10%
    or less of the total combined voting power of all classes of stock of the Company or an Affiliate, the exercise price per share of
    the Shares covered by each ISO shall not be less than 100% of the Fair Market Value per share of the Common Stock on the date of
    grant of the Option; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
    than 10% of the total combined voting power of all classes of stock of the Company or an Affiliate, the exercise price per share
    of the Shares covered by each ISO shall not be less than 110% of the Fair Market Value per share of the Common Stock on the date
    of grant of the Option.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    of Option: For Participants who own:</span></td></tr>
</table>

<p style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10%
    or less of the total combined voting power of all classes of stock of the Company or an Affiliate, each ISO shall terminate not more
    than ten years from the date of the grant or at such earlier time as the Option Agreement may provide; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
    than 10% of the total combined voting power of all classes of stock of the Company or an Affiliate, each ISO shall terminate not
    more than five years from the date of the grant or at such earlier time as the Option Agreement may provide.</span></td></tr>
</table>

<p style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitation
    on Yearly Exercise: The Option Agreements shall restrict the amount of ISOs which may become exercisable in any calendar year (under
    this or any other ISO plan of the Company or an Affiliate) so that the aggregate Fair Market Value (determined on the date each ISO
    is granted) of the stock with respect to which ISOs are exercisable for the first time by the Participant in any calendar year does
    not exceed $100,000.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 67.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 67.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
TERMS AND CONDITIONS OF STOCK GRANTS.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Stock Grant to a Participant shall state the principal terms in an Agreement duly executed by the Company and, to the extent required
by law or requested by the Company, by the Participant. The Agreement shall be in a form approved by the Administrator and shall contain
terms and conditions which the Administrator determines to be appropriate and in the best interest of the Company, subject to the following
minimum standards:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    Agreement shall state the purchase price per share, if any, of the Shares covered by each Stock Grant, which purchase price shall
    be determined by the Administrator but shall not be less than the minimum consideration required by the Delaware General Corporation
    Law, if any, on the date of the grant of the Stock Grant;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Each
    Agreement shall state the number of Shares to which the Stock Grant pertains;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Each
    Agreement shall include the terms of any right of the Company to restrict or reacquire the Shares subject to the Stock Grant, including
    the time period or attainment of Performance Goals or such other performance criteria upon which such rights shall accrue and the
    purchase price therefor, if any; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
    (other than stock dividends to be issued pursuant to Section 25 of the Plan) may accrue but shall not be paid prior to the time,
    and may be paid only to the extent that the restrictions or rights to reacquire the Shares subject to the Stock Grant lapse.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
TERMS AND CONDITIONS OF OTHER STOCK-BASED AWARDS.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator shall have the right to grant other Stock-Based Awards based upon the Common Stock having such terms and conditions as
the Administrator may determine, including, without limitation, the grant of Shares based upon certain conditions, the grant of securities
convertible into Shares and the grant of stock appreciation rights, phantom stock awards or stock units. The principal terms of each
Stock- Based Award shall be set forth in an Agreement, duly executed by the Company and, to the extent required by law or requested by
the Company, by the Participant. The Agreement shall be in a form approved by the Administrator and shall contain terms and conditions
which the Administrator determines to be appropriate and in the best interest of the Company. Each Agreement shall include the terms
of any right of the Company including the right to terminate the Stock-Based Award without the issuance of Shares, the terms of any vesting
conditions, Performance Goals or events upon which Shares shall be issued, provided that dividends (other than stock dividends to be
issued pursuant to Section 25 of the Plan) or dividend equivalents may accrue but shall not be paid prior to and may be paid only to
the extent that the Shares subject to the Stock-Based Award vest. Under no circumstances may the Agreement covering stock appreciation
rights (a) have an exercise or base price (per share) that is less than the Fair Market Value per share of Common Stock on the date of
grant or (b) expire more than ten years following the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends that the Plan and any Stock-Based Awards granted hereunder be exempt from the application of Section 409A of the Code
or meet the requirements of paragraphs (2), (3) and (4) of subsection (a) of Section 409A of the Code, to the extent applicable, and
be operated in accordance with Section 409A so that any compensation deferred under any Stock-Based Award (and applicable investment
earnings) shall not be included in income under Section 409A of the Code. Any ambiguities in the Plan shall be construed to effect the
intent as described in this Paragraph 8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
PERFORMANCE-BASED AWARDS.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee shall determine whether, with respect to a performance period, the applicable Performance Goals have been met with respect
to a given Participant and, if they have, to so certify and ascertain the amount of the applicable Performance-Based Award. No Performance-Based
Awards will be issued for such performance period until such certification is made by the Committee. The number of Shares issued in respect
of a Performance-Based Award determined by the Committee for a performance period shall be paid to the Participant at such time as determined
by the Committee in its sole discretion after the end of such performance period, and any dividends (other than stock dividends to be
issued pursuant to Section 25 of the Plan) or dividend equivalents that accrue shall only be paid in respect of the number of Shares
earned in respect of such Performance-Based Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
EXERCISE OF OPTIONS AND ISSUE OF SHARES.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
Option (or any part or installment thereof) shall be exercised by giving written notice to the Company or its designee (in a form acceptable
to the Administrator, which may include electronic notice), together with provision for payment of the aggregate exercise price in accordance
with this Paragraph for the Shares as to which the Option is being exercised, and upon compliance with any other condition(s) set forth
in the Option Agreement. Such notice shall be signed by the person exercising the Option (which signature may be provided electronically
in a form acceptable to the Administrator), shall state the number of Shares with respect to which the Option is being exercised and
shall contain any representation required by the Plan or the Option Agreement. Payment of the exercise price for the Shares as to which
such Option is being exercised shall be made (a) in United States dollars in cash or by check; or (b) at the discretion of the Administrator,
through delivery of shares of Common Stock held for at least six months (if required to avoid negative accounting treatment) having a
Fair Market Value equal as of the date of the exercise to the aggregate cash exercise price for the number of Shares as to which the
Option is being exercised; or (c) at the discretion of the Administrator, by having the Company retain from the Shares otherwise issuable
upon exercise of the Option, a number of Shares having a Fair Market Value equal as of the date of exercise to the aggregate exercise
price for the number of Shares as to which the Option is being exercised; or (d) at the discretion of the Administrator, in accordance
with a cashless exercise program established with a securities brokerage firm, and approved by the Administrator; or (e) at the discretion
of the Administrator, by any combination of (a), (b), (c) and (d) above or (f) at the discretion of the Administrator, by payment of
such other lawful consideration as the Administrator may determine. Notwithstanding the foregoing, the Administrator shall accept only
such payment on the exercise of an ISO as is permitted by Section 422 of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall then reasonably promptly deliver the Shares as to which such Option was exercised to the Participant (or to the Participant&#8217;s
Survivors, as the case may be). In determining what constitutes &#8220;reasonably promptly,&#8221; it is expressly understood that the
issuance and delivery of the Shares may be delayed by the Company in order to comply with any law or regulation (including, without limitation,
state securities or &#8220;blue sky&#8221; laws) which requires the Company to take any action with respect to the Shares prior to their
issuance. The Shares shall, upon delivery, be fully paid, non-assessable Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
PAYMENT IN CONNECTION WITH THE ISSUANCE OF STOCK GRANTS AND STOCK-BASED AWARDS AND ISSUE OF SHARES.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Stock Grant or Stock-Based Award requiring payment of a purchase price for the Shares as to which such Stock Grant or Stock-Based Award
is being granted shall be made (a) in United States dollars in cash or by check; or (b) at the discretion of the Administrator, through
delivery of shares of Common Stock held for at least six months (if required to avoid negative accounting treatment) and having a Fair
Market Value equal as of the date of payment to the purchase price of the Stock Grant or Stock-Based Award; or (c) at the discretion
of the Administrator, by any combination of (a) and (b) above; or (d) at the discretion of the Administrator, by payment of such other
lawful consideration as the Administrator may determine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall when required by the applicable Agreement, reasonably promptly deliver the Shares as to which such Stock Grant or Stock-Based
Award was made to the Participant (or to the Participant&#8217;s Survivors, as the case may be), subject to any escrow provision set
forth in the applicable Agreement. In determining what constitutes &#8220;reasonably promptly,&#8221; it is expressly understood that
the issuance and delivery of the Shares may be delayed by the Company in order to comply with any law or regulation (including, without
limitation, state securities or &#8220;blue sky&#8221; laws) which requires the Company to take any action with respect to the Shares
prior to their issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
RIGHTS AS A SHAREHOLDER.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Participant to whom a Stock Right has been granted shall have rights as a shareholder with respect to any Shares covered by such Stock
Right except after due exercise of an Option or issuance of Shares as set forth in any Agreement, tender of the aggregate exercise or
purchase price, if any, for the Shares being purchased and registration of the Shares in the Company&#8217;s share register in the name
of the Participant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
ASSIGNABILITY AND TRANSFERABILITY OF STOCK RIGHTS.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
its terms, a Stock Right granted to a Participant shall not be transferable by the Participant other than (i) by will or by the laws
of descent and distribution, or (ii) as approved by the Administrator in its discretion and set forth in the applicable Agreement provided
that no Stock Right may be transferred by a Participant for value. Notwithstanding the foregoing, an ISO transferred except in compliance
with clause</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
above shall no longer qualify as an ISO. The designation of a beneficiary of a Stock Right by a Participant, with the prior approval
of the Administrator and in such form as the Administrator shall prescribe, shall not be deemed a transfer prohibited by this Paragraph.
Except as provided above during the Participant&#8217;s lifetime a Stock Right shall only be exercisable by or issued to such Participant
(or his or her legal representative) and shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise)
and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other
disposition of any Stock Right or of any rights granted thereunder contrary to the provisions of this Plan, or the levy of any attachment
or similar process upon a Stock Right, shall be null and void.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
EFFECT ON OPTIONS OF TERMINATION OF SERVICE OTHER THAN FOR CAUSE OR DEATH OR DISABILITY.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in a Participant&#8217;s Option Agreement, in the event of a termination of service (whether as an Employee, director
or Consultant) with the Company or an Affiliate before the Participant has exercised an Option, the following rules apply:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    Participant who ceases to be an Employee, director or Consultant of the Company or of an Affiliate (for any reason other than termination
    for Cause, Disability, or death for which events there are special rules in Paragraphs 15, 16, and 17, respectively), may exercise
    any Option granted to him or her to the extent that the Option is exercisable on the date of such termination of service, but only
    within such term as the Administrator has designated in a Participant&#8217;s Option Agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as provided in Subparagraph (c) below, or Paragraph 16 or 17, in no event may an Option intended to be an ISO, be exercised later
    than three months after the Participant&#8217;s termination of employment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    provisions of this Paragraph, and not the provisions of Paragraph 16 or 17, shall apply to a Participant who subsequently becomes
    Disabled or dies after the termination of employment, director status or consultancy; provided, however, in the case of a Participant&#8217;s
    Disability or death within three months after the termination of employment, director status or consultancy, the Participant or the
    Participant&#8217;s Survivors may exercise the Option within one year after the date of the Participant&#8217;s termination of service,
    but in no event after the date of expiration of the term of the Option.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything herein to the contrary, if subsequent to a Participant&#8217;s termination of employment, termination of director status
    or termination of consultancy, but prior to the exercise of an Option, the Administrator determines that, either prior or subsequent
    to the Participant&#8217;s termination, the Participant engaged in conduct which would constitute Cause, then such Participant shall
    forthwith cease to have any right to exercise any Option.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    Participant to whom an Option has been granted under the Plan who is absent from the Company or an Affiliate because of temporary
    disability (any disability other than a Disability as defined in Paragraph 1 hereof), or who is on leave of absence for any purpose,
    shall not, during the period of any such absence, be deemed, by virtue of such absence alone, to have terminated such Participant&#8217;s
    employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise expressly
    provide; provided, however, that, for ISOs, any leave of absence granted by the Administrator of greater than three months, unless
    pursuant to a contract or statute that guarantees the right to reemployment, shall cause such ISO to become a Non-Qualified Option
    on the date that is six months following the commencement of such leave of absence.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as required by law or as set forth in a Participant&#8217;s Option Agreement, Options granted under the Plan shall not be affected
    by any change of a Participant&#8217;s status within or among the Company and any Affiliates, so long as the Participant continues
    to be an Employee, director or Consultant of the Company or any Affiliate.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR CAUSE.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in a Participant&#8217;s Option Agreement, the following rules apply if the Participant&#8217;s service (whether
as an Employee, director or Consultant) with the Company or an Affiliate is terminated for Cause prior to the time that all his or her
outstanding Options have been exercised:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    outstanding and unexercised Options as of the time the Participant is notified his or her service is terminated for Cause will immediately
    be forfeited.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cause
    is not limited to events which have occurred prior to a Participant&#8217;s termination of service, nor is it necessary that the
    Administrator&#8217;s finding of Cause occur prior to termination. If the Administrator determines, subsequent to a Participant&#8217;s
    termination of service but prior to the exercise of an Option, that either prior or subsequent to the Participant&#8217;s termination
    the Participant engaged in conduct which would constitute Cause, then the right to exercise any Option is forfeited.</span></td></tr>
  </table>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR DISABILITY.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in a Participant&#8217;s Option Agreement:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    Participant who ceases to be an Employee, director or Consultant of the Company or of an Affiliate by reason of Disability may exercise
    any Option granted to such Participant to the extent that the Option has become exercisable but has not been exercised on the date
    of the Participant&#8217;s termination of service due to Disability; and in the event rights to exercise the Option accrue periodically,
    to the extent of a pro rata portion through the date of the Participant&#8217;s termination of service due to Disability of any additional
    vesting rights that would have accrued on the next vesting date had the Participant not become Disabled. The proration shall be based
    upon the number of days accrued in the current vesting period prior to the date of the Participant&#8217;s termination of service
    due to Disability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    Disabled Participant may exercise the Option only within the period ending one year after the date of the Participant&#8217;s termination
    of service due to Disability, notwithstanding that the Participant might have been able to exercise the Option as to some or all
    of the Shares on a later date if the Participant had not been terminated due to Disability and had continued to be an Employee, director
    or Consultant or, if earlier, within the originally prescribed term of the Option.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Administrator shall make the determination both of whether Disability has occurred and the date of its occurrence (unless a procedure
    for such determination is set forth in another agreement between the Company and such Participant, in which case such procedure shall
    be used for such determination). If requested, the Participant shall be examined by a physician selected or approved by the Administrator,
    the cost of which examination shall be paid for by the Company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
EFFECT ON OPTIONS OF DEATH WHILE AN EMPLOYEE, DIRECTOR OR CONSULTANT.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in a Participant&#8217;s Option Agreement:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the event of the death of a Participant while the Participant is an Employee, director or Consultant of the Company or of an Affiliate,
    such Option may be exercised by the Participant&#8217;s Survivors to the extent that the Option has become exercisable but has not
    been exercised on the date of death; and in the event rights to exercise the Option accrue periodically, to the extent of a pro rata
    portion through the date of death of any additional vesting rights that would have accrued on the next vesting date had the Participant
    not died. The proration shall be based upon the number of days accrued in the current vesting period prior to the Participant&#8217;s
    date of death.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the Participant&#8217;s Survivors wish to exercise the Option, they must take all necessary steps to exercise the Option within one
    year after the date of death of such Participant, notwithstanding that the decedent might have been able to exercise the Option as
    to some or all of the Shares on a later date if he or she had not died and had continued to be an Employee, director or Consultant
    or, if earlier, within the originally prescribed term of the Option.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
EFFECT OF TERMINATION OF SERVICE ON UNACCEPTED STOCK GRANTS AND STOCK- BASED AWARDS.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a termination of service (whether as an Employee, director or Consultant) with the Company or an Affiliate for any reason
before the Participant has accepted a Stock Grant or a Stock-Based Award and paid the purchase price, if required, such grant shall terminate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Paragraph 18 and Paragraph 19 below, a Participant to whom a Stock Grant or a Stock-Based Award has been issued under
the Plan who is absent from work with the Company or with an Affiliate because of temporary disability (any disability other than a Disability
as defined in Paragraph 1 hereof), or who is on leave of absence for any purpose, shall not, during the period of any such absence, be
deemed, by virtue of such absence alone, to have terminated such Participant&#8217;s employment, director status or consultancy with
the Company or with an Affiliate, except as the Administrator may otherwise expressly provide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, for purposes of this Paragraph 18 and Paragraph 19 below, any change of employment or other service within or among the Company
and any Affiliates shall not be treated as a termination of employment, director status or consultancy so long as the Participant continues
to be an Employee, director or Consultant of the Company or any Affiliate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF TERMINATION OF SERVICE OTHER THAN FOR CAUSE, DEATH OR DISABILITY.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in a Participant&#8217;s Agreement, in the event of a termination of service for any reason (whether as an Employee,
director or Consultant), other than termination for Cause, death or Disability for which there are special rules in Paragraphs 20, 21,
and 22 below, before all forfeiture provisions or Company rights of repurchase shall have lapsed, then the Company shall have the right
to cancel or repurchase that number of Shares subject to a Stock Grant or Stock-Based Award as to which the Company&#8217;s forfeiture
or repurchase rights have not lapsed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF TERMINATION OF SERVICE FOR CAUSE.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in a Participant&#8217;s Agreement, the following rules apply if the Participant&#8217;s service (whether as an
Employee, director or Consultant) with the Company or an Affiliate is terminated for Cause:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Shares subject to any Stock Grant or Stock-Based Award that remain subject to forfeiture provisions or as to which the Company shall
    have a repurchase right shall be immediately forfeited to the Company as of the time the Participant is notified his or her service
    is terminated for Cause.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cause
    is not limited to events which have occurred prior to a Participant&#8217;s termination of service, nor is it necessary that the
    Administrator&#8217;s finding of Cause occur prior to termination. If the Administrator determines, subsequent to a Participant&#8217;s
    termination of service, that either prior or subsequent to the Participant&#8217;s termination the Participant engaged in conduct
    which would constitute Cause, then all Shares subject to any Stock Grant or Stock-Based Award that remained subject to forfeiture
    provisions or as to which the Company had a repurchase right on the date of termination shall be immediately forfeited to the Company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.
EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF TERMINATION OF SERVICE FOR DISABILITY.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in a Participant&#8217;s Agreement, the following rules apply if a Participant ceases to be an Employee, director
or Consultant of the Company or of an Affiliate by reason of Disability: to the extent the forfeiture provisions or the Company&#8217;s
rights of repurchase have not lapsed on the date of Disability, they shall be exercisable; provided, however, that in the event such
forfeiture provisions or rights of repurchase lapse periodically, such provisions or rights shall lapse to the extent of a pro rata portion
of the Shares subject to such Stock Grant or Stock-Based Award through the date of Disability as would have lapsed had the Participant
not become Disabled. The proration shall be based upon the number of days accrued prior to the date of Disability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator shall make the determination both as to whether Disability has occurred and the date of its occurrence (unless a procedure
for such determination is set forth in another agreement between the Company and such Participant, in which case such procedure shall
be used for such determination). If requested, the Participant shall be examined by a physician selected or approved by the Administrator,
the cost of which examination shall be paid for by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.
EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF DEATH WHILE AN EMPLOYEE, DIRECTOR OR CONSULTANT.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in a Participant&#8217;s Agreement, the following rules apply in the event of the death of a Participant while
the Participant is an Employee, director or Consultant of the Company or of an Affiliate: to the extent the forfeiture provisions or
the Company&#8217;s rights of repurchase have not lapsed on the date of death, they shall be exercisable; provided, however, that in
the event such forfeiture provisions or rights of repurchase lapse periodically, such provisions or rights shall lapse to the extent
of a pro rata portion of the Shares subject to such Stock Grant or Stock-Based Award through the date of death as would have lapsed had
the Participant not died. The proration shall be based upon the number of days accrued prior to the Participant&#8217;s date of death.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.
PURCHASE FOR INVESTMENT.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the offering and sale of the Shares shall have been effectively registered under the Securities Act, the Company shall be under no obligation
to issue Shares under the Plan unless and until the following conditions have been fulfilled:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    person who receives a Stock Right shall warrant to the Company, prior to the receipt of Shares, that such person is acquiring such
    Shares for his or her own account, for investment, and not with a view to, or for sale in connection with, the distribution of any
    such Shares, in which event the person acquiring such Shares shall be bound by the provisions of the following legend (or a legend
    in substantially similar form) which shall be endorsed upon the certificate evidencing the Shares issued pursuant to such exercise
    or such grant of a Stock Right:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;The
    shares represented by this certificate have been taken for investment and they may not be sold or otherwise transferred by any person,
    including a pledgee, unless (1) either (a) a Registration Statement with respect to such shares shall be effective under the Securities
    Act of 1933, as amended, or (b) the Company shall have received an opinion of counsel satisfactory to it that an exemption from registration
    under such Act is then available, and (2) there shall have been compliance with all applicable state securities laws.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    the discretion of the Administrator, the Company shall have received an opinion of its counsel that the Shares may be issued in compliance
    with the Securities Act without registration thereunder.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.
DISSOLUTION OR LIQUIDATION OF THE COMPANY.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the dissolution or liquidation of the Company, all Options granted under this Plan which as of such date shall not have been exercised
and all Stock Grants and Stock-Based Awards which have not been accepted, to the extent required under the applicable Agreement, will
terminate and become null and void; provided, however, that if the rights of a Participant or a Participant&#8217;s Survivors have not
otherwise terminated and expired, the Participant or the Participant&#8217;s Survivors will have the right immediately prior to such
dissolution or liquidation to exercise or accept any Stock Right to the extent that the Stock Right is exercisable or subject to acceptance
as of the date immediately prior to such dissolution or liquidation. Upon the dissolution or liquidation of the Company, any outstanding
Stock-Based Awards shall immediately terminate unless otherwise determined by the Administrator or specifically provided in the applicable
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.
ADJUSTMENTS.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the occurrence of any of the following events, a Participant&#8217;s rights with respect to any Stock Right granted to him or her hereunder
shall be adjusted as hereinafter provided, unless otherwise specifically provided in a Participant&#8217;s Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Dividends and Stock Splits. If (i) the shares of Common Stock shall be subdivided or combined into a greater or smaller number of
    shares or if the Company shall issue any shares of Common Stock as a stock dividend on its outstanding Common Stock, or (ii) additional
    shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such
    shares of Common Stock, each Stock Right and the number of shares of Common Stock deliverable thereunder shall be appropriately increased
    or decreased proportionately, and appropriate adjustments shall be made including, in the exercise, base or purchase price per share
    and in the Performance Goals applicable to outstanding Performance-Based Awards to reflect such events. The number of Shares subject
    to the limitations in Paragraph 3(a) and 4(c) shall also be proportionately adjusted upon the occurrence of such events.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    Transactions. If the Company is to be consolidated with or acquired by another entity in a Corporate Transaction, the Administrator
    or the board of directors of any entity assuming the obligations of the Company hereunder (the &#8220;Successor Board&#8221;), shall,
    as to outstanding Options, either: (i) make appropriate provision for the continuation of such Options by substituting on an equitable
    basis for the Shares then subject to such Options either the consideration payable with respect to the outstanding shares of Common
    Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity; or (ii) upon written notice
    to the Participants, provide that such Options must be exercised (either (A) to the extent then exercisable or (B) at the discretion
    of the Administrator, any such Options being made partially or fully exercisable for purposes of this Subparagraph), within a specified
    number of days of the date of such notice, at the end of which period such Options which have not been exercised shall terminate;
    or (iii) terminate such Options in exchange for payment of an amount equal to the consideration payable upon consummation of such
    Corporate Transaction to a holder of the number of shares of Common Stock into which such Option would have been exercisable (either
    (A) to the extent then exercisable or, (B) at the discretion of the Administrator, any such Options being made partially or fully
    exercisable for purposes of this Subparagraph) less the aggregate exercise price thereof. For purposes of determining the payments
    to be made pursuant to Subclause (iii) above, in the case of a Corporate Transaction the consideration for which, in whole or in
    part, is other than cash, the consideration other than cash shall be valued at the fair value thereof as determined in good faith
    by the Board of Directors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    respect to outstanding Stock Grants, the Administrator or the Successor Board, shall make appropriate provision for the continuation
    of such Stock Grants on the same terms and conditions by substituting on an equitable basis for the Shares then subject to such Stock
    Grants either the consideration payable with respect to the outstanding Shares of Common Stock in connection with the Corporate Transaction
    or securities of any successor or acquiring entity. In lieu of the foregoing, in connection with any Corporate Transaction, the Administrator
    may provide that, upon consummation of the Corporate Transaction, each outstanding Stock Grant shall be terminated in exchange for
    payment of an amount equal to the consideration payable upon consummation of such Corporate Transaction to a holder of the number
    of shares of Common Stock comprising such Stock Grant (to the extent such Stock Grant is no longer subject to any forfeiture or repurchase
    rights then in effect or, at the discretion of the Administrator, all forfeiture and repurchase rights being waived upon such Corporate
    Transaction).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    taking any of the actions permitted under this Paragraph 25(b), the Administrator shall not be obligated by the Plan to treat all
    Stock Rights, all Stock Rights held by a Participant, or all Stock Rights of the same type, identically.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recapitalization
    or Reorganization. In the event of a recapitalization or reorganization of the Company other than a Corporate Transaction pursuant
    to which securities of the Company or of another corporation are issued with respect to the outstanding shares of Common Stock, a
    Participant upon exercising an Option or accepting a Stock Grant after the recapitalization or reorganization shall be entitled to
    receive for the price paid upon such exercise or acceptance if any, the number of replacement securities which would have been received
    if such Option had been exercised or Stock Grant accepted prior to such recapitalization or reorganization.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    to Stock-Based Awards. Upon the happening of any of the events described in Subparagraphs (a), (b) or (c) above, any outstanding
    Stock-Based Award shall be appropriately adjusted to reflect the events described in such Subparagraphs. The Administrator or the
    Successor Board shall determine the specific adjustments to be made under this Paragraph 25, including, but not limited to the effect
    of any, Corporate Transaction and, subject to Paragraph 4, its determination shall be conclusive.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modification
    of Options. Notwithstanding the foregoing, any adjustments made pursuant to Subparagraph (a), (b) or (c) above with respect to Options
    shall be made only after the Administrator determines whether such adjustments would (i) constitute a &#8220;modification&#8221;
    of any ISOs (as that term is defined in Section 424(h) of the Code) or (ii) cause any adverse tax consequences for the holders of
    Options, including, but not limited to, pursuant to Section 409A of the Code. If the Administrator determines that such adjustments
    made with respect to Options would constitute a modification or other adverse tax consequence, it may in its discretion refrain from
    making such adjustments, unless the holder of an Option specifically agrees in writing that such adjustment be made and such writing
    indicates that the holder has full knowledge of the consequences of such &#8220;modification&#8221; on his or her income tax treatment
    with respect to the Option. This paragraph shall not apply to the acceleration of the vesting of any ISO that would cause any portion
    of the ISO to violate the annual vesting limitation contained in Section 422(d) of the Code, as described in Paragraph 6(b)(iv).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    of Control. In the event that the successor corporation refuses to assume or substitute the Stock Right as set forth in this Paragraph
    25, the Participant shall fully vest and become exercisable or earned, if applicable, in each outstanding Stock Right as to which
    it would not otherwise be vested, exercisable or earned. If a Stock Right becomes fully vested and exercisable or earned, as applicable
    in lieu of assumption or substitution in the event of a Corporate Transaction or Change of Control, the Administrator shall notify
    each Participant in writing or electronically that (i) the Stock Right shall be fully vested and exercisable for a period determined
    by the Administrator, and all outstanding Stock Rights shall terminate upon the expiration of such period and (ii) any Stock Rights
    to which shares or other payment shall be due shall be paid out immediately prior to the Corporate Transaction or Change of Control
    as if fully vested or earned. For the purposes of this paragraph, the Stock Right shall be considered assumed if, following the Corporate
    Transaction or Change of Control, the assumed Stock Right confers the right to purchase or receive, for each Share subject to a Stock
    Right immediately prior to the Corporate Transaction or Change of Control, the consideration (whether stock, cash, or other securities
    or property) received in the Corporate Transaction or Change of Control by holders of Common Stock for each share of Common Stock
    they hold on the effective date of the transaction (and if holders are offered a choice of consideration, the type of consideration
    chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if such consideration received
    in the Corporate Transaction or Change of Control is not solely common stock of the successor corporation or its parent, the Administrator
    may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise (or payout or
    vesting, as applicable) of the Stock Right, for each Share subject to the Stock Right, to be solely common stock of the successor
    corporation or its parent equal in Fair Market Value to the per share consideration received by holders of Common Stock in the Corporate
    Transaction or Change of Control.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 34.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.
ISSUANCES OF SECURITIES.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock
of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares subject
to Stock Rights. Except as expressly provided herein, no adjustments shall be made for dividends paid in cash or in property (including
without limitation, securities) of the Company prior to any issuance of Shares pursuant to a Stock Right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.
FRACTIONAL SHARES.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares shall be issued under the Plan and the person exercising a Stock Right shall receive from the Company cash in lieu
of such fractional shares equal to the Fair Market Value thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.
WITHHOLDING.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that any federal, state, or local income taxes, employment taxes, Federal Insurance Contributions Act withholdings or other
amounts are required by applicable law or governmental regulation to be withheld from the Participant&#8217;s salary, wages or other
remuneration in connection with the issuance of a Stock Right or Shares under the Plan or for any other reason required by law, the Company
may withhold from the Participant&#8217;s compensation, if any, or may require that the Participant advance in cash to the Company, or
to any Affiliate of the Company which employs or employed the Participant, the statutory minimum amount of such withholdings unless a
different withholding arrangement, including the use of shares of the Company&#8217;s Common Stock or a promissory note, is authorized
by the Administrator (and permitted by law). For purposes hereof, the fair market value of the shares withheld for purposes of payroll
withholding shall be determined in the manner set forth under the definition of Fair Market Value provided in Paragraph 1 above, as of
the most recent practicable date prior to the date of exercise. If the Fair Market Value of the shares withheld is less than the amount
of payroll withholdings required, the Participant may be required to advance the difference in cash to the Company or the Affiliate employer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.
NOTICE TO COMPANY OF DISQUALIFYING DISPOSITION.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Employee who receives an ISO must agree to notify the Company in writing immediately after the Employee makes a Disqualifying Disposition
of any Shares acquired pursuant to the exercise of an ISO. A Disqualifying Disposition is defined in Section 424(c) of the Code and includes
any disposition (including any sale or gift) of such Shares before the later of (a) two years after the date the Employee was granted
the ISO, or (b) one year after the date the Employee acquired Shares by exercising the ISO, except as otherwise provided in Section 424(c)
of the Code. If the Employee has died before such Shares are sold, these holding period requirements do not apply and no Disqualifying
Disposition can occur thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.
TERMINATION OF THE PLAN.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Plan will terminate on March 29, 2028, the date which is ten years from the earlier of the date of its adoption by the Board of Directors
and the date of its approval by the shareholders of the Company. The Plan may be terminated at an earlier date by vote of the shareholders
or the Board of Directors of the Company; provided, however, that any such earlier termination shall not affect any Agreements executed
prior to the effective date of such termination. Termination of the Plan shall not affect any Stock Rights theretofore granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.
AMENDMENT OF THE PLAN AND AGREEMENTS.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Plan may be amended by the shareholders of the Company. The Plan may also be amended by the Administrator; provided that any amendment
approved by the Administrator which the Administrator determines is of a scope that requires shareholder approval shall be subject to
obtaining such shareholder approval including, without limitation, to the extent necessary to qualify any or all outstanding Stock Rights
granted under the Plan or Stock Rights to be granted under the Plan for favorable federal income tax treatment as may be afforded ISOs
under Section 422 of the Code and to the extent necessary to qualify the Shares issuable under the Plan for listing on any national securities
exchange or quotation in any national automated quotation system of securities dealers. Other than as set forth in Paragraph 25 of the
Plan, the Administrator may not without shareholder approval reduce the exercise price of an Option or cancel any outstanding Option
in exchange for a replacement option having a lower exercise price, any Stock Grant, any other Stock-Based Award or for cash. In addition,
the Administrator not take any other action that is considered a direct or indirect &#8220;repricing&#8221; for purposes of the shareholder
approval rules of the applicable securities exchange or inter-dealer quotation system on which the Shares are listed, including any other
action that is treated as a repricing under generally accepted accounting principles. Any modification or amendment of the Plan shall
not, without the consent of a Participant, adversely affect his or her rights under a Stock Right previously granted to him or her, unless
such amendment is required by applicable law or necessary to preserve the economic value of such Stock Right. With the consent of the
Participant affected, the Administrator may amend outstanding Agreements in a manner which may be adverse to the Participant but which
is not inconsistent with the Plan. In the discretion of the Administrator, outstanding Agreements may be amended by the Administrator
in a manner which is not adverse to the Participant. Nothing in this Paragraph 31 shall limit the Administrator&#8217;s authority to
take any action permitted pursuant to Paragraph 25.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.
EMPLOYMENT OR OTHER RELATIONSHIP.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
in this Plan or any Agreement shall be deemed to prevent the Company or an Affiliate from terminating the employment, consultancy or
director status of a Participant, nor to prevent a Participant from terminating his or her own employment, consultancy or director status
or to give any Participant a right to be retained in employment or other service by the Company or any Affiliate for any period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33.
SECTION 409A.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Participant is a &#8220;specified employee&#8221; as defined in Section 409A of the Code (and as applied according to procedures of
the Company and its Affiliates) as of his separation from service, to the extent any payment under this Plan or pursuant to the grant
of a Stock-Based Award constitutes deferred compensation (after taking into account any applicable exemptions from Section 409A of the
Code), and to the extent required by Section 409A of the Code, no payments due under this Plan or pursuant to a Stock- Based Award may
be made until the earlier of: (i) the first day of the seventh month following the Participant&#8217;s separation from service, or (ii)
the Participant&#8217;s date of death; provided, however, that any payments delayed during this six-month period shall be paid in the
aggregate in a lump sum, without interest, on the first day of the seventh month following the Participant&#8217;s separation from service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator shall administer the Plan with a view toward ensuring that Stock Rights under the Plan that are subject to Section 409A
of the Code comply with the requirements thereof and that Options under the Plan be exempt from the requirements of Section 409A of the
Code, but neither the Administrator nor any member of the Board, nor the Company nor any of its Affiliates, nor any other person acting
hereunder on behalf of the Company, the Administrator or the Board shall be liable to a Participant or any Survivor by reason of the
acceleration of any income, or the imposition of any additional tax or penalty, with respect to a Stock Right, whether by reason of a
failure to satisfy the requirements of Section 409A of the Code or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.
INDEMNITY.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the Board nor the Administrator, nor any members of either, nor any employees of the Company or any parent, subsidiary, or other Affiliate,
shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with their responsibilities
with respect to this Plan, and the Company hereby agrees to indemnify the members of the Board, the members of the Committee, and the
employees of the Company and its parent or subsidiaries in respect of any claim, loss, damage, or expense (including reasonable counsel
fees) arising from any such act, omission, interpretation, construction or determination to the full extent permitted by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35.
CLAWBACK.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything to the contrary contained in this Plan, the Company may recover from a Participant any compensation received from any Stock
Right (whether or not settled) or cause a Participant to forfeit any Stock Right (whether or not vested) in the event that the Company&#8217;s
Clawback Policy as then in effect is triggered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36.
GOVERNING LAW.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Plan shall be construed and enforced in accordance with the law of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_088_labels -->
<!-- eJxVjb0OgjAURncT3+GmM6FENzY0MpnYoZtxKPT6W3pJewV8e6mJic7fOecTlbU3vpE3DvamQRdFJq7MfSnlOI751ASXU7jIVVGsZSCH0iVMLBcCW1tW9q5JIW2p62uvceKNo/YxR+blGblDz6AJ1O4AiUEfTbrLoCZiT4xwTBZ8tNM3q4Zem8bhb1CZFwwRFIYzhc74NqkJgv/AG76OR7s= -->
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>formdef14a_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formdef14a_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %' R$# 2(  A$! Q$!_\0
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M=_SX6O\ WY7_  H_L73O^?"U_P"_*_X5=HH I?V+IW_/A:_]^5_PH_L73O\
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MK_WY7_"C^Q=._P"?"U_[\K_A5VB@"E_8NG?\^%K_ -^5_P */[%T[_GPM?\
MORO^%7:* *7]BZ=_SX6O_?E?\*/[%T[_ )\+7_ORO^%7:* *7]BZ=_SX6O\
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M%8*'+_,6(). .@Q0!]=T5\=ZQX*L]+_9\\+?%0WNIWGQ!_XEM[_;UU?RO/\
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MY'3>U>B^+/&Z?&JS^"FDSR36_A_QDUQ<:O%:S-%YI@MRS6K,I!V&3<",\[*
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M(^E 'OM%?)$/B*]^*?PT^&OPQO06UB?5SIWB&%C\RVVFN#-N]"^(>O7=7UL
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M;NCD?=NV-G_5XQCOUXJ)24(N4MD;T*%3$U(T:2O)[?TST>BOD'_AX#_U(?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7O[^UTJRGO+VYAL[.
MW0RS7%PX2.- ,EF8\  <DFN:\/?%;PGXE\*W7B2TU[3UT2UFD@N+V6[B$4+(
M^WYWW%5!^5ADC*NI[U#\7;+1M0\"7D.O:N^@Z>9K=_[37;BVE69&BD;<I0*)
M%3.\;<=2!S7G%KXOT?Q?X<\6V?BCQ'HT6CI=V4:^.?#Z);6MU+A9%#/(9HP\
M;1JI+.Z_.@^4G;0![!IWC;P[K&A7&MV&OZ9>Z-;[S-J-M>1R6\6T9;=(&*C
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MX.,@5Z?5+1M;T[Q%IL.HZ5?VNIZ?,"8KNSF6:*0 D':ZD@\@C@]JNT %%%%
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M>SK#$F2 ,NQ &20.O4U6N/&.@6GAU=?GUS38="95==4DNXUM2K$!2)2=N"2
M#GG-><_%/Q5HT7CKP@U]>Q1:=X>U83:M+<@I!9--9SBVED=@$ +<!LX#,N<$
MBN.L;BRTV+PIXCO'AM?!2^,M3U!+V8A+6**6.X6WN&8@*L;2,2KG@F5""=P-
M 'N]QXQT"T\.KK\^N:;#H3*KKJDEW&MJ58@*1*3MP20 <\YJ]IFIV>M:?!?:
M?=P7]C<()(;FVD62.13T964D$>XKYZL;BRTV+PIXCO'AM?!2^,M3U!+V8A+6
M**6.X6WN&8@*L;2,2KG@F5""=P-=A\.-;M+;PSJ-I9SB"3Q'JNKW'A\1QL%N
M(]SOYB,%P%)W.K'A@P()R* /1M*\9^']>O[^QTS7=-U&]T\E;RVM+R.62V()
M!$BJ24Y!'..AI?#WC'0/%UK/<Z%KFFZU;P-LEFT^[CG2-L9PQ0D XYP:^7=3
M2W\3_#3PYH_A6,7>M:-X,O[36+&R&ZYM"T4*O;3*!N25Y$?",0S%6(!P375^
M+[BR\>VGC^[\#/#K&G_\(;'I\DFCD2+)*'E86ZE!S(L18; <CS%&!N&0#WCP
MYXOT'QA;S3Z#K>G:W!"_ERRZ==QW"HV,[6*$@''8UKUY/X U?1?%/Q4U#5O"
MUS9W^B0Z!:64UWI[*\/G"61DAW*,;D0G*YRH=<@9&?6* "BD8,5.T@-C@D9
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M'_GZM?\ P&;_ ..5]P?BI=HJEY6H_P#/U:_^ S?_ !RCRM1_Y^K7_P !F_\
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M-_\ '*/*U'_GZM?_  &;_P".4 7:*I>5J/\ S]6O_@,W_P <H\K4?^?JU_\
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MF_\ CE %VBJ7E:C_ ,_5K_X#-_\ '*/*U'_GZM?_  &;_P".4 7:*I>5J/\
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MW_;]_P"V]>SD_P#OU/Y_DSR\S_W2?R_-'R91117Z8?!A5>]_U0_WJL57O?\
M5#_>KPL]_P"1;7]#ZOA7_D=X7_%_F4J***_ C^NBYI6KW>BW:W%G,T4@ZXZ,
M/0CN*]I^%?Q,C/BK2]4@M(AX@T_S)(D="RLIC99-I'.-A;([=>V:\*KU[]DH
M!OV@O"H(R#]KR#_UZ35B\-&O4BT^65U9K='R^?99A\5AJF(:M4A%M26CT3T?
M=/:Q]T_#_P"*FD>/8!'$XL]35<R64K?-[E#_ !#]?4"NTKQ_X@? N.\G.K^%
M7&FZFA\S[,C;$=ASE"/N-^GTZU3\#_&^XTR\_L/QI$]I=Q'R_MKIM(/I(O\
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M>Q:X%R!#);&:1ED+QAF++D*H0?*S.#[K0 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%R__ !5 %VBJ7]DP?\]+K_P+E_\ BJ/[)@_YZ77_ (%R_P#Q5 %VODS]O/\
MYD;_ +?O_;>OJ;^R8/\ GI=?^!<O_P 57RG^W5:):_\ "$;&E;=]NSYDK/\
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M5']DP?\ /2Z_\"Y?_BJ +M%4O[)@_P">EU_X%R__ !5']DP?\]+K_P "Y?\
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M@"[15+^R8/\ GI=?^!<O_P 51_9,'_/2Z_\  N7_ .*H NT52_LF#_GI=?\
M@7+_ /%4?V3!_P ]+K_P+E_^*H NT52_LF#_ )Z77_@7+_\ %4?V3!_STNO_
M  +E_P#BJ +M%4O[)@_YZ77_ (%R_P#Q5']DP?\ /2Z_\"Y?_BJ +M%4O[)@
M_P">EU_X%R__ !5']DP?\]+K_P "Y?\ XJ@"[7&?%3XJ:3\(?#UOK&L6][<V
ML]TMHJ6*([AV1W!(9E&,(>_IQ73?V3!_STNO_ N7_P"*KY^_;8L8[;X5Z4R-
M,2=:B'[R=W'^HG[,2*[<%2C7Q$*<]FSEQ525*A*<=TBQ_P -P>!?^@3XB_\
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MBY^1EG0&&7;'+ GRR-C '0 U[+0 4444 %%%% !1110 4444 %%%% !1110
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M@PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*60"0?5#R/Q%=N%S"CBO=^&:WB]&O\RXS4O4VJ***],L**** "BBB@ HHHH
M**** "BBB@ HHHH **** ,'7O'WACPM>)::UXCTG2+IXQ*L%_?10.R$D!@K,
M"1D$9]CZ5F_\+C\ _P#0\>&__!M;_P#Q=?(7[=W_ "5W2/\ L!P_^E%Q7SC7
MCUL=*G4<%'8_1,OX7HXS"T\1*HTY*^R/U+_X7'X!_P"AX\-_^#:W_P#BZ/\
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M31-/8I?VM!_SSNO_  $E_P#B:/[6@_YYW7_@)+_\35VBM!E+^UH/^>=U_P"
MDO\ \31_:T'_ #SNO_ 27_XFKM% 'R7\:_#7QCUGXFZS>>$IO$<?AZ3R?LJV
MFHO;1C$,8?$9D7;\X;L,G)[UP_\ P@_[0W_/SXK_ /!VW_QVONRBO<IYM4IP
MC!4XNRMM_P $\F>70G)S<Y:Z[_\  /A/_A!_VAO^?GQ7_P"#MO\ X[1_P@_[
M0W_/SXK_ /!VW_QVONRBM/[9J_\ /J'W/_,C^RZ?_/R7W_\  /SM\3? ;XR^
M*[^.[U;1=6U>Y2(1+/?7R3.J DA07D)QEB<>YK(_X9?^*/\ T*-U_P!_X?\
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M_P#B:/[6@_YYW7_@)+_\35VB@"E_:T'_ #SNO_ 27_XFC^UH/^>=U_X"2_\
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M(R3HC!"%;#XQ\K<\&JFG_&+PIJFG7MY#?7*I9K$\D$^FW,-RRRG$31P/&))
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MKH2LB66FW5S.@B.V4R0QQM)'L;Y6WJNTD X/%6M:^)_AS0M(T_5)[R>YL;^
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M8>+KX_VSJ.GW4=IMUOQ%I[V%[<3*KAHA$T<(\J-=A!6)!ND?ESD@ ]8HHHH
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M 9VK^'-+U^/9J6GVU\N,#SX@Q'T)Y'X5Y_KO[/'AG4]SV+7.E2GH(I/,3/\
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M^L6$^>GEW2-_(UPUS^SQX2GSL6]M\_\ /.XSC_OH&LJY_9GT-O\ 4:KJ$?\
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MN4445J,**** "BBB@ HHHH **** "BBB@ HHJGI6KVFN68N[&87%N9)(MX!
MW([(XY'9E8?A0!<HHHH **** "J6M316^CWTL^H?V1"D#L^H;HU^S*%.9<R
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M 'A6GZ;9:C#X4\-74,=SX*D\9ZI9QV,HWVLL44=PT$!4DJT2RHVU#\N8E&.
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M@XWNBG+$98(,DXKUFLGP[X2T/P?:RVV@Z-I^B6TK^;)#IUK';H[X W$( "<
M#/M6M0 C%@IV@%L< G )JGYNH_\ /K:_^!+?_&ZNT4 4O-U'_GUM?_ EO_C=
M'FZC_P ^MK_X$M_\;J[10!2\W4?^?6U_\"6_^-T>;J/_ #ZVO_@2W_QNKM%
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MW4?^?6U_\"6_^-T>;J/_ #ZVO_@2W_QNKM% %+S=1_Y];7_P);_XW1YNH_\
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MA#%-;W"!XY$(P593P01P0:L44 8/AKP!X8\&2SR>'_#FD:%). LKZ;8Q6YD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%% !1110 4444 %%%% !1110 4444 %%%% 'C-%%% 'K.B_\@:P_P"O>/\
M]!%7:I:+_P @:P_Z]X__ $$5=H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "N-^)?Q%7X=:=:W)TZ74&N)"
M@"OY:+@9^9L'!YX&.<&NRHK&M&<Z;C3ERRZ.U[?(3NUH>$?\-0_]2S_Y/_\
MVJC_ (:A_P"I9_\ )_\ ^U5[O17D?4\P_P"@O_R2)GRS_F_ \(_X:A_ZEG_R
M?_\ M56-/_:92[OH('\-R*LCA28;OS'Y]%\L9/MFO;Z*:PF8)ZXK_P DB'+/
M^;\#RRRTUOB7XS\9PZIJNL65OH=['IUE9Z7J4]@(P;:*9IW\EU,K,TI W[E
MC&%Y8LV]^).N:3JVH>&#':3^(5U:RM-,>=3MN+.9-[3R*K#+*L-WG;M!,0P
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M/^$QTC_G[_\ (3_X444 '_"8Z1_S]_\ D)_\*/\ A,=(_P"?O_R$_P#A110
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M_A,=(_Y^_P#R$_\ A110 ?\ "8Z1_P _?_D)_P#"C_A,=(_Y^_\ R$_^%%%
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M ,A/_A110 ?\)CI'_/W_ .0G_P */^$QTC_G[_\ (3_X444 '_"8Z1_S]_\
MD)_\*/\ A,=(_P"?O_R$_P#A110 ?\)CI'_/W_Y"?_"C_A,=(_Y^_P#R$_\
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<\*/^$QTC_G[_ /(3_P"%%% 'FNP^E%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>formdef14a_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formdef14a_002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $] R$# 2(  A$! Q$!_\0
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M=_SX6O\ WY7_  H_L73O^?"U_P"_*_X5=HH I?V+IW_/A:_]^5_PH_L73O\
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MK_WY7_"C^Q=._P"?"U_[\K_A5VB@"E_8NG?\^%K_ -^5_P */[%T[_GPM?\
MORO^%7:* *7]BZ=_SX6O_?E?\*/[%T[_ )\+7_ORO^%7:* *7]BZ=_SX6O\
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MUM0U3XE_"WX%KJNK7R7ESXEDL9=5MIBEQ-%&ES%YBR Y#.B_?'.22#GF@#[
MHKY]T+P=H_P@_:1\/Z-X4MI-*TG7M#NY;ZQ6XD>*6:)T*3$.Q^?!(W=2#]<_
M05 'FGQW^,W_  I?PU::A!HDGB+4+J9TBTZ*?R6,<<3RS2[MK<(D9)X[BN\T
M#6K7Q)H6G:M8OYMG?V\=U"X[HZAE/Y$5\^>*?B':S_M&:G->>'O$?B/2?#6E
M'2X4T329;Z-+NXVO.7*#"GRO+3'7DUR7ASXJ:IX3_9;^(6F6,6H:9K'A*=]/
MLUOH'MKR"SGE7[/*R,-R,L<AQ_US'UH ^OZYKP9X]T_QQ/XABL(;F)M$U.72
M;DW"JH>5%5BR88Y7#C!.#UXKC_!_[./@/PQ+8ZGI^FS#4O(>.YO3>S,U^)(R
MLGG@OMDW;BW(X/(Q7!_LT?"+P?I7BSQ[JUKH-M#J.C>*;RQT^X!8M;0>3&-B
MY/3#O_WT: /I&BO!_@8ZM\)OB" 02NO:X" >A\US_45R^A7GAR?]GWX0Z#KM
MIK.NSZK:1K9^'-&G\IM19(B6$IWQCRD!W$,X7ID-C% 'TOJ-PUGI]U.@!>*)
MG4-TR 3S7B^A_''7=3\%_"#5Y;33EN?&&H):7Z)'($B0QRL3$-^0<QC[Q;O7
M,_!2U?PO\0OB3X;M/#][X/T1=(MK^'0+N\CN5@E<2J\D9CDD50^T9 ;J.W%8
M7A/_ ))9^S/_ -AJ+_T1<4 ?6E%?+DOBU_@"?C'X;MU:-L+KGAR'^^UX1#L0
M>BW!' ]37N7P>\#+\-OACX<\.8'G6-HBW!'\4[?-*WXNS&@#F_''Q<\2:+\3
M(O!GAGP7#XFO#I(U:2:?6%L@B&9HMN#$^3D ]>_3BMKX6?%2/XCKK-G<Z3<>
M'O$.B7 M=3TFZD21H'*[E977AT8=&&,X/'3/FGC=_%T?[549\'0:)/?_ /"'
M+YJZY--%$(_MC<J8E8[LXX(QC/-:]OX1C^%'@/X@^*_'WB60:IKS"YU;4=#1
MH/LZ!1%%!:YRPQG:K'YB6!X(S0![?6#H6K:[?Z[KMKJ>@+I>FVDL:Z=?B]28
MWZ%<LWE@9BVGC#=:^:=,T6U\$?%[X:ZAX<\!:WX"@UB]EM+NXU#48Y3J4+6[
MN%FC6XE;>" V7Y!ZG-7/%'B?4O!NE_M*:MI$DD.HPWMHL4\1PT)>UA0R ]BH
M8MGVH ]L^,WCS4/AWX6L=2TV&VGGGU:RL66Z5F41S3+&Q&UE.X G'.,]C7>5
M\I?%KX$>$_A]X"\*ZKH/VRWOQK>E"ZNH[V1EU,M.F7G4L5<Y.\' (/0XXKZ1
M\<^$[3QWX/UGP]?*&M=2M9+9_P#9W# 8>X."/I0!N45\CV_B2\^*OPR^&OPR
MNR7U>?5SIWB&(G)6VTUP9MW^_B'Z[JM164OQ/^('Q#G\0?#G5/'T.FZN^DV"
M)J-K!!IT,:)@11R3QE7?.\R 9Y&",$4 ?5U%?)7B'PMXKN/ OP<\.>+[C4=*
MU4^*9+-IS=QR7@M#%<! 98V8;S"0NX'(ZYS7=?$_X&)IGAWPSIW@[PU%JOA;
M3=2>\U3PB+YH$U%63 ;<[;6*, ^QR%8]?< ][HKY9\>:QX1O_P!G2Y7PGI=S
MX=L;+Q+90WFDWT30RV-P+R%I(V1F(7 *G"G;SQWKT;XV?\E'^#G_ &,$O_I)
M+0![!17S!XN\-:=X$^(/B3Q-\3?"EQXCT*\U&*?3O%]K,TS:1#\NR!X@PDA1
M'!.^,$-OYZXKZ>5@RA@<@C(- 'D4?[0UM%\>KKX;7VC26<2[(K76OM&Z.>X:
M!9A"R;!L)4M@[CDKTYXZ=OB5M^,Z> ?[.SNT(ZU_:'G],3^5Y7E[?QW;O;'>
MO&-<^'C_ !(^(OQQL+*06VNVDNC7^D7G :WO(K4M$P)Z9(VD^C&D^$OCM_B1
M^T1HNNS0?9M0_P"$'EL]0M3PUO>0WX6:,CMAN1[,* /I^N:\0>/=/\-^+/#'
MAZYAN9+WQ#)/%:R1*IC0Q1&1O,)8$9 XP#SZ5\L^%=#U#XM^#=8\0ZG\.=;\
M3>)]2NKT6OB*/5[2%M/9)72%+</<*T0B*C@*,D$G<"*V_%OPKL_%'CGX&_\
M"?Z#!<^)=4M[FUU[S9 QN'ALR5#F-MIPPW96@#ZPKCOAO\0_^%@CQ*?[/^P?
MV-K=UH_^N\SSO)('F?=&W.?N\X]373:3I5IH6EVFFZ?;I:V-I$L$$$?W8XU
M"J/8  5Y1^S?]SXE_P#8[:G_ .A)0![%17S_ '_A?3?C9\?_ !EH?BZ.;4M!
M\+V-B++1Y)GCMWEG5W>=E5AO8 !1G('/>L30O"6LP1_&?X6>"]7N+"ST^"TD
MT1YKEV^P-/$6DMUD)+JIV<=UWD_4 ^FZ*^?OA-8^'=.NM:\)Z7X/N/A?\07T
M4[XRQEAEC^ZMQ%*CE)MKLN6.'R<'H:SO@CI&A_#KQ7H&@>*/!<_ASXB3V\R1
M:^D[7-OK; ;IG\]6RSL 9"DJ@KGCM0!])4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!XS1110!ZSHO_(&L/^O>/_T$
M5=JEHO\ R!K#_KWC_P#015V@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** .'^(WP?T/XE7&GWUW-J&D:WIV19ZUHUR;:\MP
MWWE#@$%3_=8$<GU-5=#^"FDZ?9:M;:QK&O>,5U.V:SN/^$BU%KA?);&46-0J
M)T'S*H;CK7H5% 'D.D?LS>']/N-.2^U_Q1XATC395FLM#UC5#-8V[(08\(%4
MN$P H=F  QBNYM? 6GVGQ!O_ !BDUR=3O=/BTV2)F7R1'&[.I VYW9<Y.XCI
MQ72T4 <QX7^'NG>$KOQ-<6<UU(_B"_?4;H3NI"2,BH0F%&%PHX.3G/->/_$G
MX'V=IX=^$O@JPLM4UCP]IVO?Z3+\S2Q0F*<F1Y(@NS#,,.-N#CG-?0]% 'GG
M@GX)Z5X.\2R>(9]8USQ/K?D&U@O?$%[]I>UA)RT<6%4*"0,D@L?7DYRK_P#9
MTTEM8U*]T;Q1XL\*0:E<-=WFGZ%JGD6TLS'+N%*,49NY0K^@KUBB@#D1\,=)
M3Q3X:UU);Q+GP_8S:?:1&;>C12! 3(6!=F C&#N]<YJ&\^$VB:AXL\0Z_<O=
MS3Z[I2Z/=V_FA8O(&[[NT!U8[CSN^F*[2B@#S;PG\"M*\,^);/7+K7O$7B>\
ML(WBT]=?U#[3'8AQM8Q*%7YBOR[FW-CO6#J7[+'AS4=%U'05\0>)[+PO>/+*
M- M-06.S@=R6)0>7NP&)<(S,F[G::]GHH X7QS\(-*\=:;H,$NH:II%[H<@D
MT_5=*N%BNH#LV, Q5EPR\$%>?:K47PQT]?$OAC7IM0U*[U'P_82Z?!)<S*YN
M%D"!WF.W+.=@.00,D\5V%% 'D>H_LTZ#<ZGJD^G>(/%'AW3M5F-Q?Z+HVJ>1
M97$C']XQ3:67?T;8RY'%=/>?"+P]<6W@ZUMHIM,LO"EVEWIUK9L FY8V0*^X
M,6&')/()/)/6NUHH Y?4OA[IVJ?$'1O&$LUTNIZ5:3V<,2.HA9)2"Q8;<DC:
M,88?0UU%%% ',^!/ -A\/[/4X;*>ZO)=2U";4[NZO65I99I2"Q)55&  % QP
M *SM0^$'A_5?%7B#6[Q)KC^W],32]2T]V7[-<1H3M<C;NW@,5W!NG;/-=O10
M!YIX+^!=EX+U?3[R/Q9XLU:VTY66RTS4]4\RT@!4H,(JJ7VJ2%WEL=JN:3\&
M]-T'XA7WBO3=8UNQ-_.;J[T:"[4:?<3F/897CV;BQ&#][&0#CBN_HH \EU3]
MFGPUJ>M:U=+JOB"QTO6YC<:EH%EJ)BT^ZE88=WC"[LMQN 8!L#((XJ]<_ +0
M)/"?A+1;?4-6TZX\+*%TK6;.=$OH!MVL-VPHP=>&!3!':O3** /._!GP1TCP
M7KNMZS'JVM:MJFM6B6E]=:K=B=Y I8AQ\HVG#XPN$ 5<*.<FG? [0M,T#P-I
M$5WJ+6W@^Z6[L'>2,O*X5U E.S!&)#]T+VKT2B@#POXK_#K_ (6%^T'\-I#I
M-T;/0H9]2OM2,+"V=0Z&"WWXVL_FKOVYR%R<<U[I110!S0\ Z>/B,?&GG7/]
MJ'2QI/D[E\CRA*9=V-N[=N.,[L8[=ZM^,O"&E>/O#&H>']:MOM6F7T?ES1YV
MGJ""".A! (/8@5M44 >5Z?\ L]Z;!XC\/ZYJ/BGQ3X@U#0IO-L6U6_21(QY;
M(4*+&JG(8$MC>2J_-C@[\7PC\/\ F^-3=)/J%OXN=6U*UN7'EX$0BVIM 91M
M .<D@\@BNUHH \8'[*_AR:VL;?4/$7BK68=-G@GTV/4=3$R6'E2*ZK$NS&"%
M"$L&;;D!AFO9Z** //O#7P0\.>%/B=KOCJR-V=7U="LL$LBFWB+;#(T:A059
MS&I8DG..U5/%'P%TK7O%%]XATWQ!XC\(ZIJ"HM_)X>OQ MV57:K2(R.NX#@,
M #^9KTRB@#A9?@_H\UIX1@DO=4E_X1J__M*VFGNS-+<3%7#&=Y S/GS&)P1S
MC&!Q5OQ]\-;7Q\^GW!UG6O#^HV'F"WU#0[S[/*JOMWH00R,IV+PRG&!C%=?1
M0!YY;? GPK%\.]4\&W,5WJ6G:K(\]_=7URTMW<SL0?/>4\F0%5P>VT<5D:/^
MS?HFG>(/#^NWOB+Q/XAUC0YO-L[S6=1%PRKL9#$1L"[3NR2 &)5<L<8KUJB@
M#RK6OV=="U[5KJ:[USQ(VBW=V;VZ\.#4V_LV>4OO;=&06VLWS% X7/:O5  H
M  P!T I:* .:T'P#I_A[QCXF\26TUR]]X@-L;J.5E,2>3'Y:; %!&1UR3STQ
M6'H'P-\->&/BOK/Q!T];J#6M6MC;W, D7[,<LC,X7;D,QC7)W8Z\9->@T4 >
M3W_[.FDMK&I7NC>*/%GA2#4KAKN\T_0M4\BVEF8Y=PI1BC-W*%?T%;?C3X-:
M-XSTGP_:&^U71KG0'#Z;J>F76R[@PFPCS'#[@R\-N!)KO:* *>CZ=_8^DV=C
M]JN;W[-"D/VF\D\R:7: -[M@;F.,DXZFO+1^SC;6FK:U>Z5X]\::$NK7\VI7
M%IIU_ D(FE.6*@P$@=!R3TKUZB@#SCQ?\#-*\6:U8ZY%K>O>'O$5M;+9OK&B
M7BP7%U"/X)LHR.,_-]WK]!4FF? OPSI7@W5/#T3ZG(-4F6ZO=5DOY#J%Q<*5
M9)FGSNWJ44C& ,=.3GT.B@#S;P[\!]$T>75[C4M5UWQ5J&J6+:9-?Z[?^;-'
M:M]Z*,HJ"-2>3M .0#FCPG\"M*\,>);/7+K7O$7B:]L(WCT]=?U#[3'8AQM8
MQ*%7YBOR[FW-CO7I-% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'C-%%% 'K.B_\@:P_Z]X__015VJ6B_P#(&L/^
MO>/_ -!%7: "BBB@ HHHH AENX+>6"*6:..6=BD2.P#2,%+$*.YP"<#L":FK
MP[XAZ;<:)XXN_$WBJ+79_#UI/;3Z7K.A:FT<>CJ J2">T#J'5F+EG"3$I(RL
M%5173^(5OK#XV>#F36=1DL]0@O\ ?IYF"VJ!(HMN$4#<<DMN?<P)."!Q0!Z5
M17FWQJUC6+>/PMHFB@^?KNJ?9)B+U[+,2V\TS(+A$=XMQB W(I;!.W!((X^V
MUV7Q!8^#/#"/JN@P7'B"^TW5DCURYN;AFMHII/+CO683%'9$;(*MM!7 &10!
M[S17@-GJ6J:D/#OA&XUK5!ILOBK4=,EO4O98[R>VMXYI8H3<*5DSE5!<-O81
MD%CDD]Q\-]7OK3P5XC26YN=3?1=1U"TM9KR1I99(HG;RU9S\SD#";CDG;R2>
M: /1J*^7-5\3Z]X&^'_A_P 3:?XBU2]U37_"UYJ%])>W<ES MQY44JW$<3EH
MX0C2, L85<$ @X&.E\5ZEJGPH@\:VFBZUJEW%#X534X9=6O9;YK:Y\R2,S!I
MBQ (PVS.S,?"C)R >_45YCX)L)O"7Q+O?#UOJNJZEI<FB6]^1JM_+>ND_FO&
MS!Y2S*' !VAMH*Y"C)SZ=0 44C$JI(4L0,[1U-4_M\__ $#;K_OJ+_XN@"[1
M5+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[
M?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+
MH NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#;K_OJ+_X
MNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\
MXN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO
M^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_X
MN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - V
MZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;
MK_OJ+_XN@"[15+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ
M_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\
MT#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?
M/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\
M] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT
M52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#;K_OJ+_XNC[?
M/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"
M[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO
M_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[
M15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[Z
MB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ
M+_XN@"[15+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^
MHO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K
M_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#
M;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15(7TY(_XEUR/?=%_P#%U=H *AENX+>6
M"*6:..6=BD2.P#2,%+$*.YP"<#L":FKP[XAZ;<:)XXN_$WBJ+79_#UI/;3Z7
MK.A:FT<>CJ J2">T#J'5F+EG"3$I(RL%510![C16/9>*K*_UZYTB*'4EN[=2
M[RS:7<Q6S#C[EPT8B<_,.%<GKZ'&Q0 4444 %%%% !1110 4444 %%%% 'C-
M%%% 'K.B_P#(&L/^O>/_ -!%7:I:+_R!K#_KWC_]!%7: "O//$FH_$_4=1>#
MPQHWAS2+"*\$9U#Q!>2W$LT  W2);0* .2=NZ8$A>57/'H=>%^*-?\?^%-;\
M4V LM3\0ZOKD$%OH%[I-A*FFV6=Z$S!I9%A9"^]G8C> N.F% .H6]^+FA:K>
M27>G^%/%FBHJ&%=+EGTR_;IOQ'*9HF/7"F5 <#+#.!Z6#D XQ[&O%/"7PYN_
MA/\ $73K'P?8W5YINH6$ESXAN=5U&Z\F:Y\V)1<J[K*K7##SB8P4W#&2 !7M
ME '":M\'M%USQ?)K-X]W+93*'N='%Y<+97-PI3;-+ )!$Y"Q@89"#U.2!B[K
M7PKT#Q!XF@U^]_M8ZI;G,,D&MWL$<7 !"11S*BA@HW +AN^:F\0?$WPSX7\3
M:/X?U+6+*UU?59/+M[22YC63E6*DJS X8KL4@'+$ 5MS:WIUOJUOI<M_:Q:G
M<QM+#9/,HFE1?O,J9R0,C) XS0!RUQ\*-)U:^UZ[U=IKZ?5+R"Z66"62TDM1
M"@6%8I(G#JR_.2ZD$^8P/&!5M_A=X:;PS:Z"NGR0Z?:S_:H&@NYHKB.8EB9A
M<*XE$C%GW/OW-O;).XYZ>XN(K2WEGGE2&")2\DDC!510,DDG@ #O65-XS\/V
MWAU?$$VNZ9%H+*&75'O(Q:D$[01*3MP3P.>M &?-\,O#DWAJTT'[!)%I]I+]
MHMV@NIHKB*;+$RK<*XE$C%WW/OW-O;).XYKV'PQTO2]:T"ZLP8+#1(+E;6R&
MYB9YR/,GDD9BSL1OSNR29&8DG!&S<>,= M/#JZ_/KFFPZ$RJZZI)=QK:E6("
MD2D[<$D '/.:O:9J=GK6GP7VGW<%_8W""2&YMI%DCD4]&5E)!'N* .9TCX2>
M$]$DNS;:3OCN;>2S:"ZN);B&*W<Y>&**1V2&-CC*1A5.U>/E&)]"^&7ASP]9
M:C:V]A)<Q:C$+>[.I74U\\T(4JL1>=W;RP&;"9VC<V!R<Z&E>,_#^O7]_8Z9
MKNFZC>Z>2MY;6EY'+);$$@B15)*<@CG'0TOA[QCH'BZUGN="US3=:MX&V2S:
M?=QSI&V,X8H2 <<X- %;PGX!T7P2;EM*@N!-<A$EN+R]GNYF1 0B>9,[L$7+
M80':-S$#DYZ&LCPYXOT'QA;S3Z#K>G:W!"_ERRZ==QW"HV,[6*$@''8UKT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5PFK?![1=<\7R:S>/=RV4RA[G1Q>7"V5S<*4VS2P"01.0L8&&0@]3D
M@8[NB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#UG1?\ D#6'_7O'
M_P"@BKM4M%_Y UA_U[Q_^@BKM !7GGB3X=^*I=1>]\+?$34M!\V\%U-8:C90
M:G9E<#=&@<+,BL0#A9<+EMH7(QZ'7C/QTT"PT+3X/$,VI>*=.L7U")M8O]*U
MS4L65H%9GD6WBE*JI*(C%4^42,V 1D &TOPX\;ZQJMY+XA^)ET=)G5 NE>'-
M+BTU4QC<//9IIP&QR5D5ADX8< >E@8 'IZUXA\,-5T"^^+^H1^#?$6L^*M"C
MTHK>S3ZS>:A865SOC,:Q22R-&[R([%@"Q7RL KE@?<* / O'WB/3/!7BSQ'<
MZ-K^CZMJNH7=H=0\#:M 'N[V91$B&TP1("8PA!*2IN3C9AC6EXU\4>#- ^/G
M@\2:MH6F:JR7HU$/<PQ3F1X85A$W(;<5P%W<D8 KUYM'LVUE-5,.;]+=K59M
MQXC9@Q7&<<E5.<9X%7: /+/B?KESXBU)/"VEZ+?^(K*VD27Q!;:<\$<JQ%=\
M,.;B6)2LI!W%68A492!O!'F_@O5H[7X=_![6-<M)-&\/Z7JMP;JYU&2$01$P
M7"PSNRNRHGF/L#.00Q''*D_1NFZ)9:1-?S6D AEO[@W5R^XDRR;53<23_=10
M!T 48J]0!\X6-Q9:;%X4\1WCPVO@I?&6IZ@E[,0EK%%+'<+;W#,0%6-I&)5S
MP3*A!.X&NP^'&MVEMX9U&TLYQ!)XCU75[CP^(XV"W$>YW\Q&"X"D[G5CPP8$
M$Y%>OU1?1+*36H=7> -J,-N]K'.6)*1LRLR@9P,E$).,G:/2@#Y3U-+?Q/\
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M]WG[MN\G&=JYQUP/2M:.-C6FH);GGYAPU5R_#2Q,JB:C;2SZM+]3Z9\K4?\
MGZM?_ 9O_CE'E:C_ ,_5K_X#-_\ '*NT5Z1\<4O*U'_GZM?_  &;_P".4>5J
M/_/U:_\ @,W_ ,<J[10!2\K4?^?JU_\  9O_ (Y1Y6H_\_5K_P" S?\ QRKM
M% %+RM1_Y^K7_P !F_\ CE'E:C_S]6O_ (#-_P#'*NT4 4O*U'_GZM?_  &;
M_P".4>5J/_/U:_\ @,W_ ,<J[10!2\K4?^?JU_\  9O_ (Y1Y6H_\_5K_P"
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M2\K4?^?JU_\  9O_ (Y1Y6H_\_5K_P" S?\ QRKM% %+RM1_Y^K7_P !F_\
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M4>5J/_/U:_\ @,W_ ,<J[10!2\K4?^?JU_\  9O_ (Y1Y6H_\_5K_P" S?\
MQRKM% %(1:AD9NK;'_7LW_QRKM%% !115.\U>TL+RPM)YA'<7TC16Z8),C*C
M.PX'&%5CSZ4 7**** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ]9T7_D#6
M'_7O'_Z"*NU2T7_D#6'_ %[Q_P#H(J[0 5P'C[7-4\$V.H:K-XMT_3K6ZO;>
M&QAO-#EOFCW*$\B.."9))I'D^88R0,C:0,COZ\J^,'C[P9H'B#PO9:]XGBT3
M5;&^CU:)'M9;A!%\UNQF*#$*-YY42.0H;!YP10 ?"WXG3^,O$4MA+XCM-7Q9
M?:UMX/"&HZ2VPOL63S;F5T920X  R2#@_*:]5KSOP+\+[KPMXA749?$9U72K
M6VGM=)L1:K&;:&:82L))0Q,Q&R-5.%PJ]"237HE 'G^L_$^[A\7KI.C>'=1U
MNRL+N.VUN_M$B9;,R1AD"JTJR.1OB=BB. A/5@0-BY^(-C:^.K'PJUEJ/VR[
MCE=+MK8I;9C1790[$;SAQR@90<@D$8KS;XC6%]J7CRZM/#OAK4](\;2I%-:^
M)=/U**&SEMT>,;[R/S090I9T\MX9#C.P\DKT/C)O$$OQ7\*W]GX/U;4=,TE+
MJ.>_@N+)8W\^., HLEPKX4J=V5!XX#4 =SXEU^;0+2*2WT;4==N)9!&EIIJ1
M[SP226E=(T4 'EG&3@#)(!YD?&/2IO#&EZK;:;J=W>:G>OIMMHL4<8O&NHRX
MEB(:01J4\J0LQ?;A,ACD9SO%_C[Q9<KKUAX.\+S:I/97D-@-1CN(/W9:/?-(
ML4SQ*YBW( N_#,W)&UA63'X3U'2]&\$:AH_A;5HW\-ZA/+<:3?W-F;Z\2:&1
M)9PZ3F$R&27S#ND7/S]#M! .H;XPZ8?#VGZA#IFJ7.H7]^^EP:(D4:WIND+^
M;$=T@C&P1NQ<R;,+D,<C._X3\86?B[0CJD,5Q8K')+!<6U\@26VEC8K(CX)7
M*E3RI*GJ"00:\QM_ _B/2H="\3+H[W.I6_B&^UBYT*">#SU@N8Y8PBNSK$9$
M#1LV7V\. S<$Z/A2/4M,9_#=[I9@OO%,VJ:M>(LZ,=+@<@1A]H*NY+HI"M][
M<07"DT :&G?'K0+JU:^O;'5=&TA]/GU6SU._@00WUK%@O)$$=G'RLC!9%1F#
M A3SB]IWQATR2SUF?6=,U3PLVDV"ZI<0ZO%'O-JP8B5?)DD!Y1@4SO!&"HR,
M^97WPL\6^-?!ND>&[S2!HD_A_P /7.EI?W-Q#)!?731QQ1M$(V9Q$?++$R!&
M&Y1M)SC>U_P/XC^)]OXMN[G1W\+7%YX>71[*VU&>"5I)P[REV,#R 1[BBCYM
MQ^<[1QD [_P=\0XO%FH76GS:+JOA_4H+>*[^QZM'$'D@D+!)%,4DBXRK J2&
M!'*C(SUE>>^#;#6M9\>7GB?5M"N/#D:Z5#ID-I>3P2S2.)'DDDS"[J$&5"Y;
M)^;*KQGT*@ HI&4.I4YP1C@X/YU3_LF#_GI=?^!<O_Q5 %VBJ7]DP?\ /2Z_
M\"Y?_BJ/[)@_YZ77_@7+_P#%4 7:*I?V3!_STNO_  +E_P#BJ\/^.'[0,'P9
M\66FB_\ "/W6L>?9)>>?_;,L&W=)(FW;M;/^KSG/?IQ710P]3$S]G25W_7<Q
MK5H4(\]1V1[[17Q__P -NP?]"5=?^%#+_P#&J/\ AMV#_H2KK_PH9?\ XU7H
M_P!CX[_GW^*_S.'^T\)_/^#_ ,C[ KX2_;N_Y*[I'_8#A_\ 2BXKK?\ AMV#
M_H2KK_PH9?\ XU7A7QV^*:?%SQ=::PFER:2(+%+3R)+UKHMMDD;=N95(^_C&
M.WO7CYMEV*PV&=2K"RNNJ_1GVO"&-P]?-%"G*[Y7T?\ D><T445\2?N@5]>_
M\$_O^9\_[</_ &YKY"KZW_8&M$NO^$ZWM*NW[!CRY63_ )^.NTC-=N"_CQ^?
MY,^:XD_Y%5;_ +=_]*1]B452_LF#_GI=?^!<O_Q5']DP?\]+K_P+E_\ BJ^H
M/P\NT52_LF#_ )Z77_@7+_\ %4?V3!_STNO_  +E_P#BJ +M%4O[)@_YZ77_
M (%R_P#Q5']DP?\ /2Z_\"Y?_BJ +M%4O[)@_P">EU_X%R__ !5']DP?\]+K
M_P "Y?\ XJ@"[15+^R8/^>EU_P"!<O\ \51_9,'_ #TNO_ N7_XJ@"[15+^R
M8/\ GI=?^!<O_P 51_9,'_/2Z_\  N7_ .*H NT52_LF#_GI=?\ @7+_ /%4
M?V3!_P ]+K_P+E_^*H NT52_LF#_ )Z77_@7+_\ %4?V3!_STNO_  +E_P#B
MJ +M%4O[)@_YZ77_ (%R_P#Q5']DP?\ /2Z_\"Y?_BJ +M%4O[)@_P">EU_X
M%R__ !5']DP?\]+K_P "Y?\ XJ@"[15+^R8/^>EU_P"!<O\ \51_9,'_ #TN
MO_ N7_XJ@"[15+^R8/\ GI=?^!<O_P 51_9,'_/2Z_\  N7_ .*H NT52_LF
M#_GI=?\ @7+_ /%4?V3!_P ]+K_P+E_^*H NT52_LF#_ )Z77_@7+_\ %4?V
M3!_STNO_  +E_P#BJ +M%4O[)@_YZ77_ (%R_P#Q5']DP?\ /2Z_\"Y?_BJ
M+M%4O[)@_P">EU_X%R__ !5']DP?\]+K_P "Y?\ XJ@"[15+^R8/^>EU_P"!
M<O\ \51_9,'_ #TNO_ N7_XJ@"[15+^R8/\ GI=?^!<O_P 51_9,'_/2Z_\
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M +7_ +_+_C1_;6G?\_\ :_\ ?Y?\: +M%4AK6GD@"^MB3_TV7_&KM !1110
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MAX(U/2=>N]=U_6;?6M7FM(K".2SL#9Q10(S-]PR2$NS.2S;L<* JX.>RHHH
M**** "BBB@ KX?\ VX/^2L:3_P!@2+_T?/7W!7P_^W!_R5C2?^P)%_Z/GKZ#
M(_\ ?%Z,\;-O]V?JCYYHHHK]%/B JE>_ZT?[M7:I7O\ K1_NU\?Q7_R+7ZH_
M2/#_ /Y'<?\ #(KT445^*G].A7U[_P $_O\ F?/^W#_VYKY"KZ]_X)_?\SY_
MVX?^W-=N"_CQ^?Y,^:XD_P"156_[=_\ 2D?7U%%%?4'X>%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7G7Q4U7Q7I>I^&Y=%M]'_LU=0C$\VHZZVGF5W21%A*B!PRLS1XP68M@!.-P
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M-NO^^HO_ (NC[?/_ - VZ_[ZB_\ BZNT4 4OM\__ $#;K_OJ+_XNC[?/_P!
MVZ_[ZB_^+J[10!2^WS_] VZ_[ZB_^+H^WS_] VZ_[ZB_^+J[10!2^WS_ /0-
MNO\ OJ+_ .+H^WS_ /0-NO\ OJ+_ .+J[10!2^WS_P#0-NO^^HO_ (NC[?/_
M - VZ_[ZB_\ BZNT4 4OM\__ $#;K_OJ+_XNC[?/_P! VZ_[ZB_^+J[10!2^
MWS_] VZ_[ZB_^+H^WS_] VZ_[ZB_^+J[10!2^WS_ /0-NO\ OJ+_ .+H^WS_
M /0-NO\ OJ+_ .+J[10!2^WS_P#0-NO^^HO_ (NC[?/_ - VZ_[ZB_\ BZNT
M4 4OM\__ $#;K_OJ+_XNC[?/_P! VZ_[ZB_^+J[10!2^WS_] VZ_[ZB_^+H^
MWS_] VZ_[ZB_^+J[10!2^WS_ /0-NO\ OJ+_ .+H^WS_ /0-NO\ OJ+_ .+J
M[10!2^WS_P#0-NO^^HO_ (NC[?/_ - VZ_[ZB_\ BZNT4 4OM\__ $#;K_OJ
M+_XNC[?/_P! VZ_[ZB_^+J[10!2^WS_] VZ_[ZB_^+H^WS_] VZ_[ZB_^+J[
M10!2^WS_ /0-NO\ OJ+_ .+H^WS_ /0-NO\ OJ+_ .+J[10!2^WS_P#0-NO^
M^HO_ (NC[?/_ - VZ_[ZB_\ BZNT4 4OM\__ $#;K_OJ+_XNC[?/_P! VZ_[
MZB_^+J[10!2^WS_] VZ_[ZB_^+I&U&95+-IUR !DDO%Q_P"/UG^+O&^D>";#
M[3JER(RP/EP)\TLI]%7^O0=S7BUUKOC#XY7<EGID)TKP^&VR-DA"/]M_XS_L
MCCIGUKR\5F%/#2]E%<]1[16_S[(SE-1TZGJ.F_%W0]8\1C0[);BYOFW;?+"&
M-BH)(#[\'@'IQQ74_;Y_^@;=?]]1?_%US7@+X6Z/X!B#VR&ZU%EVR7LP^8^H
M4=%'L/Q)KLJZ,*\0Z=\392?1=%V]2HWM[Q2^WS_] VZ_[ZB_^+H^WS_] VZ_
M[ZB_^+J[17844OM\_P#T#;K_ +ZB_P#BZ/M\_P#T#;K_ +ZB_P#BZNT4 4OM
M\_\ T#;K_OJ+_P"+H^WS_P#0-NO^^HO_ (NKM% %(7TY(_XEUR/?=%_\75VB
MB@ KE+SX6^%]1\<P>+KK1;*XUV"'RH[F6UB9E(92LFXKNWKM #9X&0.IKJZ*
M (+VRM]2LY[2\MXKJTGC:*:"= Z2(PPRLIX(()!!ZUS^E?"_P;H4%[#IOA+0
MM.AOHC;W<=IIL,2W$9ZI(%4;E]CD5T]% ',W?PY\/S^&X/#UMIT&EZ''<1W!
MT[3H4@@DVR"38R*N"C, 6  W<@\$U?NO"&@WVOVVNW.B:=<:W;)L@U*6TC:Y
MB7GA9"-RCYFX!_B/K6O10!D6_A#0;7Q#/KT&B:=#KEPGES:G':1K<R+@#:TH
M&XC"KP3V'I1;^$-!M?$,^O0:)IT.N7">7-J<=I&MS(N -K2@;B,*O!/8>E:]
M% !7!>+/B-<>&O'OA[1KFT33-%OFF\[6M0DB6WE*PLXAB(F#+)D9)=,;4;&>
MJ][7!?%+3=?U.R:*S\*>'?'.B^0SS:)K4WD2/.I!0H[1RQ-D9&UU3!P=^#@
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M;RV3:OW7;<P;[I# YP02 =Y#XQT"Y\13:!#KFFRZ["N^72TNXS=(N <M$#N
MPP.2.X]:-(\8Z!X@U&^T_2]<TW4K^Q;9=VMG=QRRV[9(Q(JDE#D$<XY!KY\T
M^2*ZTS0O#%C+#_PG]GXKU&^NK0,/M<"LUV3<R#!98WCDC"N<!A(@!Y JY\/+
MBRUJ/X=:=X:>'^VM"\,7=KJD,)'FZ?*T4*>3<<9CD,ZD[6()*.<'!- 'N^D>
M,= \0:C?:?I>N:;J5_8MLN[6SNXY9;=LD8D522AR".<<@UL5\^?".\TK5-3^
M%EEHK0/J&@>'[BWUJWBQYM@Q2!3#< #,<AF5CM8@DHYP<$U]!T %%(P8J=I
M;'!(R :I^5J/_/U:_P#@,W_QR@"[15+RM1_Y^K7_ ,!F_P#CE'E:C_S]6O\
MX#-_\<H NU\/_MP?\E8TG_L"1?\ H^>OM/RM1_Y^K7_P&;_XY7Q1^VPLR_%3
M2A/)'(_]BQ8,:%!CSY^Q)KZ#(_\ ?%Z,\;-O]V?JCY]HHHK]%/B JE>_ZT?[
MM7:I7O\ K1_NU\?Q7_R+7ZH_2/#_ /Y'<?\ #(KT445^*G].A7U[_P $_O\
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MH\K4?^?JU_\  9O_ (Y0!=HJEY6H_P#/U:_^ S?_ !RCRM1_Y^K7_P !F_\
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MY17"^#_B[IWC+4K*UATK5=/@U*VDO-+O;Z&-8=1@0J#)'LD9EX=& E5&*L"
M><=U0 4444 %%%% !7P_^W!_R5C2?^P)%_Z/GK[@KX?_ &X/^2L:3_V!(O\
MT?/7T&1_[XO1GC9M_NS]4?/-%%%?HI\0%4KW_6C_ ':NU2O?]:/]VOC^*_\
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M,MK$S*0RE9-Q7=O7: &SP,@=30!<_M&YUK4M1T:YT#5['3S"RC5_M,$44P(
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M#7QO#X1UP:@;"_U&'Q6FOV=I:0?9OM21W*R/AFGD"^8H.Q6*[3@,Q!R/>**
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M_P#BJ/[)@_YZ77_@7+_\55VB@"E_9,'_ #TNO_ N7_XJC^R8/^>EU_X%R_\
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M;R.!%@-]]H1L>0@S,"C!5#\*N17T_0 4444 >,T444 >LZ+_ ,@:P_Z]X_\
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M#A2#Q?L_@Q)#?6UI<ZQ%=>$K/4;C5;72?L6V=9IO,)5[CS"&C5II"JB-6'R
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M7=YE"/5],B142]M$10 JK*H 'H.:=_;6G?\ /_:_]_E_QJ[17NFI2_MK3O\
MG_M?^_R_XT?VUIW_ #_VO_?Y?\:NT4 4O[:T[_G_ +7_ +_+_C1_;6G?\_\
M:_\ ?Y?\:NT4 ?#?[;%U#=_%32G@FCF0:+$"T;!AGSY^.*^?:^AOVX/^2L:3
M_P!@2+_T?/7SS7ZEEG^YT_0_/L?_ +S/U"BBBO3. JW_ /!^-5*MW_\ !^-5
M*_"^)?\ D:UO^W?_ $E']6<$?\D_AO\ M_\ ]+D%%%%?,GW)];_L#7MO9_\
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M[NIE97\MENI4C98W5@59I&'W222,M0!WU%%% !12,2JDA2Q SM'4U3^WS_\
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M (W1_P ,0?$7_GKHO_@6_P#\;K\I^JUOY6?T!_;F6_\ /Y'S]7U[_P $_O\
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MO@7_ *'7P[_X-8/_ (NOSXB^%VHR?>OK"/\ WFD_HAJ[#\'KR9@O]NZ.A/\
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M:P_Z]X__ $$5=H *\N_:&L4U'P=IT%W9:QJVC/J<*ZGI6B07$L][;%75H_W
MW!02KG)4$1[<Y8 ^HUYW\<_%5YX/\(6E]!KL7ABS?4K:WO\ 67BCFDM+=VP6
MC20%68ML7)5MJLS;3MH X/PCJ?A?P/\ $V]N_#7AGQ/X>\.7.G@7=M;>%=42
MUNKLL@C>.!;?$;)'&P9MJ[O,7[Q#$>_@Y /KZUYU\.]?T35=;FBT[XL_\)U.
M(&8Z=]KTR7RUW+^]Q:P(_&0,D[?FZ9Q7HU !117+M\3?#*^.XO!W]L63>(9(
M'F^Q+<Q^8NW:=A3=N#E6WA<<JK'H* .HHJKJ>J66B:?/?ZC=P6%C;H9)KFZE
M6..-1U9F8@ >YK*3X@>%Y/#C>(5\2:0V@*VUM5%]$;4'=MP9=VW.X@=>O% &
M_16/<>,= M/#JZ_/KFFPZ$RJZZI)=QK:E6("D2D[<$D '/.:O:9J=GK6GP7V
MGW<%_8W""2&YMI%DCD4]&5E)!'N* .<\=?#JT\<2Z;.][?Z7=V<HS=:;>W%K
M+) 65I("T,B':^Q>N<8R!GFM[0]#L/#6D6NEZ7:QV5A;)LB@C'"C^9).22>2
M2222:K:1XQT#Q!J-]I^EZYINI7]BVR[M;.[CEEMVR1B15)*'((YQR#2:5XS\
M/Z]?W]CIFNZ;J-[IY*WEM:7D<LEL02")%4DIR".<=#0!LT5D>'/%^@^,+>:?
M0=;T[6X(7\N673KN.X5&QG:Q0D X[&M>@ HHHH **** "BBB@ HHK(\2WVLV
M-I%_8>DV^K7LD@0I=WOV2&-<$EG<)(W8 !48Y(S@9( ->BO,+;XR7.I>&M!G
ML=!27Q%J^IW&DQ:9+?;+>.:W:43NUP(V/E*('(81DG*C:"3BS9_$CQ'K?AYK
MS2/"MG-J%I-=6VI6]]K'D06\L#;61)5A=I-W528T&WEBIPI /1J*\VUOXQ2V
M7PWT/QCIWAVXO[+4H+:Y<2W,<"VR3-&H#GYF9OWG 52#M.67()])H **** "
MBBB@ HHHH **** "BBB@#Y7_ &J/@IXT^)'Q"T_4_#FC?VC91:7';/+]JABQ
M()9F*X=U/1U.<8YKQO\ X93^*?\ T*__ )4+7_X[7Z&45[]#.L1AZ4:48QLO
M)_YGCULKHUJCJ2;N_3_(_//_ (93^*?_ $*__E0M?_CM'_#*?Q3_ .A7_P#*
MA:__ !VOO7Q+?:S8VD7]AZ3;ZM>R2!"EW>_9(8UP26=PDC=@ %1CDC.!DCA[
M;XR7.I>&M!GL=!27Q%J^IW&DQ:9+?;+>.:W:43NUP(V/E*('(81DG*C:"3C?
M_6#%?RQ^Y_YF/]C8?^:7X?Y'EWP2_9-T>3PK=GXC^%<ZY]M<0_\ $Q?_ (]_
M+CV_ZB7;][S.O/X8KT'_ (9)^%'_ $*G_E1N_P#X[6S9_$CQ'K?AYKS2/"MG
M-J%I-=6VI6]]K'D06\L#;61)5A=I-W528T&WEBIPIM+\0-:UWP7H?B'PQX<@
MU"'4M/&HNNJ:E]B6%"BL$W+%*6<[N/E"X4DL. ?F\1RXJK*M4@KR\CZC#8O%
M82C&A1K348Z)<S_0YS_ADGX4?]"I_P"5&[_^.T?\,D_"C_H5/_*C=_\ QVO1
MO!OB:#QIX2T;7[:&2WM]3LXKR.*7&]%= P!QQD9[<5LUS>PI?R+[D=/]IX__
M )_S_P# I?YG'_#_ .$GA/X6_;_^$7TK^S/MWE_:/])EFW[-VS_6.V,;VZ8Z
MUV%%%:QBHJT59'#5JU*TW4JR<I/JW=_>%%%%49!1110 4444 -DC252KJKJ>
MS#(K.N/#.CWF?/TFQGSG/F6R-UZ]16G142A&7Q*X',W'PS\*7)._P]IXS_SS
M@5/_ $'%9ES\$O!=R.=%6,^L<\JX_ -BNYK(\2WVLV-I%_8>DV^K7LD@0I=W
MOV2&-<$EG<)(W8 !48Y(S@9(YI8/#3^*G%_)$\L7T.*N/V>O",Q^2.\@Y_Y9
MW&?_ $(&I_#GP(\+^'=06\V7.I2)RB7SJZ*?7:% )^N:JVWQDN=2\-:#/8Z"
MDOB+5]3N-)BTR6^V6\<UNTHG=K@1L?*40.0PC).5&T$G%FS^)'B/6_#S7FD>
M%;.;4+2:ZMM2M[[6/(@MY8&VLB2K"[2;NJDQH-O+%3A3BLMP<9*:I*Z\A<D>
MQZ+TI:\]OOB;J=U\.]+\7:#H-M=V-UIAU:?^UM2^Q+;1",2;=RQR;G()QP%P
MI)8<9[/0-8C\0:%IVJ0Q2PPWMO'<I'.NV1%=0P##L1GFO2++]%%% !1110 4
M444 %%%% !1110 4444 %%9'B6^UFQM(O[#TFWU:]DD"%+N]^R0QK@DL[A)&
M[  *C')&<#)'#VWQDN=2\-:#/8Z"DOB+5]3N-)BTR6^V6\<UNTHG=K@1L?*4
M0.0PC).5&T$G !Z?17G-G\2/$>M^'FO-(\*V<VH6DUU;:E;WVL>1!;RP-M9$
ME6%VDW=5)C0;>6*G"EFO_&FVTSX6:5XOLM+EO[G5;-+RRTEY1%(X,7G/N?#;
M52,,Q8 CCC.1D ])HJCH6I_VUHFGZCY?D_:[>.X\O=NV;E#8S@9QGKBKU !1
M110 4444 %%%% !117+^(/B;X9\+^)M'\/ZEK%E:ZOJLGEV]I)<QK)RK%259
M@<,5V*0#EB * .HHIDTT=O$\LKK'$BEF=S@*!R23V%<_9?$GPCJ6BWFL6GBG
M1;K2+-@MS?PZC"\$!.,!Y VU3R.I[B@#HZ*S/#_B?1_%MA]NT/5K'6;+>8_M
M.GW*3Q[AC*[D)&1D<>]17GC'0-/U^VT.ZUS3;;6[I=\&FS7<:7,R\\I&3N8?
M*W0=CZ4 ;%%8\/C'0+GQ%-H$.N:;+KL*[Y=+2[C-TBX!RT0.X## Y([CUHA\
M8Z!<^(IM AUS39==A7?+I:7<9ND7 .6B!W 88')'<>M &Q1110 4444 %%%%
M 'C-%%% 'K.B_P#(&L/^O>/_ -!%7:I:+_R!K#_KWC_]!%7: "O/?C9I5Y=^
M'--U33VT2&[T+4H=42Y\0WC6UE"$#*S.PC?/RNP'W<$AMV5P?0J\U^-&CR>+
MM'@L-,L=,\3ZEI5U#JEQX7O[B-%OX=LBK&^X,%RV64N-I:/D\&@#1^'7CS4?
M'3SS@>%+K2HLH;SPYXC;4R)N"$8?9HU7Y3G.[/3CG([FO(_!,5WK/QGU76KC
MPW;^#I8M+6":TEOK:74-2#LGESSQ0,X5(_*DC1F=B=QQ@#%>N4 %>!6'B/3/
M"_C:VTGP[K^D>*[;4/$<DEQX9N8 =6TR>1Y#/<(P.Y4C?<W[R+.UCB7!45[[
M5*VT>SM-4O=1BAVWMXL:3R[B=ZQ[M@P3@8W-TQU- '(>)_&@\(>'-8UOQ_I^
MD:;H6GR1RVTEM>O>O*PD_=DH\$81]WE[<%L$]1MR?(=-UC0GU70/&%WKNB7&
MGW'BF75=9%AJ,-S::1(]@\%J)I$;8I^107/'F/P2-IKZ:HH ^<+&XLM-B\*>
M([QX;7P4OC+4]02]F(2UBBECN%M[AF("K&TC$JYX)E0@G<#78?#C6[2V\,ZC
M:6<X@D\1ZKJ]QX?$<;!;B/<[^8C!<!2=SJQX8,""<BO7ZHOHEE)K4.KO &U&
M&W>UCG+$E(V9690,X&2B$G&3M'I0!\_?#RXLM:C^'6G>&GA_MK0O#%W:ZI#"
M1YNGRM%"GDW'&8Y#.I.UB"2CG!P37*:FEOXG^&GAS1_"L8N]:T;P9?VFL6-D
M-US:%HH5>VF4#<DKR(^$8AF*L0#@FOKJB@#R?P!J^B^*?BIJ&K>%KFSO]$AT
M"TLIKO3V5X?.$LC)#N48W(A.5SE0ZY R,^L444 (P8J=I ;'!(R :I^5J/\
MS]6O_@,W_P <J[10!2\K4?\ GZM?_ 9O_CE'E:C_ ,_5K_X#-_\ '*NT4 4O
M*U'_ )^K7_P&;_XY1Y6H_P#/U:_^ S?_ !RKM% %+RM1_P"?JU_\!F_^.5R?
MQ+TWQYJ7AX6?A*]TB&\GD"7$]V\ML\<&#N\EU67$AX )0@9)Z@5W-% 'D1^'
MOBR+0_"<]A8^'=*U7PQ=.]GI45Y<2VDT+0M$RO<-$'5B)"V?+8EE&2=Q(R]7
M^&WQ%/AM=+LI_#]S!JU]<ZAX@@>]N;0R>:VX6T,RQ2-Y6/E9MJ,P'&W<<>XT
M4 >4?$/PKX\\5?#VVT+3[#PO:W$OE_:8FOKB.&U$4J.BQ,("9 0F#E4V]LUZ
M!I0UZ;3X'U)M.M+XKF:&U62>)&]%D8H6'N5'TK7HH I>5J/_ #]6O_@,W_QR
MCRM1_P"?JU_\!F_^.5=HH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\!F_^.5=H
MH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\!F_^.5=HH I>5J/_ #]6O_@,W_QR
MCRM1_P"?JU_\!F_^.5=HH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\!F_^.5=H
MH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\!F_^.5=HH X;XEZ;X\U+P\+/PE>Z
M1#>3R!+B>[>6V>.#!W>2ZK+B0\ $H0,D]0*YL_#WQ9%H?A.>PL?#NE:KX8NG
M>STJ*\N);2:%H6B97N&B#JQ$A;/EL2RC).XD>NT4 >':O\-OB*?#:Z793^'[
MF#5KZYU#Q! ][<VAD\UMPMH9EBD;RL?*S;49@.-NXXU_'/AGXC>(_#>D:186
MOAFTT]T*:OI\>HW-N'B& EO#.L#'RV'#G8C8^4$9S7K5% &'H%OK<6C6D=ZF
ME:;<I&$:TL%DF@B X"HY\LD8 _@7TQ5_RM1_Y^K7_P !F_\ CE7:* *7E:C_
M ,_5K_X#-_\ '*/*U'_GZM?_  &;_P".5=HH I>5J/\ S]6O_@,W_P <H\K4
M?^?JU_\  9O_ (Y5VB@"EY6H_P#/U:_^ S?_ !RCRM1_Y^K7_P !F_\ CE7:
M* *7E:C_ ,_5K_X#-_\ '*/*U'_GZM?_  &;_P".5=HH I>5J/\ S]6O_@,W
M_P <H\K4?^?JU_\  9O_ (Y5VB@"EY6H_P#/U:_^ S?_ !RN3^)>F^/-2\/"
MS\)7ND0WD\@2XGNWEMGC@P=WDNJRXD/ !*$#)/4"NYHH \B/P]\61:'X3GL+
M'P[I6J^&+IWL]*BO+B6TFA:%HF5[AH@ZL1(6SY;$LHR3N)&7J_PV^(I\-KI=
ME/X?N8-6OKG4/$$#WMS:&3S6W"VAF6*1O*Q\K-M1F XV[CCW&B@#ROQEX/\
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M_P"?JU_\!F_^.4>5J/\ S]6O_@,W_P <J[10!2$6H9&;JVQ_U[-_\<J[110
M5X%X^\1Z9X*\6>([G1M?T?5M5U"[M#J'@;5H ]W>S*(D0VF") 3&$()25-R<
M;,,:]]JDVCV;:RFJF'-^ENUJLVX\1LP8KC..2JG.,\"@# UO6+FPBUR;Q1IV
MC6W@NVM))9;V2^>>1XP 6$MN;<*%QNSB1^@&#GCQVP\5> _B+'XJ\1ZIXSTO
M0K?6DL;>%++4K9KBQM[>5G@FN<ATB=Y'/$@(4;$/S$BOHZB@#RSX?_$46_AK
MQ/JVMZ\VM>&=,U#RK#Q(\"9O8"D>6Q @20+*[QAXU .WID$G@_%-Q90W?Q \
M/73PCQAJWB>PNM+LY"/M-U$HM/*FB4@EHX_+ERP&$\N3)&":^@=7T2RUV&"&
M_@%S%!<1W2(S$ 21L'1B ><, 0#QD#TJ]0!\X>%KBREE\*>'$>%O&MCXROM0
MU"RR#=0Q&2Z9[B1<%EC>.2,*YP&$B 'D"CPM<64LOA3PXCPMXUL?&5]J&H66
M0;J&(R73/<2+@LL;QR1A7. PD0 \@5]'T4 %%%% !1110 4444 >,T444 >L
MZ+_R!K#_ *]X_P#T$5=JEHO_ "!K#_KWC_\ 015V@ KR/4M7U'X6?$C7M4NO
M#6LZ_H?B26T*:CH=L;V2Q>.+RV2:%?W@B 7>&16Y=AC)&?7** /*?!%[J7Q"
M^)0\8'P[JWAG1K+2IM+A76X1;75[(\Z.6\G)98T$0VE\$^:<#K7JU%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?.?
M[1G[1GB3X0^-['1]'L=*N;6?3DNV>^BE=P[2RH0"LBC&$';UYKRO_AN#QU_T
M"?#O_@-/_P#'J]JCE&*KTU4@E9^9Y=7,L/1FZ<F[KR/N"BOA_P#X;@\=?] G
MP[_X#3__ !ZC_AN#QU_T"?#O_@-/_P#'JV_L/&=E]YE_:V&[O[C[@HKQ3X1_
M&/7?B3\&_%/B6_BLK'4]/>ZB@-C$P0;+=)%8AV?)W.?;@<5A:%\3]7ETR]FT
M7QN?&\*^%KG4[Z[,=G(-)O413"@>WB1,N3+F*0,W[H'(&0?%K4I4*CISW1ZE
M*I&K!5([,^B**\/L/'NI:5X$N=7M/$'B+7-5G^PV<,?BG0Q86L$]S*D2R+BT
MMS*JE\D!VX Y&0:Z.=_$?P^\4>%([SQ5>^*--UJ[;3+F'4;2VC>&7R))4EB-
MO#'@9B965]W# @C:<XFIZ;17GNL:EK'BOXB7WA?3-<N/#EGI6GV]]<W=A##)
M<SR3O*J1@SQR1JBB%B?D+$LN"H4[DN_&'B/3=4_X1C2-/M/%FMZ=I\=YJ%Y?
MWG]FH5=G6( )%+F1_*<D;50;<Y&0H /0Z*\IG^->H:I;PS>&?#"ZFLFA1Z\W
M]HZB+/9&Q<&$[8Y3YN4P !M/S99<#<6GQMN_)FGO_#BV,-QX?G\1Z8JWXEEG
MMX@A9)P(PL+GS8^%:4<GGCD ]6HKRY?C3<Z*QF\5>'UT.PGT>XUNSDM[X7<K
M0P!&DCE0(H24+(A 1I%/S?/QSD>'_P!I"TU==21XM!NKJ#1I]9@AT+Q FHG;
M" 7BN"L2^2_SIC&]3\^#\O(![117F%G\7=8B^U?VMX1>UD;1)-<L+73[W[9<
M7$:%0T+H(U"2_O(\!&D4[CAN.<ZY^.T]KX.MM=8^"?*N99$AG/C!4LGV*"8Q
M,]L&\\DG]V(R %)9U. 0#V"BO)M0^)'B/6=4^&=YX;L;%]%\1PM<S17UZ89&
M4VQE"G$$F-HPP(8;B-IP#FC3OBMJ=YXCU/P_I&G?VQK?]J7L<<6IWZ6UO!;6
MXA#OYD=N6 W3(%79(V6)+X' !ZS17ET7Q@U;4SH5EI?A9)];U"6^MKBUN]2$
M,-G-:.J2[I1&Y>,DG:RIN(*909.WK?!7C)?%?@^#7+FV&EL/.2Z@:7S%@DBD
M>.4!\#<H9&PV!D8.!TH Z2BO(?A=\1=9U+6[D^(KKS-/URQ?7M$4P+&8+196
M4Q' !8B-K9\MDYD;L *H^)OBMXXO/A5>^*=(\-6.EVMQ9+?:?>3ZKOF2%F7:
M983;D+(RLK! 77[P+*0-P![917(6GC:^37+G1]2TNWMKZVTA-4F-K>--%N,D
MB>6K-&A(_=YW%1U^[QSQGBS]H6+PKX2T+Q!/::-;P:AID6J26FHZ]':W+HZA
MFCM8S&QN'4'D'RP25 ))(4 ]BHKP7XB>)M6M$^+K6NJ7MN+*VTE[3RKAU^SE
M\[S'@_)N[XQGO7<:1\5Y-6FT>Q71C'J]WJUWIEW9&X_X]$M]YDF+;?F4J(BH
MP,^>G- 'H5%>.?%3QL-#\>IIM[\0F\"Z?_8K7D.P66ZYN!*5P!<1.7. /D3!
M-0Z_\>=1\"^"?#^J>)-/T6QU*XTR.^O[+4-973[AFP/,2UMV1WE=>248I@LJ
MAF.< 'M-%>8ZO\4WT#6_&">1/?/8-IEM8V4D\<<4UQ=DI&JD1;HP79=S,TF!
MR ,8,O@#7/$&I?$SQ?:Z]:KISVMCIQCL[:_:[M1N-R3)$S(A^8!0V44Y3N K
M$ ])HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBB
MB@#UG1?^0-8?]>\?_H(J[5+1?^0-8?\ 7O'_ .@BKM !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y7\5/V<
M_#?Q>\0V^L:Q?:K;74%JMHJ6,L2(45W<$AHV.<N>_IQ7&_\ ##_@7_H+>(O_
M  )@_P#C->E^._CEX(^&>KPZ7XEUO^S;Z: 7*1?9)Y<QEF4-F-&'5&&,YXKF
M_P#AK;X4?]#7_P"4Z[_^-5U1S6M12IQK62Z71:R.IB/WJPTI7ZJ+=SF/^&'_
M  +_ -!;Q%_X$P?_ !FC_AA_P+_T%O$7_@3!_P#&:Z?_ (:V^%'_ $-?_E.N
M_P#XU1_PUM\*/^AK_P#*==__ !JJ_MJO_P __P 4/_5VK_T"2_\  9?Y'0^
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MF0AVH9,^9R1@#/2O3O\ A8O_ %#_ /R-_P#8T?\ "Q?^H?\ ^1O_ +&M#C.
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M?_8T?\+%_P"H?_Y&_P#L: .SHKC/^%B_]0__ ,C?_8T?\+%_ZA__ )&_^QH
*XRBG^7[T4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cycc-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa+CGbP9z5Z86ekhvWB4bXmqXykrlARGxyFjqOZGMfsG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:CYCC="http://cyclacel.com/20241231" elementFormDefault="qualified" targetNamespace="http://cyclacel.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://cyclacel.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="CYCC_ReportedSCTStockOptionAwardValueMember" name="ReportedSCTStockOptionAwardValueMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" name="YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" name="ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" name="ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>cycc-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cycc-20241231.xsd#Cover" roleURI="http://cyclacel.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:loc xlink:type="locator" xlink:href="cycc-20241231.xsd#CYCC_ReportedSCTStockOptionAwardValueMember" xlink:label="loc_CYCCReportedSCTStockOptionAwardValueMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CYCCReportedSCTStockOptionAwardValueMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20241231.xsd#CYCC_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" xlink:label="loc_CYCCYearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CYCCYearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cycc-20241231.xsd#CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" xlink:label="loc_CYCCChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CYCCChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cycc-20241231.xsd#CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" xlink:label="loc_CYCCChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CYCCChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember" xlink:label="loc_ecdPeoMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ecdPeoMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember" xlink:label="loc_ecdNonPeoNeoMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ecdNonPeoNeoMember" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cycc-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember" xlink:label="ecd_PeoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoMember" xlink:to="ecd_PeoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoMember_lbl" xml:lang="en-US">PEO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20241231.xsd#CYCC_ReportedSCTStockOptionAwardValueMember" xlink:label="CYCC_ReportedSCTStockOptionAwardValueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ReportedSCTStockOptionAwardValueMember" xlink:to="CYCC_ReportedSCTStockOptionAwardValueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ReportedSCTStockOptionAwardValueMember_lbl" xml:lang="en-US">Reported SCT Stock Option Award Value [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember" xlink:label="ecd_NonPeoNeoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoMember" xlink:to="ecd_NonPeoNeoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoMember_lbl" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20241231.xsd#CYCC_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" xlink:label="CYCC_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" xlink:to="CYCC_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_lbl" xml:lang="en-US">Year-end Fair Value of Unvested Awards Granted in the Applicable Fiscal Year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20241231.xsd#CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" xlink:label="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" xlink:to="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_lbl" xml:lang="en-US">Change in Fair Value of Awards Granted in Prior Years Outstanding and Unvested as of the Applicable Fiscal Year End [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20241231.xsd#CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" xlink:label="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" xlink:to="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_lbl" xml:lang="en-US">Change in Fair Value of Awards Granted in Prior Years that Vested during the Applicable Year as of the Vesting Date [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ReportedSCTStockOptionAwardValueMember" xlink:to="CYCC_ReportedSCTStockOptionAwardValueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ReportedSCTStockOptionAwardValueMember_doc" xml:lang="en-US">Reported SCT Stock Option Award Value [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" xlink:to="CYCC_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_doc" xml:lang="en-US">Year-end Fair Value of Unvested Awards Granted in the Applicable Fiscal Year [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" xlink:to="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_doc" xml:lang="en-US">Change in Fair Value of Awards Granted in Prior Years Outstanding and Unvested as of the Applicable Fiscal Year End [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" xlink:to="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_doc" xml:lang="en-US">Change in Fair Value of Awards Granted in Prior Years that Vested during the Applicable Year as of the Vesting Date [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cycc-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cycc-20241231.xsd#Cover" roleURI="http://cyclacel.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember" xlink:label="loc_ecdPeoMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ecdPeoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember" xlink:label="loc_ecdNonPeoNeoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ecdNonPeoNeoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20241231.xsd#CYCC_ReportedSCTStockOptionAwardValueMember" xlink:label="loc_CYCCReportedSCTStockOptionAwardValueMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CYCCReportedSCTStockOptionAwardValueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20241231.xsd#CYCC_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" xlink:label="loc_CYCCYearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CYCCYearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20241231.xsd#CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" xlink:label="loc_CYCCChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CYCCChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20241231.xsd#CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" xlink:label="loc_CYCCChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_CYCCChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">DEFA14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CYCLACEL
PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001130166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_eecd--PvpTableTextBlock_zJPt1OAR181g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_48C_eecd--PeoTotalCompAmt_zEgUwmHuaGpe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    Compensation Table Total for CEO<sup id="xdx_F51_zsVPO07nSCxe">(1)(2)</sup> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_489_eecd--PeoActuallyPaidCompAmt_zj6JkcwW7uol" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
    Actually Paid to CEO<sup id="xdx_F50_zpE70shQObnf">(1)(3)</sup></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_48B_eecd--NonPeoNeoAvgTotalCompAmt_zEO0q8JuNnhf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate
    Summary Compensation Table Total for Non-CEO Named Executive Officers<sup id="xdx_F50_zR7ojIh3jDGe">(1)(2)</sup> &#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_487_eecd--NonPeoNeoAvgCompActuallyPaidAmt_z2GyD0bH5WQ5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate
    Compensation Actually Paid to Non-CEO Named Executive Officers<sup id="xdx_F5E_z5O92NP8n0ug">(1)(3)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_483_eecd--TotalShareholderRtnAmt_pp2d_zJjHPzgGQRA7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value
    of initial fixed $100 investment based on total shareholder return (TSR)<sup id="xdx_F55_zQkRoOsms684">(4)</sup> &#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_488_eus-gaap--NetIncomeLoss_iN_pn3n3_di_zYgbgYvdMJM" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
    Loss (in thousands)<sup id="xdx_F50_zXBR1Ha20gt5">(5)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_41D_20240101__20241231_zPsDiEJ1CDJ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">585,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">547,706</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">363,988</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">342,889</p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">0.64</p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,212</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_411_20230101__20231231_zXMq8AvNxwu9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">661,049</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,807</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">833,233</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">172,676</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.58</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,555</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_41C_20220101__20221231_zSps6lkNEcra" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">763,551</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(77,717</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">918,518</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(36,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">17.15</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21,198</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NamedExecutiveOfficersFnTextBlock', window );">Named Executive Officers, Footnote [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_890_eecd--NamedExecutiveOfficersFnTextBlock_dU_zPZm4oUoimXd" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    each year shown, the CEO was <span id="xdx_90E_eecd--PeoName_c20240101__20241231_zVr6SEV7L95d"><span id="xdx_90E_eecd--PeoName_c20230101__20231231_z6Nfdkdj3od1"><span id="xdx_901_eecd--PeoName_c20220101__20221231_z9mgvA6fsj32">Spiro Rombotis</span></span></span> and the Non-CEO named executive officers (the &#8220;<b>NEO</b>s&#8221;) were Paul McBarron
    and Mark Kirschbaum, MD.</span></td></tr>
</table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 585,000<span></span>
</td>
<td class="nump">$ 661,049<span></span>
</td>
<td class="nump">$ 763,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">$ 547,706<span></span>
</td>
<td class="nump">65,807<span></span>
</td>
<td class="num">(77,717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToPeoCompFnTextBlock', window );">Adjustment To PEO Compensation, Footnote [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_891_eecd--AdjToPeoCompFnTextBlock_dU_zBMjhFW4DbT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fiscal
    Year 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fiscal
    Year 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fiscal
    Year 2022&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NON-
    CEO NEO&#8217;s</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NON-
    CEO NEO&#8217;s</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NON-
    CEO NEO&#8217;s</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCT
    Total Compensation</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eecd--PeoTotalCompAmt_c20240101__20241231_zc0dwJoSZvea" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">585,000</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_zFXuUQC00M1e" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">363,988</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eecd--PeoTotalCompAmt_c20230101__20231231_zSBBBOkRw0lb" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">661,049</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_zXcbXM8h6Wzj" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">833,233</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eecd--PeoTotalCompAmt_c20220101__20221231_zrOqzcW4zrj2" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">763,551</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_ziCRRTAM7Oi" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">918,518</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subtract
    Reported SCT Stock Option Award Value ($)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zYOQ3Bio9JL1" style="font: 10pt Times New Roman, Times, Serif; text-align: right">0<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zzCahFB4mBrj" style="font: 10pt Times New Roman, Times, Serif; text-align: right">0<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zQ9Do2Ux9OM2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(100,421</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zpZQw2OHbF7a" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(118,167</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_z9rdp09mnI3d" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zThlN5bADQ6a" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add
    Year-end Fair Value of Unvested Awards Granted in the Applicable Fiscal Year ($)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_ztI6EcOqBu2c" style="font: 10pt Times New Roman, Times, Serif; text-align: right">0<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_zAGo71P6QmU8" style="font: 10pt Times New Roman, Times, Serif; text-align: right">0<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_zp6pKuMCHrj9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,961</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_zhb5L77soGjk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,051</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_z87U2qJRbbvd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_ztbpLL5tEdq1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add
    Change in Fair Value of Awards Granted in Prior Years Outstanding and Unvested as of the Applicable Fiscal Year End ($)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_z8hWRNNhV1mj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(21,986</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_zB4OtY9dkfcd" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(13,042<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_zgEOBUlogWVa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(164,307</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_zKow5dJEzFK" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(172,971</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_z7hefwmNlp86" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(494,733</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_zhqHaVdVfqIc" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(545,667</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add
    Change in Fair Value of Awards Granted in Prior Years that Vested during the Applicable Year as of the Vesting Date</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: right"><p id="xdx_98A_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_zs3fZW3UWtxf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(21,986</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_z55wJ025rOB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(13,042</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_zGkh7RQE1DW1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(352,475</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_zeXn5GKAMRSi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(395,470</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_z9nY85d5wdS4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(346,535)
                                            </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_zDhTwMKp9eHe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(409,198</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Compensation Actually Paid </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><p id="xdx_989_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_zbD00DjU6oai" style="font: 10pt Times New Roman, Times, Serif; margin: 0">547,706</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><p id="xdx_982_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_zTDsoWutOJE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">342,889</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_zcRpHEf1z6i3" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,807</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_zamBkiHKc9X5" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">172,676</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_zfKILg7y8fC9" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(77,717</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_zXDddc62Sypa" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(36,347</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>


<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 363,988<span></span>
</td>
<td class="nump">833,233<span></span>
</td>
<td class="nump">918,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">$ 342,889<span></span>
</td>
<td class="nump">172,676<span></span>
</td>
<td class="num">(36,347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_EquityValuationAssumptionDifferenceFnTextBlock', window );">Equity Valuation Assumption Difference, Footnote [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_894_eecd--EquityValuationAssumptionDifferenceFnTextBlock_dU_zfxnDlcNtmH7" style="display: none; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative
    Total Shareholder Return (&#8220;<b>TSR</b>&#8221;) measures the cumulative value of $100 invested on the last trading day before
    the earliest fiscal year in the table, or December 31, 2021, including the reinvestment of dividends, through and including the end
    of the applicable fiscal year for which TSR is calculated, or December 31, 2022, December 31, 2023 and December 31, 2024. We did
    not pay dividends in the periods presented.</span></td></tr>
</table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock', window );">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_893_eecd--CompActuallyPaidVsTotalShareholderRtnTextBlock_dU_zzGs4pfMW9s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Relationship Between PEO and Non-PEO NEO Compensation
Actually Paid and Company Total Shareholder Return (&#8220;TSR&#8221;)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify">The following chart sets forth
the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and the
Company&#8217;s cumulative TSR over the three most recently completed fiscal years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="formdef14a_001.jpg"/>&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsNetIncomeTextBlock', window );">Compensation Actually Paid vs. Net Income [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_89C_eecd--CompActuallyPaidVsNetIncomeTextBlock_dU_zoAUkXGtd4q9" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Relationship Between PEO and Non-PEO NEO Compensation Actually
Paid and Net Income (Loss)</i></b><b><i> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following chart sets forth the relationship
between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Net Income (Loss)
during the three most recently completed fiscal years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="formdef14a_002.jpg"/></span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="nump">4.58<span></span>
</td>
<td class="nump">17.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">$ (11,212,000)<span></span>
</td>
<td class="num">$ (22,555,000)<span></span>
</td>
<td class="num">$ (21,198,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Spiro Rombotis<span></span>
</td>
<td class="text">Spiro Rombotis<span></span>
</td>
<td class="text">Spiro Rombotis<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_PeoMember', window );">PEO [Member] | Reported SCT Stock Option Award Value [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (100,421)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_PeoMember', window );">PEO [Member] | Year-end Fair Value of Unvested Awards Granted in the Applicable Fiscal Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,961<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_PeoMember', window );">PEO [Member] | Change in Fair Value of Awards Granted in Prior Years Outstanding and Unvested as of the Applicable Fiscal Year End [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,986)<span></span>
</td>
<td class="num">(164,307)<span></span>
</td>
<td class="num">(494,733)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_PeoMember', window );">PEO [Member] | Change in Fair Value of Awards Granted in Prior Years that Vested during the Applicable Year as of the Vesting Date [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,986)<span></span>
</td>
<td class="num">(352,475)<span></span>
</td>
<td class="num">(346,535)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Reported SCT Stock Option Award Value [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(118,167)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Year-end Fair Value of Unvested Awards Granted in the Applicable Fiscal Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,051<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Change in Fair Value of Awards Granted in Prior Years Outstanding and Unvested as of the Applicable Fiscal Year End [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,042)<span></span>
</td>
<td class="num">(172,971)<span></span>
</td>
<td class="num">(545,667)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Change in Fair Value of Awards Granted in Prior Years that Vested during the Applicable Year as of the Vesting Date [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (13,042)<span></span>
</td>
<td class="num">$ (395,470)<span></span>
</td>
<td class="num">$ (409,198)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    in this column represent the &#8220;Total&#8221; column set forth in the Summary Compensation Table (&#8220;<b>SCT</b>&#8221;) in
    the &#8220;Executive and Director Compensation&#8221; section. See the footnotes to the SCT for further details regarding the amounts
    in these columns.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">For
    each year shown, the CEO was Spiro Rombotis and the Non-CEO named executive officers (the &#8220;<b>NEO</b>s&#8221;) were Paul McBarron
    and Mark Kirschbaum, MD.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The
    dollar amounts reported in these columns represent the amounts of &#8220;compensation actually paid.&#8221; The Amounts are computed
    in accordance with SEC rules by deducting and adding the following amounts from the &#8220;Total&#8221; column of the SCT (pursuant
    to SEC rules, fair value at each measurement date is computed in a manner consistent with the fair value methodology used to account
    for share-based payments in our financial statements under GAAP):</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Cumulative
    Total Shareholder Return (&#8220;<b>TSR</b>&#8221;) measures the cumulative value of $100 invested on the last trading day before
    the earliest fiscal year in the table, or December 31, 2021, including the reinvestment of dividends, through and including the end
    of the applicable fiscal year for which TSR is calculated, or December 31, 2022, December 31, 2023 and December 31, 2024. We did
    not pay dividends in the periods presented.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">The
    dollar amounts reported represent the amount of net loss reflected in the Company&#8217;s audited financial statements for the applicable
    year.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToPeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToPeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsNetIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsNetIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_EquityValuationAssumptionDifferenceFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_EquityValuationAssumptionDifferenceFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NamedExecutiveOfficersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NamedExecutiveOfficersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ecd_PeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ecd_PeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=CYCC_ReportedSCTStockOptionAwardValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=CYCC_ReportedSCTStockOptionAwardValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=CYCC_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=CYCC_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ecd_NonPeoNeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ecd_NonPeoNeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock', window );">Insider Trading Policies and Procedures Not Adopted [Text Block]</a></td>
<td class="text">Our
<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_" id="xdx_90C_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbF_c20240101__20241231_zeFPqbmDt6I">Insider</span> Trading Policy provides that no employee, officer or director may acquire, sell or trade in any interest or position relating
to the future price of Company securities, such as a put option, a call option or a short sale (including a short sale &#8220;against
the box&#8221;), or engage in hedging transactions (including &#8220;cashless collars&#8221;).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>27</ContextCount>
  <ElementCount>20</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>6</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="formdefa14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="formdefa14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="formdefa14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cycc-20241231.xsd</File>
    <File>cycc-20241231_def.xml</File>
    <File>cycc-20241231_lab.xml</File>
    <File>cycc-20241231_pre.xml</File>
    <File doctype="DEFA14A" isUsgaap="true" original="formdefa14a.htm">formdefa14a.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>formdef14a_001.jpg</File>
    <File>formdef14a_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="62">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "formdefa14a.htm": {
   "nsprefix": "CYCC",
   "nsuri": "http://cyclacel.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "cycc-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "cycc-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cycc-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cycc-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "formdefa14a.htm"
     ]
    }
   },
   "keyStandard": 20,
   "keyCustom": 0,
   "axisStandard": 2,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 4,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 27,
   "entityCount": 1,
   "segmentCount": 6,
   "elementCount": 100,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ecd/2024": 62,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 3
   },
   "report": {
    "R1": {
     "role": "http://cyclacel.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdefa14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdefa14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdefa14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdefa14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "ecd:InsiderTrdPoliciesProcNotAdoptedTextBlock",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdefa14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "ecd:InsiderTrdPoliciesProcNotAdoptedTextBlock",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdefa14a.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r67",
      "r77",
      "r87",
      "r112"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r70",
      "r80",
      "r90",
      "r115"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r71",
      "r81",
      "r91",
      "r108",
      "r116",
      "r120",
      "r128"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r126"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r119"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20241231",
     "localname": "ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value of Awards Granted in Prior Years Outstanding and Unvested as of the Applicable Fiscal Year End [Member]",
        "documentation": "Change in Fair Value of Awards Granted in Prior Years Outstanding and Unvested as of the Applicable Fiscal Year End [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20241231",
     "localname": "ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value of Awards Granted in Prior Years that Vested during the Applicable Year as of the Vesting Date [Member]",
        "documentation": "Change in Fair Value of Awards Granted in Prior Years that Vested during the Applicable Year as of the Vesting Date [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r67",
      "r77",
      "r87",
      "r112"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r64",
      "r74",
      "r84",
      "r109"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r81",
      "r91",
      "r116"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r81",
      "r91",
      "r116"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r81",
      "r91",
      "r116"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r81",
      "r91",
      "r116"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r81",
      "r91",
      "r116"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r81",
      "r91",
      "r108",
      "r116",
      "r120",
      "r128"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r126"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r63",
      "r131"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r63",
      "r131"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r63",
      "r131"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net Income (Loss) Attributable to Parent",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r132"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r69",
      "r79",
      "r89",
      "r114"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r72",
      "r82",
      "r92",
      "r117"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r72",
      "r82",
      "r92",
      "r117"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r64",
      "r74",
      "r84",
      "r109"
     ]
    },
    "CYCC_ReportedSCTStockOptionAwardValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20241231",
     "localname": "ReportedSCTStockOptionAwardValueMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reported SCT Stock Option Award Value [Member]",
        "documentation": "Reported SCT Stock Option Award Value [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r65",
      "r75",
      "r85",
      "r110"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r66",
      "r76",
      "r86",
      "r111"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r73",
      "r83",
      "r93",
      "r118"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r68",
      "r78",
      "r88",
      "r113"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "CYCC_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20241231",
     "localname": "YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Unvested Awards Granted in the Applicable Fiscal Year [Member]",
        "documentation": "Year-end Fair Value of Unvested Awards Granted in the Applicable Fiscal Year [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001641172-25-016520-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-016520-xbrl.zip
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M?!HPP]#>4L)>OOO?79![O?I[I_K7>_._-ZO/\^(SS@*D-$ D>31?=OF6E\U
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M4%%3_7$3#*Q;'FP<?!P<?"IB0F*J_W9#=P+D>!AJ6'>Q,-@!3'(,+'(,=#?
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MB$H=7*WG,+(Y*DH&IP))0/SRS%RK)4Y9-UZ_1&GF &H7Y\KELA8Z'ZRXZZG
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M/ 8H>TNI#CHM)'\JRDI2KQC_;-:&/*6$@O>5H<YNI 4CJ9GNT+TS2\E**_,
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M MT/S9N&(%1ZTIP/JWKU'I3Z@%EYNR]I(4(D(/\AW;J&[TF; JIWW7R\^4K
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M"3(3UL(LZ#NKKYR!$O!].KD@*RP9F$<\%G67_FN:UW%-!T 6M4&_/N>\N0^
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MGU[W75O>X.3HCY2TU[E7E";C[MG5^\?MU0>KV0/SF<UU]Z+W'6TK*/,=]?N
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M_EJ'8G* 5CKBD<_57XO?WR[JUZB9\?,7X&,-6-8?=?Z.,=3->-9[>\)?MB=
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M)"V+T=F&$X[Y5QII8,\B53[G*'NE_NH;' O4Y-T]1+\UNXT#Y/!VM:-Y@G&
M\%)O_:[L.UM2G_01MJ&B8*DSO@M/\71?+:6T6TPB16P/$TZ>_*C,6"X9^\RF
M,E30Y*Y04X4XV5%PRA^S/Y4Q[LVZ*RN(#D;ACW5U1I6B@PP<WX]CE'H0P#VO
M-T"^-I 2Y\LP"IEDR^1R8\I;,6ZK1)&%34C/$(PFOU/-2:K>U!JIIW.47810
MX4P>T56'L[J?%+S^E07(V=W%C:9&V&0.?%SP&F\=(=0<OK;TX>G8CU/GT*R[
M\-K 4@?_^Z-BS&]I'E\>JH<:'K5_/+3F[R&47*4YLAW-LOB&UNE<$!_S!5=
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M9YB<(ZWB/B4E+H3 )7]5%S^T_4HRFBTW=I#;%@L6'[,[[*"S9R?YM72;Y%9
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M-; C8P<5*SYG'],-UB"65G'G5'E0:3+2T"W)RIQQE:K8'<;/U8%.#S_-=HO
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MOQ*(*:C+^;!-OH><R^\>C'J4R*T5G,._815FQE1TH7P?;V .XP(GKXLJ((6
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M+/%'=#!/QZ")100[-2PI4</<:*/F7Y8:.RHU @-&VG9K3[>E@7/MTU_3UGO
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M+NM#;3CE"X]1/"HVX15VQ&_5_J;9/Z=8Z/\CS?YOQ?ZG7K,  0;:[<O#( 5
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MZTQG9!VI$J$I&6^S<'SX9/8QB*^?D;E31>LN>;N @NMF)??VNN4/FKNA0H2
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MHF;"*'O=O^M)]((I?8*EZV!!S9XP7E5IWJ*MIAN6VL9D=@16XWNX,E>W08#
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MP,5QC>MBZ0R[7KT*^;2IOKQIC^9HW?H6ZR2TJ@SY+'<D,N6N#6?"-']1ZJ.
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MTFPQ,D^XUE_SFXY[<U]2S?@ZVOK>K9UK5.F.*7PK@>F9(%^5*_R+I65<F)_
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MA"T1*?;6W@GB(V38&SYZM,P$:TE"<M@1V25SVY*!%?&%C^C5[=)H7F F17W
MNGL!< UYR!(CTO)*[213-Z-/U'/QYK>/?MBJ+_$/'&&;L1FQICQ^OK[J0Q^A
M3X-!.S N*[J561+"=Z7;:%Q(56T.L2UZ"^=LR5ENZ;MK%](_4%>*%M4;Y/Q9
M'#CA*@C,-W(PF U<'T1WC)=52IN<26#Q>10>_!-W=E#H%;;XKJE.@'UUPDS^
MFT=3!;=VHYY:W8)8V"VP9M.N;:7A=;NJ!2>MV*]6.4SRUO7*@F\W/ V(G#@1
M?$,^9[PA]K:S]"@R1[\"CQ2E93(A&M)4=LUG*LPCV N47V>N;,9<O:?W(K++
M>HHU D6SL%O9W*\C'-^%^267D=%B$WCPG<7=XY2SZC5; <5)VL;R5]S3>*@[
MSNN-;\1?/W?]B',*_]*+U2MY/SE#B98&5X^F'!T'!V!8I^Q$@F 'V:N\:C^F
M&+CUQI<G*@K;Q@Y=\^*?3U@^^O"=\3MM>J02NIX2U]=@OS[O_SEI_GZW9?D_
MIC_\.:MAZ+^?U7!X17YY8SM\Z88"YC+_4Y!P<7$K6PHB_CUC_I>0];BR*_D
M]R<M9IZ?FVAR.ZK[IM#X=E:[1<R&)8CL93%MS,^[M!9+#)'-UX[](%@-\M@7
M!<@E$I9?_@J$8' 'A<VVO==_CD=V)IPNHWQFL'-!^\/>KL%6<1624,$+/0.%
MY3DKW2BLQS9H[!!?/[2 R6XF5B@N#X<TT:4>GD'C71C/CA0Z]EYJS*. <:7#
MFZW5I897U*&R=[<6,1IFGN-D>'61+:J'<=_(1%9?.Y96.O@%(,CT:@XS3F*0
M!K]J=>FG;'] &G!Z_P=[;QT4Y[KM#39!@P:W( F6!$MP[Q""A4V0X- 0+%B
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MK:GUJ@@'"R.LZAQL)SKMM;3.B3 (@;5(RX-TX\\O)S-F^2@'D]]$3@C71W_
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M:X>/+(H@[7[#M$N=3+>3HWN.D8V$5LV>O9# 7>T-?3Y+08</1-X#>H(;F[4
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MB 11'5S];-,+9?;P:H#[U.^5B__7*JS_S_%8Z#^\OQP]#T?BPEK#5D3+9X3
M![S%;R=CQF.NULT3]2T_/E?OI'-:G0T]KPB=^F46MRO)+3@X5/"ZAJDGJ;%!
M1B"S>0]-UP@C0YUBS":<MQ49"H2&M;#> D9566X!=Q9O <&E=>C)=LP?7=Z)
M4\^ ?:.X_^<AZRD0]<R]B^5R)^L6L&8(05 ;K)]S((,$_3G&_7K$&R'HARWF
MP0@M)S#^JR]Q.:Z9,GO^L&/4@C#">,/#HF0TS;KT!P0:+/,0TS6(%C,61OM'
M8"9!+(N@17O^:D72W )0#JV/KXH=-ZU.\<^W##%&*?KD[)^"Q.J 2#.RX-:3
M6<S.M&%,Q+KKX2V@XJ(=0NE->0OXDGS]D=&K] !8Z0&</PE:W+QLK'5<C#H+
M"[?*V 'I&5";&@C$O6]=8R;U2EHK%W<UT++-X[+CO_80_"7QY.]2+$Q>^"J!
M,@M\_N_ :Y<__L:R'[?0+,F(.\.Q8.AMANL&G?'<%+Z<W.9"ILV+^H*'07\?
M6<U!H&I@\TQ?,*8%R;$VN!^;5<1[\XLS^AD2KW='CW:UTC'P4,#^2)A(9U^J
MRY7EDQ&Z>B?]#_D>+'_X_4&-MWT*6:!X6+NA\L5$KH?S)BFORIDS&:83<HU?
M^P1RE /9P4#Y '.$J (&/)%1WF3@O[Q^WWI%%*YKN1X594R!="R4SP5'PO9>
M-R=@?8SV21G\-B@0..# I!$HF,:==@L(;$1B++&L5RD**_$6$)+#S/@E49KP
MC?)9E"B*,D'[*=R[Q ;X1O)@E=[%Y*SF%N 0[G+)&@N\Z&$\R4+3 B-/(9>$
M2+4-X^)S_<R^JQC%8NM;0"<()8C9[N99-&#P%M#U.Z9SAX^B_2],D-C\MP!*
M[9M/W^20VD]*M8<O,WV:<:LM+S*+:P_$ 9<.*&F>UV*.?!NBP!>950>W !M'
MTA:<!;<<<K%-31'L663W.Q!Z!G)W6]+!]2Y'WPYG,K<3QNF<T1X]> "7.)'Q
M=CN.33.1-_/8&QE8*U!YFL%UU\S<=4)#&35JG(#-9$Q8S/ QSGA8ONJ&0;(1
MLD#408G5XI4/W,NI!UZ1VFFNKBM^Y@N>+U%H6K_XVI<^+ \^Z.U9G4=O2T*Q
M@2>C:JG TWO<?.LPQ_T+&;=A+RSI]<"]JZW*\_EPWV6N$^O9:W[,NM,I,,QL
MB58<%[D%D*-X72/2'DPJ>$D//+A1*I:$W+-QM_!@B,^>Q[B4SH40-F.L-0@)
MZBFR\B;C%D"0,U/K<4Y)7W=\WKUYM%QY8QN^;>XR^FJQ[B9E7\\7MJX3OHXV
MX&V\!7!1%SG1QY?N9W%L\I^(V;XI?>&0JF>@DC5^,W0A_': 7HDUW%]R8G:T
M^%K*5B3<8%"G\<7K#V\CR)C$*34A'3G(SV; ,=>]G--;@*IU2_/]:1\O1I8H
M0K3F;Z-I(#,??'DP(5@7=A-U5?Q:OWQT&!QU"\B8VN/O20:(*IY_N4\<IH,V
M0KM ;%\!F9DQ3%_K>!54=?C]\%3W"\9E]T&8J&TYDA)]%>^= V%$ ^^']P=$
M:B+M"OD31?P;9LQXSHKG(TS>3G$^9IT+O06'TT$EX+U.7[I&%9!YEX1.K,LO
M#CW'4K. ^;NL3W7>.GU5\(GPD()437:T\Z&$QFL$XQO;4:$0 WCI MX.^BFR
M8]"@+.(]!8DTSY N28R^1?3)5PE?.%E'8YE'B:YQ*8<MJK Y_?+^7/C+@LZD
MF"V?J%(@U %)BPXR(<4HOQDR-%\4TK %%[/$V<Y6I/#GW^O+C@:WT-H*^.SM
M$=P"5FR F0R-9.U[_=_XSP\C,4OT*<'?VX"UQ CVY=2( #VE1DMAJZ@&F2N,
M*#:NF5PQ>4O> C[K 9$-R,;S"01S+ P2:@":B?JI;SM3D"5/J6K^(?9A7=I'
MK8H807]2Z6[S111@FJ^\LBN-P6C]QO*:"_W%/Q^#T;&JI9EAJP<,AT$?HZ9L
M9A4V_<Z@;FB<T./*]/T!/5'-0 [5W*H&F=: 2F73$^HW]-0$CYK5^&JJD\Y=
M @D6;(R@&GC*I<_'F["L,A=)%+L$%7ZF7#*VJ/O081CSG*78B\P?:%5Z;SB#
ML1C[E;_@0U2B1$J+;NK16(H/ *^B.GWN I;0_/%=4]-X-K##_Z CKXQ1K'1T
M79$V7#>/ELY]]T:2Q4=7&CV=G/>Z(D.Q$'*_&1CO<73)K Q3"SX!951-:,T;
M8-4.89-V+K*X^(B79@+7TC=BUR=>*U_C Y&41K2H9_A=)I=[F;^;H%L HN$"
M,N^UUAK2<A?#1*HW]23-L^?I\TWI^Y>=!\>HY<7:@]ZK[A[!L=-2*RS_!(8B
M>R)^Y)VA)YMBWC]+:+$YW!UUC[C<KM)E_]H:7SF?O/A_[<X%9.7YVBT@ICS[
M%C!'P7_#(NU]8O(./9X.:-)%>/6<2_1$,>54%S%\-! P,7K_<8^G1(F0SIQ4
M\@IAK(\QG" $/MH3HSN1-*LH>=\@OUZHC:E-ARN%#0MU>#OLB1G7H_:J^;4J
MW69()ZVW+$9Y) '1N!B32:[X3X9\]28/P\'IP>M7@5R7]"?+_\,]:PFNOPE!
M/QBN?=_PM,=SN1734!W2><\;8WC3&OC1N)@_&$O[G'^I4'Z;+I0WYIN!G.\J
MGEK=?2?V&ZF*'%E(?I;PL,N%;DH2BO[DC/J4[)])!_QG,##[Z<Q@=6"T!+TT
M"-D^EAQ%<EV@1M//H1AE(7QVYGUYS>]-BQ!M!R*56VL?U#:@)Z]%8V_2Q7Q:
M3)(;W6[J;@%Z=3V>S/&'JW\PASYX- (!=#VO1M%W+SF]C-.XGA7JA)?2V@&O
M71_^/5E+*MLQI LXW8A")AI%^8Q#$*YN?H39"]+)=H]_?G/V33BPK7204ABB
M*Q&,?%4P(MA66/6/2Y1PF4Q>5LR:^C,B<8?4C11=@H>>4RBTCP?CISS%P>YY
M?EHX]1_<0?XOUM0X6F#H%F;!MQD#S=LQU(1?I7 7[!BPTU*,>KW7GLZZ:5NB
MHBCYJ$7.O+3I)Y-E[(X8[=9-(X,'Y)PR[!O35?J\6EBY!>B#LY)45-S?TT2P
MX^J'O3>*M_\YM/AZ ;"&8BM FK1A;*VC TH8FDZ)].I,E #3NLVL4$]3S.SN
M5Q"LB-&LDE<H,N+9%S8.F33)D1^M;6#O[1F[PH],QH5!#M951V% >.IKUG<2
M[@NG_=[52ZW-W44$* OBV-JMG13=+,P&40_6=JT2ET;"X.[GW;'@0"5FQW+>
M(5^S@P4WJN4Z<9T5VOL_RW\]PL[/_+GKF9,0DC<*R5]N-S5W"%0N<<C16X]0
MU'EG!F#>JHB%X0=LP-?! =[*V2)^Q=75&C[DU?AN2_3N]B,P?.,F=;P;ZJC_
M[+4.VU*N\-W)7HJ=RN8#=**[U:/AF60O)SN>KS0Z,7?&^H+L]HWK>P3P/(H/
MR.3*X#/1=CD[;N7S>H:<?3_"/V1=QKQ6YHI19H^QK8E>9\+N8H@X3\_92W+(
M@9@M\AV\/UQ/,'3KIXO6B@EBC73J$TK2#4<!2TU6YW:2#I/S5W8VBC>K<S8^
M]K^790VA5G[<QY;B(H15*6\!=NZ^(@OGW4J7G3D]<" P&4P 21Q*!BCTN)6_
M>"ZV;V?\3Q&+15$4JW8B(M$0TQV1J^K]&)S'[E[G2N9&%/I+[!%S &JZC? U
M"S\23^XAWA8!HUUCAC&K\C%-$W+;J]2>6)KOO.>#X*U:FY>'LW=$9#2#[P>2
MQWS,LF:'#:=W19'O^3+;#;-UU#C;TL2"#&UU+A9ZHW&;RD1F7L:;NL6Z:W,*
M,7J8Y1$^EV8(/;%W7*>J,2$Y!=+MK##5M59,_:BI=^(=^L!;\=MX/JGONW<W
MVUA:GZLV$UG3E?_#6TO)XF\!ME'^:4+(: 21VA1*/ MB/2^?T_O^^.8G73EK
MPCON(%=IIM=.D78]MP!H'/KW8,/26T \D0E:TB0C3K=53J++=$<ASIR1GPMM
M%67(G6605<!Y> /L0V$D/_ -,N\6\*(5K<4+01ZPP <@5!@'6/<6,!" Z82I
MM-E;Q:=H;D'^)BA[<7>V0NE>SO+1_(.(#\I6'V)$WP*TS&,$/\6(>3F&)THD
M!E;1[[M0)789M.0Y97?GJOA4K(@7+VA(5K=%1,5EXC_X8I&2OW!7;/7F;3>$
MQW<;_0XX-P?92H2B%1.]*6YB73RDN-U\V9"Z$MN+1G(8D<2HR"@(GW3K+L?B
M1=-($YJN%*// Y61&I@)YZ&U'#!&X.#]/$H)P5P+W6J:D.*V$LFP$9ZNR7'T
M*?*X9SB(;6^AK$-K(^JJ:2Y;F_#D0^X$ZOE,]2KN+]\'\-X@UJD'4U6(_(;=
MI,2Y!*I'190?NQ];2=9=OH J\XCA;R'NU_VL*-8D/#Z6R2()ZS9]U!/ ,*D1
M&>(,'-L&0F-\J2!C!9A=9FQ%2RJB!-0ZHJZH@<=9[K> 7KOQ)D:8M90-E)?1
MI"90Q<OG]0AW'RR1<1R$#7#J4?!R,A0>WG\,>7@=/7F3A]%RZ1@RM.6@K5C@
MOU?X^8*FN6E%D_MP7PL>K)@L "<LDWV'%X$SDN:,B[D2LZ;RU$5FF<74%A^F
M"S6KEE]5?(S=75Y=H=*0U_CZ?U5!F6=3UBK\V9 V), ML=XI(;WE?</9X[TM
M8UDA:MPL;S.N\4C!A*+N_G!O)Y#0*+:U<P$\BCKY] :C;[O?&:$HX*"^;7F]
MT2+G@3H4MEEC4A^"][S2W(;VG#G6L="XG_5%HGNK1:!P.T=JA]*R'Y9&I-((
MGM)6 AD),#3%I)]RD'8,5H+!2P1#ODI'K-MH_26,W_0"+P^^W19%A'17-QQ.
ME(@+&> X*<Q,!V4\Y]I+*K1'Q&QKPF<^2T?ZQR##=*<.A;Y5]3O6&/8*-[[B
M<JLC+S^.>[[Q-#PVGE&6B^8]FAT<90@_,;9AIJY,5J]*VEW4K&V9D0KFW?Q4
M4\%>2%25W%#P[,?B(+78F]#!#TXQ2=DE30']S+V9ISFETBW(Y()E;\D)%.C'
M+Y%9-U$#T^D\],Q42U?-.$%7LCO/1X>/=WNQ/F0GW+>J'!,.1LEFV"QD/U,A
M%JU!+&4[E\R3@^0 G>7T6\T/!T__@QN;_O'H*(8X5B<S*K66G2;[&)PKWZ%J
M;+YF?U9RE^>00F$?0!C^4>&#@"+9O[-J '.ZO,>_HWOT2U$V-9,R-#;&_!43
MFZWUT^\GC@>5/5YJBCWS&*V'+VJS$7?[L44*1G\E4\[,_V60?CX3DK<K8Q)[
MW@@^E&I>K'%0GQO!<TJK*YSZIRH[']&LR&1H.A$R61&.SBG2-]B]*DH#-6<G
M/BM**:3FT/_423V7C9W 2@C8?92K*N2&D*IHZ*5X_,Y=C!"?/79.%VB)X.J0
M2 CS*#( Y\DW3/#,\0ZC),+Y<7#6L39(JM78"@X?86=E5DH!83XLW34L#F-G
M=DSO!CVB#B1\!M28H>$E&^P6%DY'&L;@WN>39]?VI'M&D_;5C3FK>,G"2S;.
M B<#"J^W6+A=F*)R .\U].#_CZ>BP=[F/XR0H?9WF)Q5$T$![H,Y.4OO=F@!
MFYGX'^C>?E1TVGO.^.]?R^4K8J.;Z'M_TE55NDK)X93W%9,&G[<<>&9&_0MQ
MT4B'Z.C /OYR^X-:RP\^A$VSZPI17&%58!ZA02;!KJN$>%?2 B>HUW7PN"-T
M\6&18]U3HQI]E8B<K VX-;8B=#9*F(5)ZN035*7X"4]&$WP[>/'-0P<"!99W
M$;J;XB/[I^LID5M-4>W/0'M ^C.0[7JG&YHT@9?W;=*$X9Z-*XF2)%>B%.+Y
M"#7;<78$?6K(DI/?,^/ZY[A@ZJ#@TU$BY,*B,ORP-1M<LJB.N!]C!'ZW!7"U
M%_!@EI/N>"H9S^8S?-U761W)T:YA?*U57.4EJ:IYH1'*5%L;QJ#&!W,O\JHA
MIOP4,3S)I KXR,R%^ $/"A*.<.R]\HW._67@'3UHSU&]M])4Q'XS_PBN0'[A
MX?7!$.>,\:-WD.J,$->T"QD=:*^!HR?="?;=%62A9_MT:<&&0OISNRUG-*-9
M>K2L<^\W%(5(TI5M*."RHP<VJ!K6D<;6!+;WIFH1F#K#:?[VI3KTL7F=H5>@
MV9TB>S:*$C"G%FMJVZPI?-VPJ@8^DF5C)>:O1K[;T-P;U.549AA\(7D9W/Z!
M*G6D"/RVS?\C]^QNV*\$33OUW2. O0*C>W7DQZZXB._Z<<1K%ID43K%5GNKX
MHZMD?#S5^6@FFQ4&,*2FBI\8M+#[M4,Q.6]@_$6::B]]I)Q$;'4P>U;*?4JC
MW-P$-!?2!CK,TE$>UFRG +>\R2TWMQ U6J )I?:RB2/IY^Z+^F)&'UH.6$NZ
MV@T%'$, ME?\H;Y/;!EJ TK>'YTJN1"I/"XY/=<-&J'HZR?=I%L*?JTKKK[W
M54!P#\.,!.VAJ=EXO3CA?K;I_W2_BCHN_]]=O_+OO39*[VH6[4U*# I(_U+J
M$NS(]96CZ\*1M[(7C_2(8]JR*\CO[@L\Y5U<=R%U_&B6H!:>,#EXRCF-#--$
MM0DQ2')^1\/82,5&B)?HY< %R3U7,W;>=-X02WHN)S9^7:0]@@II[]+X& 5T
MQBOV<<X'^^,WUU<)>!37&<H)=+-YZ%WJUV0]O6^_Y'2(Z3[.6PY>&B6E#3]?
M?#&Y+\5OY\2?>/XMZ0HF9O]2,RNSJ^..!0XGJ;;(^; G7ISP3A621=->8@)9
M\BYPVB*-W5$^.I2&>5-QHOK7#T+CO\SP^[W&S'_+MZ2,,./D]6&5SH[1#MV&
MEZ*Q?10PK]J$^?7/^.XQNQ4PN3:<#&SVLSOUE?"+[FAK7\JTCM[.!IU":%B>
ME_03[L$0>\Z #.OOQM!,TJ*7 96;Y3Q9[(?LG@=46-"%UD['X+Q.NYQY->CU
M-V&[O52YKGO2!\,9L</V'0OT"8\9!WH'AJOI_=8=UB,@]Y%6,-%@E&BV#0U-
M"WW5Y#*A[96W9\1P'3CPCF&G1%OOH&EG:O#<I2S]L.<T%5;0#\,])^N9Z)7<
M^-RE;%.&B7:+) *_M2?BQ_UTV$C:26K(G_),_Q%Z^C=YJ/_]WI>H_6N$:4QZ
MA-T7U;E*(Y^!?.U%Q$*Z8U :R)>Z?YI?RL=1E403D&GI%1@L44Y!,YK051$>
M6Q>=6(@2089ZBS2 XM L]9]U6NJGI&2Q5Y86Z*5FEG@SOIM%-Q5Y%RUJ?",5
M.12[8'B$/8"R7+L%4"&3.R6TXUIHX2+Y8SW71<*/.9_.O\*;2ULQ>1#2L0$I
M# \/9Q;?]^;(L#-F@;?$YAKO:>S.)KB5MPN?=9%.&$GDX\Y]O\L>G1*C5NSB
M\E^J3?Z_?8U/@N!716SE0*%64.[EAXS]&W>=I!<'WR/:/S?VN^H[/5B[H_XI
MQO.3T3S2"]97!;P[:FH.7>;6AG=/-J?%4V]VU<2^&*OZK?3#.+[.PQ?SQW,)
M&C'N%-)NH0#X@0FTMNL-M'IB/P]^,\10?3:2 2-@/M\:Z]^J@=H3#U)%;)IO
MOEL(;W.J=>J)"O,E0X;U>!HE0N!?^0/.$L8M)VA5)V(8PW 41ON8K8E^UAYV
M4FF)R=-=RI:^S?03C\)%>NG#1[^<ICXYT@O3K*^J43+>LC.M#Z;K[5-_ZX)O
M+88MM3$S^U^\F0]H,J*3"]]#9BLAB('&WVNW?@)?=WE:^3?IPR13&4W&S^QU
MU1NK)((^55MC+Z\,9;++V?BSX_3<\]?46DIYW\EPL? WQT8_B$D<]>K+PHR2
MNQG<(NS7&NV4.1+.5;;3%,,!>BH.]AT!/?LPQ5]XI&#$(ADUF S&X_L$P5RP
M+LW_HG8FIF>%JF*J. G6L[*B ^:L[W,)65&44B+0*"<;4BK-RO]!QH.$(*@,
MD79=5S6UI2+5T%1!]>,B*24XI^/;Q\R&]UB5[PP<T8&GL&MS9;D^(U2[XT0A
M]Z2D7>!1=+8K7&4-$_L;; >B&H^JCG-#E#BRH@83>? H!V/9WR9=X>N.\U3/
MO0U$8SE3T9(O/Q2\AQ-=YF*&M4V,!4!\E7YR!O"&0NW"'EO"\X+(H8X,<\B!
M:_4IG@J2J6?T?-\/V8UH]%;$V0BWL;X$8VT02O$Z6?*T4,%A4KSKABST)K8,
M 0FR#8%L')/276'^@XR][*9&:T^C 5*?3!3'_Y<.SZ15=*=\:;R59JM52DGL
M)-!!,&5[0EL)IO+FF.[UL$&+).J;M6#<%7KJ>C>Z?OJS 8S:\";W*O!^@8R3
M>NLM60BV4JB8R)V @AS([5V]V$8B#?O[+2-PY&R\*;=22*MW_X-SO;]]J$_2
M#^BO%<"Q4+*(?1<?YMY7]=7IKU5JO'[EN)-.#'RY4_&HYY[;V593*9KQ<Z_)
MZ5WX$1I;#>-5%RYDQ9D53FJSQJ=_WYP>*CM]M]/?6,IV2/A[ 52D QD39(RK
MLQ5) KP%,&?]<UO'?2DKRXOO$#O3QM:Z:_]0A-H7"-W9:@@0#_4&9H@L*G*5
MEC[,])OK:L<;=(G6"[+J7]I>_-1M:FU">>;A,CA?9<*8SMC10E,_=50RY/:1
MA/.,_+='S"OLO]4+;#W&%CW\U$>/WUW\2NN)A/,R<\Z3Z$)<34G!7Z'<G?M2
M7@4VQCCUTP=2LC!>9^WT?9$/O;!48CV#=NFA HJ^NJI:@9^)_5B+?N+T> WB
MJUT0LB8-J-*1E+87+$+4H-%>8(M)86)!--#DH;*F7D33L[5WG#JZRYUW"!:<
M0PIVJG33]A@2RF&MP8DKM)/"@U&D^CL&/LUGP\M?GO8[2\4V_8S^+/51(3^3
MAFN#1X6/,$ RYJB'F6W250VI(!0A,]F=M)*:U^N1;VRR GF7H6NEYW>7JCX:
ME<=NK\7H'/WU!_;8K]+'Z>O&&3\-.T4#O9\V)/5G*):*GD=F\IPK=+=_.8A\
ML[7Y%,"H-IQ@1-*=U[/8RFESA!*K>;H$]H60[X36PO2M:H,?6*00='1L#T<%
MV"ARI8D#SFRY!Q/754=">QRIP3XNDG=/O2(<1E2\H.[<<@"%&''UAU_B>(*?
M*T2K#9\@1A2#;@$V1*H@5W9P%6-AOI#-V;<'8TW/DT(6"7!A==P4E_PGN<^:
MU48_'Q]C'5#I?M-'@68>7NN>UWXQGE$89Y_EX76Y7JTQ,E((D'OQBTT]!GTL
MA6-#=2CF(#Y2CSR0+OU<7#TC<_>XQ#+Z00JR7;/__!'G,\%%O)-^K@LS 8"F
M_M3:/;*WF4W)ZLAHF+25%M+* ]K(2#ONK4AD-$Q]MA.H\.:]):$3SK>%IVV!
MC,$+'TBM)UNX;=W3V*90P&R;U46&U?.<?:?N@M6<ZB::&=B]HRU%!SV225;M
M>3;+$/Y/;?A%X\8@VAX2PS<2U F)4(MTPRF.EIJZZL:I+T_GAZUW8P[C%#;7
MV5.+"NK\O\O&UA;#=<,3NWW)/AO5US 8DHGS_;#Q[O97R@9O8L%%'UF\%\%3
M(,5_!=AY5/H "4+0ZD]5-\;"N$L%U69Y3(S'J=K*O_'2Z+PA;\,-CBA.YXW]
MSEAV)Q^9#*N-Y)>A-D;F*<&G(Q/MG"QJ%WPVKDHN8V@L%RR_+'ZM$*@H>P[R
MA?-DD[0QS\M_I$D3:5']N*TX5=7H9;=G_T!8.:)X795FG3UDLU#(6NEFQ9V:
MR??H/B*-YR;##%[ZI8K_GII-EF%[ODVT;8R!K<2I6RU?9$:2I-[0>P<FV0T6
M'@JM.\H/GDN'AL)-@M,XIXLI87L&NXDUL(%%92^U)]#9_<V3IM[/QPY'X5;-
M[@R*W1["-E5>U./AGLTKQ>ZYH'G&*.2IBL^6<IC]95Q^<'[;:%K*&'Z&AK$X
MXDU/IQQBUZ:V]5YR6P/DG-M8KDS?H;Z.(KZ-EES<V4_F9;LP:2MB6P/.[^\-
M_ F.51M_[\H=(2"Y=\TKIP^2@29C#ZD8NBEZ@#PXZ'*)G@2:IP"\5*FW)%J[
M1<>$6^FXHJ5/YD2^VYM;LB-ZJ69I+;)ML^4;GH(2G065/_5ATPD@L8T0>#D(
MP>[SAK.?.Z-VYGET^P>E"X=3#J+L_90"#R[]U.?EQ5^O<=\C4_Z+>_G^,\^_
M%.V$,2;_[H,?C]*Z24&)(KRZ1*YZRGU^+H)D;6M"$P2Z@C5 2Q0,(N*#:>@4
M7<9; #%PS>2*"(RQ37?>W@+6A7=\)9&;:U&!GDT2)B&NK?N+.S]H']/.<R4^
M2[ D^38>I&4:OAVZ=0N %K=00<8P6#MNKQ4M#-(8MM-XE6*GSY<H7Q29RW91
M2/+8Y&>8NW@4$K.2.[> ,<,N$R0E_BV /@M-!VEK/:5!T*)QVF\!/79YMX#
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MU%>-P#1E-HI)!3</*[YY+.Q@G38ZQ^OM1HI;ZG,\ 9TN;73NWWJNSQW=Q+Q
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M@\3IM:==>5R-X7)^!BJ>I#SS-X W3M[:-AL-;:1#A,E91-.GE&-:6%M%QY/
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MZ-"^3/5?UQ\.U>3X8*;CC HHOW,WJ7Z5BE30>Y0-@,\7P;4PI;KO?\NT6<Q
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M^/J?1S,,8WB X$.R#SG< D#SW'47W'= \7@9^H.!P([H0&MAS.'"C'P8 /C
M)/##B;"C."R@O"(9.[GN'OB*LU[]G[T]=BJ%ZQRS2SX4+^'MOV/AV?A6XR7[
MR-T8_V1[>_K ''ECH+FOJ[U:Q1X@(%W<R1?FA2/J+I_>LME;=?;6S4]I^Z[+
M)R% 9O[*7:M%3>Q34BH@D$)U*D7-[(^F WWN%L]NH]G E^QZ.H'YFP'O2_LE
MZ_*Q4)O<]7$[GV5?>FK>PE]2Y#"X\>HI;'O! 02"?]WKBX$?P- 3.K_LIA\5
M;+K:C7E,RV+()#=A%DP$GW!A<Z2X=82SE#-7+F?N;\CELE1S6;;SS_]ZWFC4
M7B:/T^?ZRUT&BA?=2G#_ $Q31NP(+AWIT6W#(T"<(.+2PQ"H &^A]C<;-#F@
MV^8P$&*,FIR#0BV(C%[,@RE!TJBP1JUQF$R\^&4#225WS]V.)$C$ -B4<7S2
MP2^%>=F 9$9S#' AV^$A<T",]H1#@,!3N+S%\^_"=2INI!^'+LQE_QU+7'Y_
MRI*]@ET/6-KG-7-IV^K2#NG2QIVT>3B";[U0PK7"(^E[*HCL.B/NXVCIV%JL
M3[_09PA2^ED+Q.YZ#4[3D2%,HT3T"GL6C=BIZ_L@@2.B?/:#K^E?2)^-1C4_
M ]?8,0648IT0)'LGA-T4XPF>FZV/WI\0S"!YP!YR-A(.[-, <6C@VW&(DD@@
M@9<!HH(>3]LZ$MP%:&S8$+5^6#H(.\ 80#SQ@[#*/L%#_$: 2"-4]Q'NW$@<
MBW"K%X$JXK$W_M2!QT(:<T(Z"1SWC1^!H!0P!T[$CN@W^@HG2AZ"K9GX(3U'
MGY)'U0\2SR"1MH0=!_"-%L90R7+T*["D[)'GX<[#G-]9-A;C/H "4^"LI]+C
M'JEP'<\!<@^F[$H,8Y?#;L#X<33R 8)I0A>GG>Y5,R$!!58 *T1=44P$_ N0
MMA_X7T%*<6"S!1RZ(EF Q!,2=<L,1!Z]/$5H)! #'PRD*X$X0X+52[_0L_ P
M]&U)U N''])6J5."00BV9'W!8I"VQ#ZS0CC+BWAE%_'!9ES$;WBH;QS05D3*
M(7L)SV&7<0"73SA_<9YS^($UZOK.[(OH%KE.]EI&FG_GFW:?%>300,GP[BVP
M )E[%KE)_=G+4%<Z" *<Z$I,_"!"H$[]8,R>[[W/O*\ ;;?P9PW+@88%+RMB
MR@9VX"R-0RKXF;D'<5/@KS:[# 3HK'B!*D46V93B)W!!P.5 6(=$0>)%6CQT
MP9U:&I;6"<5_&\/28<ER-,NY1ANP:A=7\IRM0?"2YZS=D:B..>M_'H_ <ZC/
MT)T]AA+MB1[-:T]+,*E'8%!*D;N'2?TH@YJS)J@= PVO<;17WV^B5NVZ/-"]
MFF2$!ZK\>9=Q!!"Q@Z?/*NP-;#8/]%<5=O ,% KX9&/M T0 >'[H9[U\Z3QZ
M7_MQ"(>C/)B3P'=BVVC;^.M;B0:7=Q_/>@3(@)3:9#3$'X?%H$VJO>P'Z=FK
M-T^Y=Y<:WAK!-ZV1CTX3 =B!YH/[3 =:M?UI\T&!Z8 @K[+MYU3EY;%V1Z+Z
M9JS_>3R.CISI*E+*K%N#XR7;6;LC4>75U_\\0%Q2-#XK!HZD&+#V-^ ^D009
MXV(PD#8:V*FX_(+"\BC^(*&?\[^4)9\(> 3"# @4"54#T8Y$((#AW(Y\).@H
M\-TT! 2@YD/%W9!I\<& RR T@I.&4QGZ;<68@%G:L!UZ)!@@ JDMA G17X60
M44#9!*2P&^ZB/%(D]X8IJ#H>3'JV&SOF?>&*1()3LHT/#Y(O8"R"(6X-.G@P
M&H.KYX)<- M^C/L8S!E)^#Q57VI71!B**%1K(@\%>2Y".',)NPYO$#RV'P#_
M1?]$!/)@R F<1W(OD.GZL9G#_5$S^V74S -&S3POHV;R/JN'26=0Y[72D)=^
MLE']UP_CQWN$):C!I//'$_ZE5CM((GG.F]WFV_9YNWMM-;LGK'5Q=7EQU;QN
ML[<7']M7W6:WU7ZL=3\ #US^[/IH)%C?A:!D\<;G@8.WW(FY,3=Y1:OWBVN0
M)<4-'#_6-7L1!Q8H8@&&0:%0)!T1*KL1IIPDABL4YGQ0)K5$1G$_(,6D9BDE
M!FF9"%^=/^XJNRC\'@<'_@TS.Y:.I@*5EMDNBD+*< ?:(EJ?5 J %KY@.$\_
MA2/0UP 80$Y) MSS8I#PQD)$*D8X)]7A:D(1W*B8):ZFW)L*#JL1P;AJ+0 U
M(V5B\%(8:6$T S#ITB##X<C12"4ED'V.NZ&OC'31K9_*C23YHCIK5@!;JZ&T
M]%XN5(=W<.NUC7?F-V/MK6XH[]L6 FL/!HBO-\+BA"NGHA]@]!]K'"F3B,IQ
M*< UT%)\H <XT+OT+$*W!1H:*A$5-":',5 $Z$.B8H4PV:TD*RVBOXXEF]6
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M@35JII@3,$-AH5P+(_HP XC(WR:2H 'T0JF7D!SP"V3[T/RM.&;BQ$ZLK7+
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M]-T;X> AILB:+-R?8+/0V%/SY-!%)9";\L@5-A0>K14@\("T T G+U9E^^'
MX#[ Y5G4W5,76S>%D6\%=Z-16?Y\;=:1LEIBIGF,R9 4XFHQ3;WIG0$K5)P"
M^< ;$8RXPW;>G_7:Q_@K]OO:92&1\CF?(AD? !68>N"ZR+6F-XM:TV*/Q03]
M0C%$! V)/T4RTJ@?\?&$@$.6Q[UX %2B2H-3 V\@#*J_/181$,B$!Y$BG@'O
M!QJ1B9'[OF:;CA3$F*E'A&7+P(YEI.@S9#N7K3>[U/9QW'>GID5D!+)5VNZ(
M.(NF4/J,\AVM"]B9A^TB@>]2L79\))S"LL?P918@ M /AFH55I^'0B\@'88*
MM1.K'JMV4-BI/*S.\$55)]S1W%"FE572JN&T<<*DY%.M^MB!)6,O7AE%0IA"
M[A9.+KQ0P9C^#&^U/;P-QH0 ZIK#HY/(1'#7U0G[@X%0!^.QKG^CIJRKYB-U
M%GL1W(QX'^L.':J3:%'[#PL&^!..FIJ7/*/W]ZOL-.GZD(4FZ0>"P+LB:7V.
M&R/5J66Z<NKB[H' "U"QR!P.PB!]K/@/CRH,?8M!AW\)('!ACSS?]8=3UG.\
M*EXI5;;3Y:'#_SYF;Z\[NXCKY@[T$,%N\$IUX0;)X#W;T1VBS,"F-53:GKFN
M2JL<Z"O06M#;)W/PZ5G#:A.(U8:;?=0]8$J6O#;K(*''2KOTU.K/9J6>5!3A
MS/.]O2Q]X^>T'U1*[;#P +^Y-*+GV\"/)XBO;*=6KS^OOC_;K6(3E!N4#+!_
M M*SE=!;K?X"!>>>F$2*@HO$L0SV*:&ZE<B01J@&TDK$L'8JZ6:IIU8[V$=P
M4MG+\E$$ 5'WW17+"EK8]L#O_Z4:PX1)XW)X*A)\3 QL)-P)0 32R$1U]N@'
MQ'^5V#LUO$_3X1U\]"U)/:YU3CI%H-@=;,LA;@O\]PB7=L+E7L<>2?9>?N5?
MX\RJ4CD2NV_1>H0P%QCH+8Z;$Q9S,KKM2CS:!&943))F?O SB%RX 15S'="W
M8^%(N&5!KO9(DX#?;!#+DT;-P.P$,A;@H'HE#;V2PSN.M9>H"V^,T-DR>H-J
M(O+GV>4G=@9G=2J#<4Y\AC4*QR@0;$:!" LT"$>@4H,W<N!QT]B#)IG7MD@A
MT6=2,RMIS*\DPCZ*#ETX-@BH>.^$Q*'A5/$$3C(4TY5\R+&:DIT>9%8CT!VL
M<54H#R1B>(JB",<0R2Y5LX:Q=+BGVUPEIQB:'FQ*(U HR@<HH8!"&,:Z+8V=
M*)U 7B3,HT205.V](:$'SEZ&^ ?MB0O+WL/&,DH!*7L-KH.) VM\Z_K>56/8
M2!J3:9-&II\XG+?MX\6M^862U#(F#:7<4>LK$KJ 3'*"-8H\NG..:2<4LEL_
M^(J:&DDTF1FPZ;F#<F\U 2EE (5"UJ+F<$2/S7@(V\CJ#2WQ12.X>89*RD^E
M,VLETAG+2V=SPI.Q*:AO$9Q*LD:X5*T,NZ?KL:EVQ?"V-ZUSUG1=2?1+UH,>
M!LP!O\_(@<3N\9067;A5]DYBN_MP@OU)^]+%XFR2-'_TATZL?&-ZH.58A)I-
M_QE[(KF,,T)"=B'I(LQ=!3O6>_.9_1-TII<,,V@\Y,"79]=L!^O%B0#PY:OG
MWWK$XB4@\QL?CN2S0):IWFJ&H0]G&XEP%U6*Q,0!$\'-,A#$<,A8D>!1UHRA
M2]01 M.I!V($? TW",UDI$V0OFG/&,XLA>NJ)R#P04X-FR+^+569,E,JWIRS
M?1&^T"#X '!SX(6KY8*EO/LSZS@E,5.C];,9M*Z_*$)KCHQ3 CTV\5CAOT3U
M"=ZR8KQ%Z19?HHN61TK 92?"-O)L_<B"WQ)0BF<.Q5CNA6IZKJ?73;Y2@RFQ
M-<4E!B %5=C_5EGSO-/5$FDJA0#5:RE$HN6ZOJ_4,RL'E5K>Y^O>[))2_CP,
MN!-31SI:5,<;!!Q$CM@F.>J#E]2 ?!^#*LK.XO$D#DS7.&JI3).KFP C,T!L
M]H.D6:<CAM@]>8=^?^=[?@!< -YNYJ\EFCLWPV) 6B@W#869\D1.7$"7F4%I
M4VHO2FI=FW5H\85:(F3;(2@11B$D?847&H<_J6TYX&7F)D45,'$*D#M#"3P>
MX*$[S3EPM(@RX[W)N%^JUCN1-W9ER@@GPCPZ'+A,#%W$-G"$C*$K;PIK94U>
MK84F+V75!&'$^@&;UX_+,"@^Y(0_VXT=5(',+8<FT +S*IDXQR!$2:-.*:VK
MV"BE_0#SJE:575!'1W*W@:Q"*J>2&Z,8=GNJ[^S<.8]T<W6 FD0.(\0J<Z:9
M#TV>=&&3@RAI)=GL7#9;(#$-J:?\NTP'ZZQ7XTJ@"P,A29'-N!XLD+2-*Q!E
MJ@7');Z)P)8A2!A.C-83H"/5(1+M(N(VY_)!T(6-/2C5'I+K!<754L7ZM3P*
M>)"E>! Q!O+Q&DD!CTH+P$@E[]^=M4@.UH(C$-:8 RK-"^<* 71;*E+-4-G2
M(X5SCDHEKH-<0PRM?E!D.TMY9<K %L")TGM.;B>-*"G[7" CI](T+<TJ7AK2
M'#5)3KH=\S"#ZP5KS;)X0'\A;[0<D[G!R0)#PL!U['V-6;/OQ"Z[XB,X/<M<
M_/!<JC#."!*)>0,'-N*.-N&G5TH+/>,#F;M<@).J;[5+14&S6OOVKR7)N^.E
M#LMXJ0>,EZK7RH"I1RGI7H9(W1,B!5?<POY(J441S=Y).WH2R,^%0W[I$]\8
MN5L ?0 RT#N*S2 G1N /1\(!H:V%7'7*SOPX&E58)Q 8I5/-#6O1L",Y',%-
MEPJE*!"A]0Z9,%YA@81M4^9[O!>,7)@?B\S_Q-AG0=)3YZ_0_52CMS(:/5RW
M-;S/M-T1'ZSDIR'IT6R!5H*U)#A24PZ0=!)_TCF(BR#ZDK-(PY0*MI^4 NN
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M9"%#+=O:XS*1,4472.+NJQ)?P*H<VV0ZBJMTM3]#N8U?@>T7P@:_H(X!<!C
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M6^TO*_+(V88^D'5N>W._TJ.9GOL-S250>2:;H>_Y#N>OANOZV&RD9+(EMBR
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M\S"O8CW@/?54WK-Q%LMAJP$<IU8LCE.*Z-VDD04B>DVWXCVTTE@C,\6%=8+
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M%BJZA,*%IN8"RW8TXI>Z-E/Y)+- B0+KR#3@CNC4'*FAD7I2P=$IIVS )GT
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M4_IXVL*1HT^K1Q/KO*'GC2T\@"O,^5TS5!8VSB5<,XLPG\A<<H$'<X&S#+C
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M,6':8!S  LJ[@^8))LN:U'>,E^Q112WEY5JB"G<,0,/UZ/C'K$XLK(5GB-+
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M[U@2ZN;<1Q7%>JD( "PM:M2=5I0$7:AI1G-_6-.R=@'5+CB*(ZHWQUN[CT"
MET_^H-00?&:"KQRJBSF&(VUE@W#L8R%2=$I:/3UIN()I@E]5B@$%!&ME*:4W
MJV6M5%PPYF2&B)/2RDGI:/YQ5Q:_P!;_,VWQ4]3#>]\[/MX[NMJV7^SY/1:Q
MU5(LCSE<NE=I)L@G?>G9^E4"!"'DD4(RU*/@:WZ?>3(J#V$0(UQG$&3#/)N?
MGI4>AQP:'D(R\ANZ$NJM&'P7Z&L]>?UE/CYES._$(?T0C(/*C2%VO9,.BR =
MGFOI8$5+/54V.*!@P,'A^_X!Q7$'_O[AD0X"+_$B/!H1DL'5M8&/F-@FPP*M
MFI9T-">PQ?1&HZ(A"XX7>.  /2_ XH<):-H>&R:B*F *;R43PI\PI;&X/,WD
M,!>K:$& <,,LNGQT%QXZ':)Y#T8]#&=[#<Q]OSXU$7FA*EAIR>%[M=&'"7HC
MIV<$9[,MK\9TO9Z/OV+B(<U3H3491H;^%B86A7D2*V*J_6B8S]&9V=@*>*Q<
M1F5/'PPFD.LR]V>$S;7].80A%)-+)4%15)]F#/<])_D+DT)>(XDUD D7$"H[
MFX*YZFGQ/$_)IH.%XBFS"6>8ES0(HX<(4*>("5&>B 1.2=L45$]1:N4 "UG,
M9VRY3NKDW*R"#%%7%1NJ/T>KR5:M0"W,C/PB(N!&B2!:_PB&[F]LAT\V7F&D
M!@8RG2?,4-4\GT>L<)9"5'W0,D(#D?$NZGM#7E )SP"S!)Z7PA;:^%-C[&2Y
MV"!7BH"J &-K2-]LCU+^BK$ZI1<'MGW"[AX,)&0TJ3KRA<8.*;#!-$39@4,%
MUR\?(4K5+<L0XR><@PAB&(,6.SP6/K"C.!_-IR"%X$87+/@*JA'0U]>^M I%
MM;>SYO?@W8WBV"] Z($>IF@-^&1C/?A0Q4!HG50@(_"NPWW]^W",[X9C.D#J
MOYW'DO,)'<YS3ZYN)?:QL?[D#WU@)W"EX"-43,,D8MIFV-I@FX'9=X5BS#9$
MHF]G\9"(&S$47F:K 3PNB<;F9B&^5G(+4K%5V+4T7)4A5L<0HYKS@D!])OPI
M=[J/EFH:$3#IXN)B;23W:0U4,1=DV%^*$9");(1<]($6#Y*+8KS(RRY2P6+J
M@F+?C:ER2!7#J'"756@5GW*'E]3[,3'3Y8/W7 V]>-9!+^X1>K&UWD$OZ/\?
M,\KBCM[R[\C"F]?)#:F\T"&5WFP&RBC^YO4>:@WO8W8/>PKNA; '"0>]O3]/
M^L>?_?[!SMX!H0^1@3! IB7B$=S;?? I+F'@;$^1)7B_S]/(WUKGD,7C#@4N
MN#6RL>;M[NWW#_H4HGULAM52NH0GE&GU3-VJT!9P^$+RL)QO3AE_H3^IJ'NJ
M]7Y8.EV0BS/7E4;@3%SML/LL^;CROZ]JP8G:..#*6/<ETRA,X;_%G1;V=>?G
M.^9!R+3>>!JG<5'F(?A/@DOS<(^*%NX;G>./2^)%L&C[R1-$/."(/&QTAX?1
M69A,K()]1?N/Z!QRAD=AP4?$&0D=D\+ESNCB. LT#SX\X(HG2/+@'IP09 XC
MK:C$DO8YX.3*''Y?<&QQ(/63VYO;-C:,@Q[@'G%7I!PI8(IX'&.8LTKNP5D
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M0IZN#B-5'HZ0+OP5&$;G,9$G5Z26_7FXH4,<I2>'3\A Y:\"J6A_VHH5;'4
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M9,MP%AFD(8Z#P"$Y76,>$GENEP4RJ*NAX:0)T1MJ.B0S$&:R)6B/HJ:M_$U
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M$PTD,J5,;:G-0/,P18 OGO\P2&UG)CE&R *#7^[-4%H2K^XX$D<*1('@T)R
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M0Q3[Q==+-3UX.%B%O#.BH8LJ3K@,OT;<RY&O9M7&LF9I8]+B7"\,!QWMM'?
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M%7F=99QQ!2D 5J+$!G(_B<'9'X>V5-#1#Y0 3'98Z":!RGI#%@ZFF4)OG<N
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MT$O(K?0FK%!3[-D9QJ0RZBC4 $Z6ZZH P@ H6Q9I'"4QW'8FN==RW^PA%0F
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M04&K;6"!BT9@->0D(8*6E) #L*0D3+C!7UC$A7Z<&#L$%:A6#JFG"JQ"WEZ
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M8(1 'X$/!6IO\U7@;ZYOO@R,>F8?'?F:HU0L !U0@)^2V+!;*2\-D]CA.&,
M5RLQI:=BN\[7L)01_%KU-7+CK!RV9;]QI2)-1UPRNQL==TN6\=$;X(GG6>DZ
MB/)D3URR^B K[VP'86@25?7.>GDA60?,JT51$=42B9K,C; WB.<XO778"KW
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M1>_K[M>]\?SWT=/CPZTO+\[SS_/3U^GVTY-WT>[!L_/MWM-?TO_,?[_X7SG
M3X?9^!+_>U9.D__W_P-02P$"% ,4    " #&BME:@OL,=ST$  !:$@  $0
M            @ $     8WEC8RTR,#(T,3(S,2YX<V102P$"% ,4    " #&
MBME:V(D7NY($   E(0  %0              @ %L!   8WEC8RTR,#(T,3(S
M,5]D968N>&UL4$L! A0#%     @ QHK96NJ&FU"N$@  I>D  !4
M     ( !,0D  &-Y8V,M,C R-#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( ,:*
MV5KU#>\M%PT  'BI   5              "  1(<  !C>6-C+3(P,C0Q,C,Q
M7W!R92YX;6Q02P$"% ,4    " #&BME:I6WHS9&'  ">J@  $@
M    @ %<*0  9F]R;61E9C$T85\P,#$N:G!G4$L! A0#%     @ QHK96J),
MP$-/B   CK<  !(              ( !';$  &9O<FUD968Q-&%?,# R+FIP
M9U!+ 0(4 Q0    ( ,:*V5IAJ_HX/34! +),#  /              "  9PY
G 0!F;W)M9&5F83$T82YH=&U02P4&      < !P#% 0  !F\"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>formdefa14a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:CYCC="http://cyclacel.com/20241231"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cycc-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_PeoMember_custom_ReportedSCTStockOptionAwardValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ReportedSCTStockOptionAwardValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_ReportedSCTStockOptionAwardValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ReportedSCTStockOptionAwardValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_PeoMember_custom_ReportedSCTStockOptionAwardValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ReportedSCTStockOptionAwardValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_ReportedSCTStockOptionAwardValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ReportedSCTStockOptionAwardValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_PeoMember_custom_ReportedSCTStockOptionAwardValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ReportedSCTStockOptionAwardValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_ReportedSCTStockOptionAwardValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ReportedSCTStockOptionAwardValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_PeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_PeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_PeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">CYCC:ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000004">0001130166</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0011">DEFA14A</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000012">CYCLACEL PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <ecd:InsiderTrdPoliciesProcNotAdoptedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000013">Our
&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_" id="xdx_90C_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbF_c20240101__20241231_zeFPqbmDt6I"&gt;Insider&lt;/span&gt; Trading Policy provides that no employee, officer or director may acquire, sell or trade in any interest or position relating
to the future price of Company securities, such as a put option, a call option or a short sale (including a short sale &#x201c;against
the box&#x201d;), or engage in hedging transactions (including &#x201c;cashless collars&#x201d;).</ecd:InsiderTrdPoliciesProcNotAdoptedTextBlock>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000014">false</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:PvpTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000016">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eecd--PvpTableTextBlock_zJPt1OAR181g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48C_eecd--PeoTotalCompAmt_zEgUwmHuaGpe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    Compensation Table Total for CEO&lt;sup id="xdx_F51_zsVPO07nSCxe"&gt;(1)(2)&lt;/sup&gt; &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eecd--PeoActuallyPaidCompAmt_zj6JkcwW7uol" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Compensation
    Actually Paid to CEO&lt;sup id="xdx_F50_zpE70shQObnf"&gt;(1)(3)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48B_eecd--NonPeoNeoAvgTotalCompAmt_zEO0q8JuNnhf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate
    Summary Compensation Table Total for Non-CEO Named Executive Officers&lt;sup id="xdx_F50_zR7ojIh3jDGe"&gt;(1)(2)&lt;/sup&gt; &#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_487_eecd--NonPeoNeoAvgCompActuallyPaidAmt_z2GyD0bH5WQ5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate
    Compensation Actually Paid to Non-CEO Named Executive Officers&lt;sup id="xdx_F5E_z5O92NP8n0ug"&gt;(1)(3)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_483_eecd--TotalShareholderRtnAmt_pp2d_zJjHPzgGQRA7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value
    of initial fixed $100 investment based on total shareholder return (TSR)&lt;sup id="xdx_F55_zQkRoOsms684"&gt;(4)&lt;/sup&gt; &#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_488_eus-gaap--NetIncomeLoss_iN_pn3n3_di_zYgbgYvdMJM" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net
    Loss (in thousands)&lt;sup id="xdx_F50_zXBR1Ha20gt5"&gt;(5)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20240101__20241231_zPsDiEJ1CDJ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;585,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;547,706&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;363,988&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;342,889&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;0.64&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(11,212&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_411_20230101__20231231_zXMq8AvNxwu9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;661,049&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;65,807&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;833,233&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;172,676&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.58&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(22,555&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20220101__20221231_zSps6lkNEcra" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;763,551&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(77,717&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;918,518&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(36,347&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;17.15&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(21,198&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000017"
      unitRef="USD">585000</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000018"
      unitRef="USD">547706</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000019"
      unitRef="USD">363988</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000020"
      unitRef="USD">342889</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="2"
      id="Fact000021"
      unitRef="USD">0.64</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000022"
      unitRef="USD">11212000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000023"
      unitRef="USD">661049</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000024"
      unitRef="USD">65807</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000025"
      unitRef="USD">833233</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000026"
      unitRef="USD">172676</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2023-01-012023-12-31"
      decimals="2"
      id="Fact000027"
      unitRef="USD">4.58</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000028"
      unitRef="USD">22555000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000029"
      unitRef="USD">763551</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000030"
      unitRef="USD">-77717</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000031"
      unitRef="USD">918518</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000032"
      unitRef="USD">-36347</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2022-01-012022-12-31"
      decimals="2"
      id="Fact000033"
      unitRef="USD">17.15</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000034"
      unitRef="USD">21198000</us-gaap:NetIncomeLoss>
    <ecd:NamedExecutiveOfficersFnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000041">&lt;p id="xdx_890_eecd--NamedExecutiveOfficersFnTextBlock_dU_zPZm4oUoimXd" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
    each year shown, the CEO was &lt;span id="xdx_90E_eecd--PeoName_c20240101__20241231_zVr6SEV7L95d"&gt;&lt;span id="xdx_90E_eecd--PeoName_c20230101__20231231_z6Nfdkdj3od1"&gt;&lt;span id="xdx_901_eecd--PeoName_c20220101__20221231_z9mgvA6fsj32"&gt;Spiro Rombotis&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; and the Non-CEO named executive officers (the &#x201c;&lt;b&gt;NEO&lt;/b&gt;s&#x201d;) were Paul McBarron
    and Mark Kirschbaum, MD.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ecd:NamedExecutiveOfficersFnTextBlock>
    <ecd:PeoName contextRef="From2024-01-01to2024-12-31" id="Fact000042">Spiro Rombotis</ecd:PeoName>
    <ecd:PeoName contextRef="From2023-01-012023-12-31" id="Fact000043">Spiro Rombotis</ecd:PeoName>
    <ecd:PeoName contextRef="From2022-01-012022-12-31" id="Fact000044">Spiro Rombotis</ecd:PeoName>
    <ecd:EquityValuationAssumptionDifferenceFnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000046">&lt;p id="xdx_894_eecd--EquityValuationAssumptionDifferenceFnTextBlock_dU_zfxnDlcNtmH7" style="display: none; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cumulative
    Total Shareholder Return (&#x201c;&lt;b&gt;TSR&lt;/b&gt;&#x201d;) measures the cumulative value of $100 invested on the last trading day before
    the earliest fiscal year in the table, or December 31, 2021, including the reinvestment of dividends, through and including the end
    of the applicable fiscal year for which TSR is calculated, or December 31, 2022, December 31, 2023 and December 31, 2024. We did
    not pay dividends in the periods presented.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ecd:EquityValuationAssumptionDifferenceFnTextBlock>
    <ecd:AdjToPeoCompFnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000048">&lt;p id="xdx_891_eecd--AdjToPeoCompFnTextBlock_dU_zBMjhFW4DbT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fiscal
    Year 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fiscal
    Year 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fiscal
    Year 2022&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CEO&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NON-
    CEO NEO&#x2019;s&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CEO&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NON-
    CEO NEO&#x2019;s&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CEO&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NON-
    CEO NEO&#x2019;s&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCT
    Total Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eecd--PeoTotalCompAmt_c20240101__20241231_zc0dwJoSZvea" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;585,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_zFXuUQC00M1e" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;363,988&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eecd--PeoTotalCompAmt_c20230101__20231231_zSBBBOkRw0lb" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;661,049&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_zXcbXM8h6Wzj" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;833,233&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eecd--PeoTotalCompAmt_c20220101__20221231_zrOqzcW4zrj2" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;763,551&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_ziCRRTAM7Oi" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;918,518&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subtract
    Reported SCT Stock Option Award Value ($)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zYOQ3Bio9JL1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zzCahFB4mBrj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zQ9Do2Ux9OM2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(100,421&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zpZQw2OHbF7a" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(118,167&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_z9rdp09mnI3d" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ReportedSCTStockOptionAwardValueMember_zThlN5bADQ6a" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Add
    Year-end Fair Value of Unvested Awards Granted in the Applicable Fiscal Year ($)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_ztI6EcOqBu2c" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_zAGo71P6QmU8" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_zp6pKuMCHrj9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,961&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_zhb5L77soGjk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;26,051&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_z87U2qJRbbvd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember_ztbpLL5tEdq1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Add
    Change in Fair Value of Awards Granted in Prior Years Outstanding and Unvested as of the Applicable Fiscal Year End ($)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_z8hWRNNhV1mj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(21,986&lt;/p&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_zB4OtY9dkfcd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(13,042&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_zgEOBUlogWVa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(164,307&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_zKow5dJEzFK" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(172,971&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_z7hefwmNlp86" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(494,733&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember_zhqHaVdVfqIc" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(545,667&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Add
    Change in Fair Value of Awards Granted in Prior Years that Vested during the Applicable Year as of the Vesting Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: right"&gt;&lt;p id="xdx_98A_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_zs3fZW3UWtxf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(21,986&lt;/p&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;p id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_z55wJ025rOB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(13,042&lt;/p&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_zGkh7RQE1DW1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(352,475&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_zeXn5GKAMRSi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(395,470&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_z9nY85d5wdS4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(346,535)
                                            &lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eecd--AdjToCompAmt_c20220101__20221231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember_zDhTwMKp9eHe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(409,198&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    Compensation Actually Paid &lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;p id="xdx_989_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_zbD00DjU6oai" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;547,706&lt;/p&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;p id="xdx_982_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_zTDsoWutOJE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;342,889&lt;/p&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_zcRpHEf1z6i3" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;65,807&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_zamBkiHKc9X5" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;172,676&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_zfKILg7y8fC9" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(77,717&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_zXDddc62Sypa" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(36,347&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</ecd:AdjToPeoCompFnTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000049"
      unitRef="USD">585000</ecd:PeoTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000050"
      unitRef="USD">363988</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000051"
      unitRef="USD">661049</ecd:PeoTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000052"
      unitRef="USD">833233</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000053"
      unitRef="USD">763551</ecd:PeoTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000054"
      unitRef="USD">918518</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_ReportedSCTStockOptionAwardValueMember"
      decimals="0"
      id="Fact000055"
      unitRef="USD">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_ReportedSCTStockOptionAwardValueMember"
      decimals="0"
      id="Fact000056"
      unitRef="USD">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_ReportedSCTStockOptionAwardValueMember"
      decimals="0"
      id="Fact000057"
      unitRef="USD">-100421</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_ReportedSCTStockOptionAwardValueMember"
      decimals="0"
      id="Fact000058"
      unitRef="USD">-118167</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_PeoMember_custom_ReportedSCTStockOptionAwardValueMember"
      decimals="0"
      id="Fact000059"
      unitRef="USD">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_ReportedSCTStockOptionAwardValueMember"
      decimals="0"
      id="Fact000060"
      unitRef="USD">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember"
      decimals="0"
      id="Fact000061"
      unitRef="USD">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember"
      decimals="0"
      id="Fact000062"
      unitRef="USD">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember"
      decimals="0"
      id="Fact000063"
      unitRef="USD">21961</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember"
      decimals="0"
      id="Fact000064"
      unitRef="USD">26051</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_PeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember"
      decimals="0"
      id="Fact000065"
      unitRef="USD">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember"
      decimals="0"
      id="Fact000066"
      unitRef="USD">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember"
      decimals="0"
      id="Fact000067"
      unitRef="USD">-21986</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember"
      decimals="0"
      id="Fact000068"
      unitRef="USD">-13042</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember"
      decimals="0"
      id="Fact000069"
      unitRef="USD">-164307</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember"
      decimals="0"
      id="Fact000070"
      unitRef="USD">-172971</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember"
      decimals="0"
      id="Fact000071"
      unitRef="USD">-494733</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsOutstandingAndUnvestedAsOfTheApplicableFiscalYearEndMember"
      decimals="0"
      id="Fact000072"
      unitRef="USD">-545667</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember"
      decimals="0"
      id="Fact000073"
      unitRef="USD">-21986</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember"
      decimals="0"
      id="Fact000074"
      unitRef="USD">-13042</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember"
      decimals="0"
      id="Fact000075"
      unitRef="USD">-352475</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember"
      decimals="0"
      id="Fact000076"
      unitRef="USD">-395470</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_PeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember"
      decimals="0"
      id="Fact000077"
      unitRef="USD">-346535</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_custom_ChangeInFairValueOfAwardsGrantedInPriorYearsThatVestedDuringTheApplicableYearAsOfTheVestingDateMember"
      decimals="0"
      id="Fact000078"
      unitRef="USD">-409198</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">547706</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">342889</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">65807</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">172676</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000083"
      unitRef="USD">-77717</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000084"
      unitRef="USD">-36347</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000086">&lt;p id="xdx_893_eecd--CompActuallyPaidVsTotalShareholderRtnTextBlock_dU_zzGs4pfMW9s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Relationship Between PEO and Non-PEO NEO Compensation
Actually Paid and Company Total Shareholder Return (&#x201c;TSR&#x201d;)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"&gt;The following chart sets forth
the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and the
Company&#x2019;s cumulative TSR over the three most recently completed fiscal years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;img alt="" src="formdef14a_001.jpg"/&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock>
    <ecd:CompActuallyPaidVsNetIncomeTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000088">&lt;p id="xdx_89C_eecd--CompActuallyPaidVsNetIncomeTextBlock_dU_zoAUkXGtd4q9" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Relationship Between PEO and Non-PEO NEO Compensation Actually
Paid and Net Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following chart sets forth the relationship
between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Net Income (Loss)
during the three most recently completed fiscal years.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;img alt="" src="formdef14a_002.jpg"/&gt;&lt;/span&gt;&lt;/p&gt;

</ecd:CompActuallyPaidVsNetIncomeTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000017"
          xlink:label="Fact000017"
          xlink:type="locator"/>
        <link:footnote id="Footnote000035" xlink:label="Footnote000035" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">For
    each year shown, the CEO was Spiro Rombotis and the Non-CEO named executive officers (the &#x201c;<xhtml:b>NEO</xhtml:b>s&#x201d;) were Paul McBarron
    and Mark Kirschbaum, MD.</link:footnote>
        <link:footnote id="Footnote000036" xlink:label="Footnote000036" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    in this column represent the &#x201c;Total&#x201d; column set forth in the Summary Compensation Table (&#x201c;<xhtml:b>SCT</xhtml:b>&#x201d;) in
    the &#x201c;Executive and Director Compensation&#x201d; section. See the footnotes to the SCT for further details regarding the amounts
    in these columns.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000017"
          xlink:to="Footnote000035"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000017"
          xlink:to="Footnote000036"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000018"
          xlink:label="Fact000018"
          xlink:type="locator"/>
        <link:footnote id="Footnote000037" xlink:label="Footnote000037" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    dollar amounts reported in these columns represent the amounts of &#x201c;compensation actually paid.&#x201d; The Amounts are computed
    in accordance with SEC rules by deducting and adding the following amounts from the &#x201c;Total&#x201d; column of the SCT (pursuant
    to SEC rules, fair value at each measurement date is computed in a manner consistent with the fair value methodology used to account
    for share-based payments in our financial statements under GAAP):</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000018"
          xlink:to="Footnote000035"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000018"
          xlink:to="Footnote000037"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000019"
          xlink:label="Fact000019"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000019"
          xlink:to="Footnote000035"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000019"
          xlink:to="Footnote000036"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000020"
          xlink:label="Fact000020"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000020"
          xlink:to="Footnote000035"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000020"
          xlink:to="Footnote000037"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000023"
          xlink:label="Fact000023"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000023"
          xlink:to="Footnote000035"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000023"
          xlink:to="Footnote000036"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000024"
          xlink:label="Fact000024"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000024"
          xlink:to="Footnote000035"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000024"
          xlink:to="Footnote000037"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000025"
          xlink:label="Fact000025"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000025"
          xlink:to="Footnote000035"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000025"
          xlink:to="Footnote000036"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000026"
          xlink:label="Fact000026"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000026"
          xlink:to="Footnote000035"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000026"
          xlink:to="Footnote000037"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000029"
          xlink:label="Fact000029"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000029"
          xlink:to="Footnote000035"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000029"
          xlink:to="Footnote000036"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000030"
          xlink:label="Fact000030"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000030"
          xlink:to="Footnote000035"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000030"
          xlink:to="Footnote000037"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000031"
          xlink:label="Fact000031"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000031"
          xlink:to="Footnote000035"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000031"
          xlink:to="Footnote000036"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000032"
          xlink:label="Fact000032"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000032"
          xlink:to="Footnote000035"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000032"
          xlink:to="Footnote000037"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000021"
          xlink:label="Fact000021"
          xlink:type="locator"/>
        <link:footnote id="Footnote000038" xlink:label="Footnote000038" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Cumulative
    Total Shareholder Return (&#x201c;<xhtml:b>TSR</xhtml:b>&#x201d;) measures the cumulative value of $100 invested on the last trading day before
    the earliest fiscal year in the table, or December 31, 2021, including the reinvestment of dividends, through and including the end
    of the applicable fiscal year for which TSR is calculated, or December 31, 2022, December 31, 2023 and December 31, 2024. We did
    not pay dividends in the periods presented.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000021"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000027"
          xlink:label="Fact000027"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000027"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000033"
          xlink:label="Fact000033"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000033"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000022"
          xlink:label="Fact000022"
          xlink:type="locator"/>
        <link:footnote id="Footnote000039" xlink:label="Footnote000039" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    dollar amounts reported represent the amount of net loss reflected in the Company&#x2019;s audited financial statements for the applicable
    year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000022"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000028"
          xlink:label="Fact000028"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000028"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000034"
          xlink:label="Fact000034"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000034"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
